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Abstract 
 
   Ubiquitin-specific proteases (USPs; Ubps in yeast) are the most abundant family of 
deubiquitinating enzymes. Their involvement in various cellular processes, which are implicated 
in development and diseases such as cancer, have made them an important subject of investigation. 
Protein function correlates with its three-dimensional fold; therefore, structural studies can help 
identify evolutionary conserved features, catalytic mechanisms and provide clues to specificity 
and interactions. We examined the expression of soluble Saccharomyces cerevisiae 
deubiquitinating enzymes in E. coli for structural studies. Following extensive optimizations 
Ubp1, the Ubp6 catalytic domain and the Ubp12 N-terminal domain crystallized. The Ubp6 
crystals led to the determination of its three-dimensional structure and revealed that the catalytic 
triad residues are arranged in an active conformation. We showed that the Ubp6 catalytic domain 
superimposes well with that of USP14, its human homologue. This suggests a similar regulatory 
mechanism for yeast Ubp6 as compared to human USP14. Further, we investigated the mode of 
protein interaction of yeast Ubp15. Both S. cerevisiae Ubp15 and its human homologue, USP7, 
harbor a highly conserved DWGF motif in their N-terminal domains. The DWGF motif in USP7-
NTD efficiently binds substrates or interacting proteins containing (E/P/A)XXS sequences. We 
showed that similar to USP7-NTD, the DWGF motif in Ubp15-NTD mediates interaction with 
(E/P/A)XXS motifs. 
   To establish latency, human herpesviruses (HHVs) have evolved various mechanisms for host 
immune evasion. Proteins expressed by some members of the HHV family interfere with the 
USP7-p53-Hdm2 pathway. They competitively bind to USP7, block USP7-substrate interaction 
and suppress p53 mediated apoptosis. We identified an EGPS motif in both vIRF1 protein 
(expressed by Kaposi’s sarcoma-associated herpesvirus; KSHV) and pp71 protein (expressed by 
human cytomegalovirus; HCMV). This motif is identical to the sequence reported in EBNA1 (of 
Epstein-Barr virus) and ORF45 (of KSHV) responsible for mediating their interaction with USP7-
NTD. We demonstrated that both vIRF1 and pp71 interact with USP7-NTD in vitro and 
characterized the interaction using functional studies. The crystal structures of the USP7-
NTD:vIRF1 and USP7-NTD:pp71 peptide complexes revealed identical modes of binding as that 
of the EBNA1 EGPS peptide to USP7-NTD. Our results support new roles for vIRF1 and pp71 
through deregulation of the deubiquitinating enzyme USP7, which destabilize p53 and inhibit 
cellular antiviral responses. 
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Specific Proteolysis: 
 
   Proteins in cells are highly dynamic, constantly being modified, degraded and remade. 
Intracellular degradation of proteins is common and essential in all organisms including bacteria. 
In 1973 Schimke in his comprehensive review of protein turnover proposed that there must be a 
system or systems involved in protein degradation in contrast to non-specific lysosomal 
proteolysis (Schimke 1973). Almost two decades later it was demonstrated by Hershko, 
Ciechanover and Rose that the system involved in targeted protein degradation in most cases is 
the ubiquitin-proteasome pathway, which led to their 2004 Nobel prize in Chemistry (Wilkinson 
2005; Hershko & Ciechanover 1992). 
 
   Ubiquitin-mediated proteolysis is highly complex and regulated and is involved in crucial 
cellular processes such as signal transduction, cell cycle progression, destruction of abnormal 
proteins, transcriptional regulation, antigen presentation and growth control (Finley et al. 2012; 
Glickman & Ciechanover 2002). Ubiquitination modifies the surface of the substrate protein 
affecting its stability, activity, interactions or subcellular localization. With so many pathways 
involved, it is not unexpected to see that deregulations in the ubiquitin proteolytic pathways have 
been implicated in many human diseases including malignancies, neurodegenerative disorders, 
cystic fibrosis, Angelman syndrome as well as immune and inflammatory responses (Hao et al. 
2015; Margolis et al. 2015; Deng et al. 2011; Ciechanover 2003; Glickman & Ciechanover 
2002). 
 
Ubiquitin-Proteasome Pathway: 
 
Ubiquitin: 
 
   Ubiquitin (Ub) is a 76 amino acid long protein engaged in post-translational modification of 
cellular proteins (Finley et al. 2012). Ubiquitin involvement in crucial cellular processes, such as 
well-studied proteasome-dependent protein degradation and more recently discovered 
endocytosis, transcriptional regulation, protein trafficking and cell cycle progression, has made it 
one of the central elements of eukaryotic cell physiology (Grice & Nathan 2016). The structure 
of ubiquitin resembles a ß-grasp fold (consisting of a β-sheet with 5 anti-parallel β-strands and an 
alpha helix that connects β-strands 2 and 3) with a flexible C-terminal tail ending with two 
signature glycine residues (Burroughs et al. 2012). The Ub structure is conserved and identical 
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among all eukaryotes from yeast to plants and mammals (Burroughs et al. 2012; Wilkinson et al. 
1986). It is suggested that the compact structural architecture, conserved hydrophobic core and 
extensive hydrogen bonding of ubiquitin is responsible for its unusual heat stability and pH 
resistance (Callis 2014).  
 
   The Ub molecule is one of the most conserved proteins among all eukaryotes to the extent that 
budding yeast ubiquitin differs in only three amino acids from its human homologue (Zuin et al. 
2014). All eukaryotic organisms carry almost identical ubiquitin coding sequences which show 
extremely low divergence even among very distant species. This observation indicates that the 
incorporation of any mutations into the ubiquitin coding sequence has been blocked throughout 
evolution (Zuin et al. 2014). In fact, it was shown that a vector expressing Arabidopsis thaliana 
ubiquitin could fully replace Saccharomyces cerevisiae (S. cerevisiae) ubiquitin without any 
phenotypic abnormalities (Ling et al. 2000). Extreme conservation of the amino acid sequence 
and structural fold of ubiquitin has led to evolutionary conservation of its surface features as 
well. Many Ub interacting proteins and enzymes involved in the ubiquitin pathway have evolved 
structurally distinct ubiquitin binding domains (UBDs) that contact conserved surface regions on 
ubiquitin (Husnjak & Dikic 2012). For instance, ubiquitin core residues around Ile44, known as 
the Ile44 hydrophobic patch (consists of Leu8, Ile44, His68 and Val70), are essential for Ub-
proteasome interaction and Ub mediated endocytosis, while mutagenesis of these residues has no 
effect on ubiquitin-protein conjugation (Fig. 1-1) (Kulathu & Komander 2012; Haririnia et al. 
2008). Another essential surface region on ubiquitin is around Phe4 (including Thr14 and Gln2 
residues) which is important for Ub mediated endocytosis and protein internalization. Mutational 
studies indicated that Phe4 is not involved in Ub-protein conjugation or proteasomal degradation 
of ubiquitin-tagged proteins (Sloper-Mould et al. 2001). Further, extensive mutational analysis 
revealed that out of 63 surface residues on the ubiquitin Ile44 hydrophobic patch, the Phe4 patch 
and C-terminal tail are essential for viability (Zuin et al. 2014; Sloper-Mould et al. 2001). Other 
surface patches on ubiquitin worth mentioning are: the Ile36 patch, the Asp58 patch, the TEK 
box and the flexible loop (Fig. 1-1). The Ile36 hydrophobic patch, comprised of Ile36, Leu71 and 
Leu73, is involved in polyubiquitin chain formation (Suryadinata et al. 2014). The Asp58 polar 
patch binds the zinc finger UBD of Rabex-5 (guanine nucleotide exchange factor) (Fu et al. 
2012). The TEK box surface patch is essential for UBE2S and UBE2C (E2 conjugating 
enzymes) mediated Lys11-linked Ub chains catalysis (Wickliffe et al. 2011). And lastly, the 
flexible loop, located between ß-strand1 and ß-strand2 of ubiquitin, contains Leu8 which based 
on the conformation of the loop can be part of the Ile44 or Ile36 patch. The orientation of the 
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loop towards the Ile44 patch was shown to be important in Lys33-linked ubiquitin chain 
synthesis. While leaning of the loop towards Ile36 was observed in Lys6-linked Ub chains 
(Kristariyanto, Choi, et al. 2015).  
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Fig. 1-1: Ubiquitin structure depicting conserved surface motifs. Ubiquitin surface and stick 
representation (Data bank ID: IUBQ) highlighting the surface patches including the hydrophobic 
Ile44, Ile36 and Phe4 patches; the polar Asp58 patch, the TEK box and the flexible loop. 
Residues involved in forming these motifs are identified. Ubiquitin surface patches are involved 
in protein-protein interactions where the Ile44 and Phe4 patches and di-glycine C-terminal 
residues have been found essential for viability. The C-terminal tail is imperative for Ub-
substrate conjugation. (Reprinted by permission from Nature Publishing Group: Nature Reviews 
Molecular Cell Biology, (Kulathu & Komander 2012), copyright 2012).  
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   Ubiquitin is exclusively expressed as a fusion protein across all eukaryotes. These precursors 
are either N-terminal ubiquitin fusions to ribosomal protein subunits or a chain of ubiquitins 
attached head to toe. UBA52 and RPS27A ubiquitin precursors in humans (Ubi1-Ubi3 in yeast) 
are fused to two ribosomal proteins L40 and S27a (L40 and S31 in yeast), while UBB and UBC 
(similar to Ubi4 in yeast) are expressed as a chain of ubiquitin multimers attached with no spacer 
sequence (Bianchi et al. 2015; Finley et al. 2012). Attachment of even one residue to the C-
terminal tail of ubiquitin inhibits ubiquitin-protein conjugation therefore, cleavage of these 
ubiquitin precursors is essential for their function (Callis 2014; Finley et al. 2012). Abnormalities 
in expressed ubiquitin precursors are toxic to the cell and have been detected in Alzheimer’s, 
Down syndrome and liver diseases (van Tijn et al. 2011; van Tijn et al. 2007). 
 
Ubiquitination:  
 
   Ubiquitin-protein conjugation is achieved when the C-terminal glycine 76 of ubiquitin 
covalently binds to the amino group of a lysine residue on the substrate protein to form an 
isopeptide bond. Ligation of ubiquitin to a protein typically involves a three-step cascade 
mechanism: activation, conjugation and ligation (Callis 2014). Ubiquitination of the substrate 
protein is initiated when ubiquitin-activating enzyme E1 (Uba1 in yeast) adenylates Ub through 
an ATP-dependent transthiolation. This modification forms a high energy thioester bond with Ub 
glycine 76 and a thiol group of a cysteine residue in the E1 active site (Varshavsky 2012; 
Hochstrasser & Amerik 2004). Ub is then transferred to the active site cysteine residue of one of 
the ubiquitin-conjugating enzymes, E2 (or UBC) which in return catalyzes ubiquitination with 
the help of a ubiquitin-protein ligase, E3 (Finley et al. 2012). E3 ubiquitin-protein ligases 
catalyze the formation of an isopeptide bond between e-amino group of a lysine residue on the 
substrate protein and the C-terminal glycine residue of ubiquitin (Fig. 1-2) (Finley et al. 2012). 
Depending on the type of E3 enzyme involved, ubiquitin can either directly transfer from E2 to 
the substrate or first form a thioester bond with the E3 ligase which is then transferred to the 
substrate. 
   Ubiquitin moieties can be conjugated to any lysine residue on the protein, and there is no 
known consensus sequence to predict the ubiquitination site (McDowell & Philpott 2013). In 
some cases, ubiquitination has been reported on specific lysine residues, while in others no 
particular specificity has been observed. For example, yeast iso-2-cytochrome c protein is almost 
exclusively ubiquitinated on Lys13 and mammalian IκBα protein degradation is induced by 
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polyubiquitination on Lys21 and Lys22 (Baldi et al. 1996; Sokolik & Cohen 1991). While in the 
case of the T-cell receptor zeta chain, c-Jun and cyclin B, any lysine residue, even if artificially 
inserted, can form an isopeptide bond with ubiquitin (McDowell & Philpott 2013; Hou et al. 
1994). Typically ubiquitin forms an isopeptide bond with the e-NH2 group of lysine residues on 
the substrate, however, in multiple cases it was observed that removal of all surface lysine 
residues (either by substitution to arginine or by chemical reductive methylation) does not stop 
polyubiquitination and proteasomal degradation (Chicooree et al. 2013). Further, 
polyubiquitination of proteins such as p16INK4a (cell cycle inhibitor) and HPV-58 E7 (human 
papillomavirus oncoprotein) that naturally don’t contain any lysine residues was reported (Ben-
Saadon et al. 2004). Later it was shown that ubiquitin could also ligate to the N-terminal α-amino 
group of lysine-less proteins and some higher eukaryotic proteins such as MyoD (transcriptional 
activator), cyclin G1, ERK3 kinase and p21 (Noy et al. 2012; Li et al. 2009; Coulombe et al. 
2004). Furthermore, in case of Pex5p (peroxisomal import receptor), a lysine-less protein, 
polyubiquitination and degradation were still observed even when the N-terminal α-amino group 
was blocked to inhibit its ubiquitination. It was demonstrated that Pex5p both in yeast and human 
is actually ubiquitinated on a cysteine residue (Platta et al. 2014). Ubiquitin ligation to serine, 
threonine or cysteine residues forming hydroxyester or thioester bonds has been observed both in 
yeast and higher eukaryotes (McDowell & Philpott 2013).  
   A single passage through the ubiquitination cascade leads to monoubiquitination of the 
substrate while attachment of single ubiquitin moieties to multiple lysine residues on one 
substrate is referred to as multi monoubiquitination. Catalysis of the isopeptide bond between a 
lysine residue on the substrate-anchored ubiquitin and free ubiquitin leads to the formation of the 
polyubiquitin chain (Fig. 1-2) (Finley et al. 2012). Polyubiquitination at Lys48 typically 
represents a signal for proteasomal degradation, while mono or multi-monoubiquitination in 
most cases is linked to protein trafficking, localization, DNA repair, transcriptional regulation 
and proteasomal independent degradation (Callis 2014; Kulathu & Komander 2012). 
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Fig. 1-2: Schematic representation of protein ubiquitination. The E1 activating enzyme in an 
ATP dependent step forms a thioester bond with ubiquitin (Ub) C-terminal glycine. Ubiquitin is 
then passed on to the active site of an E2 enzyme. E2 with the help of an E3 ligase enzyme 
catalyzes isopeptide bond formation between e-amino group of a lysine residue on the substrate 
and terminal the carboxyl group of ubiquitin. Attachment of a single Ub moiety to the substrate 
is termed monoubiquitination while multiple rounds of ubiquitination lead to multi-
monoubiquitination or polyubiquitination of the substrate. (Reprinted by permission from 
Genetics Society of America: Genetics, (Finley et al. 2012), copyright 2012). 
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E1 Activating Enzymes: 
 
   The E1 enzyme catalyzes the first step in the ubiquitination cascade. To activate ubiquitin, the 
E1 enzyme interacts with a ubiquitin and an ATP molecule. The Ub C-terminus initially forms a 
non-covalent Ub-adenylate bond with AMP which allows the E1 enzyme active site cysteine 
residue to attack this bond, form a high energy thioester bond and release the adenylate moiety 
(Groen & Gillingwater 2015). During the ubiquitin activation process, the E1 enzyme binds a 
second ubiquitin molecule non-covalently which is important for the E1 enzyme favorable 
conformational change to transfer Ub to an E2 conjugating enzyme (Schulman & Harper 2009). 
S. cerevisiae codes for one E1 enzyme, Uba1, which is essential for viability (Ghaboosi & 
Deshaies 2007).  In humans two E1 activating enzymes have been identified, UBA1 and 
UBE1L2. The UBA1 gene codes for two essential isoforms that show high expression in all cell 
types and are recognized as the main human E1 enzymes (Groen & Gillingwater 2015). 
UBE1L2, a recently identified E1 enzyme is more tissue-specific and is mostly expressed in 
testis (Pelzer et al. 2007). Pharmacological inhibition of UBA1 activity, similar to proteasome 
inhibition, leads to cell cycle arrest and apoptosis and has been well studied as a potential anti-
cancer treatment (Lub et al. 2016; Xu et al. 2013).  
E2 Conjugating Enzymes: 
 
   Thirty-eight ubiquitin-conjugating enzymes have been identified in humans (11 in yeast) 
(Stewart et al. 2016; Ghaboosi & Deshaies 2007). E2 enzymes contain a Ub conjugating catalytic 
domain (UBC) with a conserved cysteine residue in their active site. All E2s should be able to 
interact with the E1 activating enzyme and catalyze the transfer of ubiquitin to a thiol group in 
their active site. Further, they have to be able to interact with one or more E3 ligase enzymes and 
transfer Ub thioester bond to an amino group on the substrate or to the active site of some E3 
ubiquitin ligases. (Ye & Rage 2011). Direct transfer of Ub from E2 to amino groups on the 
substrate has also been reported however, in the absence of E3 enzymes, E2s are typically 
inefficient in the transfer of ubiquitin (Ye & Rage 2011). E2s are more than just a mediator 
between E1 and E3 enzymes and show different mechanisms of action. The majority of E2 
enzymes in complex with E3 ligases (RING domain type E3s) are able to transfer Ub from their 
active site to a lysine residue on the substrate, while some E2s transfer Ub to a cysteine residue 
in the E3 enzyme’s active site (HECT domain type E3s, discussed below) (Stewart et al. 2016). 
For some E2s, such as UBE2G2 in humans (Ubc7 in yeast), transfer of polyubiquitin chain en 
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bloc to the substrate has been reported (Liu et al. 2014; Ravid & Hochstrasser 2007). 
Heterodimeric E2s, such as UBC13 in complex with Mms2 (catalytically inactive E2), promote 
Lys63-linked polyubiquitin chain formation by specifically transferring charged Ub to a 
substrate-anchored acceptor ubiquitin (Campbell et al. 2012). E2 enzymes have also been 
implicated in non-lysine ubiquitination of the substrate. In yeast, the Pex2 conjugating enzyme 
directly ubiquitinates Pex5p, a lysine-less protein, on a conserved cysteine residue (Williams et 
al. 2007). The UBE2J2 conjugating enzyme in humans can transfer ubiquitin to serine or 
threonine residues on substrate proteins. Similarly, its yeast homologue, Ubc6, is involved in 
ubiquitination of lysine-free Asi2 protein (Boban et al. 2015).  
   E2 enzymes help bring specificity to the ubiquitin pathway through selective interaction with 
different substrates and E3 ligase enzymes. For instance, depending on the type of E3 ligase it 
interacts with, Rad6/Ubc2 (UBE2A & B in humans) can promote mono or polyubiquitination 
(Imura et al. 2015). It monoubiquitinates histone H2B and proliferating cell nuclear antigen 
(PCNA), while it is also involved in N-end rule substrate polyubiquitination and degradation 
(protein degradation based on the N-terminal amino acid residues, where basic amino acids such 
as arginine and Lys are primary destabilizing due to their recognition by E3 ligases) (Kumar et 
al. 2010). Cdc34, an essential yeast E2 enzyme, and its human homologue, UBE2R1, are the 
main E2 ligases for the Skp/Cullin/F-Box (SCF) E3 ligase complex (Sandoval et al. 2015). While 
Cdc34 in complex with the San1 E3 ligase is involved in degradation of misfolded or damaged 
proteins (Finley et al. 2012). Yeast Ubc4 and Ubc5 (homologues of UBCH5 in humans) through 
interaction with Rsp5 E3 ligase recognize and monoubiquitinate misfolded proteins (Stoll et al. 
2011). While Ubc4/Ubc5 interaction with Not4p E3 ligase mediates stress response (Mulder et 
al. 2007). Also, it has been shown that in yeast Ubc1 and Ubc4 work sequentially to 
polyubiquitinate proteins involved in cell cycle progression targeted by the anaphase promoting 
complex (APC) E3 ligase. While Ubc4 supports multi-monoubiquitination of APC substrates, 
Ubc1 (and its human homologue E2-25K) promotes APC-dependent Lys48-linked ubiquitin 
chain elongation (Rodrigo-Brenni & Morgan 2007). 
E3 Ligase Enzymes:  
 
   E3 ubiquitin ligases are the largest group of enzymes involved in protein ubiquitination. They 
bring specificity to the pathway through selective substrate recognition. Based on the mechanism 
of ubiquitination and presence of the conserved domains that mediate ubiquitin transfer from E2 
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enzyme to the substrate, E3 enzymes are categorized into two major groups: The HECT domain 
(homologous to the E6-AP COOH terminus) E3 ligases and RING domain (really interesting 
new gene) E3 ligases (which also includes the U-box domain E3s) (Scheffner & Kumar 2014; 
Varshavsky 2012). The HECT domain E3s are named after human E6AP (E6 associated protein) 
enzyme which is deregulated by the E6 oncoprotein of certain human papillomaviruses. The 
HECT domain ligases mediate ubiquitination by first transferring Ub from the E2 enzyme to 
their active site’s conserved cysteine residue. This generates a thioester intermediate prior to 
transfer of ubiquitin to the substrate protein (Scheffner & Kumar 2014). In case of the RING 
domain E3s, Ub is directly transferred from ubiquitin-charged E2 enzyme to the E3 ligase-bound 
substrate (Fig. 1-3) (Finley et al. 2012; Deshaies & Joazeiro 2009). To date, bioinformatics 
analysis has identified 617 E3 ligases in humans (80 in yeast) out of which only 28 (5 in yeast) 
belong to the HECT domain E3s (Finley et al. 2012; Deshaies & Joazeiro 2009; W. Li et al. 
2008). 
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Fig. 1-3: The mechanism of ubiquitin ligation catalyzed by E3 enzymes. The HECT domain E3 
ligases initially form a thioester bond with ubiquitin on their active site cysteine residue before 
transferring Ub to the substrate. While the RING domain E3 ligases provide a platform for E2 
enzymes to directly transfer ubiquitin to the substrate. (Reprinted by permission from Genetics 
Society of America: Genetics, (Finley et al. 2012), copyright 2012). 
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The RING and U-box Domain E3 Ligases: 
 
   The RING E3 ligases belong to the zinc finger domain family of proteins that are typically 
involved in protein-protein or protein-DNA interaction. However, the RING-type zinc finger 
domain of E3s are often involved in the ubiquitin-mediated protein degradation pathway and 
especially recognize proteins such as E2 conjugating enzymes (Callis 2014). RING E3s contain 
seven cysteine and one histidine residues in their active site that coordinate two zinc ions 
(Deshaies & Joazeiro 2009). Ubiquitin-charged E2 enzymes initially interact with the zinc finger 
domain of RING E3 ligases which leads to destabilization of the Ub-E2 thioester bond and 
therefore promotes the transfer of Ub from E2 to the amino group of an E3-bound substrate (Das 
et al. 2013). U-box E3 ligases are structurally related to the RING domain E3 enzymes. The U-
box motifs similar to the zinc finger domain, interact with Ub-charged E2 enzymes however, in 
their active site instead of zinc binding cysteines and a histidine residue, they contain charged 
and polar amino acids, such as glutamic acid and serine. These residues produce a strong 
network of hydrogen bonds and salt bridges that supports the E3 enzyme’s structure and 
stabilizes its interaction with E2 enzymes (Callis 2014). Computational analysis and genome-
wide screening have identified 300 genes in humans (47 in S. cerevisiae) that code for RING 
finger domain proteins, out of which only 8 code for U-box motif containing proteins (2 in 
yeast). Including RING domain containing E3 enzyme complexes, an estimate of 616 RING or 
U-box E3 ligases are identified in humans which comprises more than 95% of the total E3 ligase 
enzymes (W. Li et al. 2008). 26 RING finger domain E3 ligases are highly conserved in 
eukaryotes from yeast to plants and humans (W. Li et al. 2008). However, not all RING finger 
domain E3s identified through bioinformatics analysis have shown E3 ligase activity. For 
example, proteins such as Hdmx and BMI1 contain a RING domain but are not active ligases 
however, their interaction with an E3 ligase, Hdm2 and RING1B respectively, stimulates 
ubiquitination activity (McGinty et al. 2014; Shadfan et al. 2012). 
 
The RBR Domain E3 Ligases: 
 
   A newly described family of the RING domain E3 enzymes with at least 14 members is 
referred to as the RBR (RING1, in between RING, RING2) domain E3 ligases (Deshaies & 
Joazeiro 2009). These enzymes that represent the second largest RING domain E3s, contain 
three RING-like domains each of which coordinates two Zn2+ ions. The N-terminal RING1 
domain highly resembles a standard RING domain E3 ligase, while the mid region and the third 
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RING motifs are more variable and do not conform to the canonical RING E3 structure (Dove et 
al. 2016). The ubiquitin-charged E2 initially interacts with the RING1 domain however, similar 
to a HECT domain E3 ligase, the Ub thioester bond is transferred to a conserved cysteine residue 
in the RING2 domain prior to its transfer to an amino group on the substrate (Spratt et al. 2014). 
All three RING-like domains in the RBR E3s are required for ubiquitin ligase activity. The RBR 
E3 ligases are complex multidomain proteins. They typically contain protein-protein interaction 
motifs in their N or C-termini which are involved in the regulation of E3 enzyme’s Ub chain 
assembly or have an inhibitory effect on the E3 activity (Spratt et al. 2014). The best studied 
RBR domain E3 ligase in humans is Parkin, which is essential for mitophagy (autophagy of 
mitochondria). Parkin contains an N-terminal ubiquitin like domain (Ubl) that contacts Parkin’s 
RING1 domain and inhibits its interaction with the E2 enzymes. Phosphorylation of the Ubl 
domain suppresses its inhibitory effect. Mutations in the Parkin gene is linked to autosomal 
recessive Juvenile Parkinson’s disease (Ham et al. 2016). 
 
The Complex RING Domain E3s: 
 
   One of the most conserved and abundant multisubunit RING domain E3s is the SCF (Skp1-
Cullin1-F-box) complex. Out of 616 RING-type ligases identified in humans about 287 genes 
code for SCF containing domains (W. Li et al. 2008). In SCF complexes, which are cullin-RING 
ligases (CRL), the E2 docking motifs and the substrate interaction motifs are on different 
subunits connected together with a cullin type protein scaffold (Zheng et al. 2016). A RING 
domain protein bound to cullin1 scaffold, such as RBX1 (RING box 1), recruits the Ub-charged 
E2 enzyme which in most cases is UBE2R1 (Cdc34 in yeast) (Sandoval et al. 2015). Skp1 (S 
phase kinase-associated protein 1) acts as a linker or adaptor that connects an F-box substrate 
binding protein to cullin1. Skp1 and cullin1 proteins are the invariant subunits of each SCF 
complex, while 69 F-box proteins that have been identified in humans bring specificity to the 
SCF complex (Gorelik et al. 2016).  
 
   The anaphase promoting complex/cyclosome (APC/C) is an essential and highly conserved 
multisubunit RING domain E3 ligase with more than ten core proteins and a minimum of 13 
subunits. Conserved Apc11 and Apc2 are the RING and cullin subunits that recruit the Ub 
charged E2 enzymes (He et al. 2013). Interaction of the APC with different activator proteins 
directs the complex’s ubiquitination activity towards certain substrates. The APC-substrate 
interaction is heavily regulated during mitosis mainly through phosphorylation. Its 
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phosphorylation by Cdk1 (cyclin-dependent kinase 1) in yeast during prophase to anaphase 
transition leads to the recruitment of Cdc20 activator protein. Cdc20 promotes the APC mediated 
destabilization of substrates such as securin and cyclin B which results in sister chromatin 
disjunction and triggers chromosome segregation (Hellmuth et al. 2015; Metzger et al. 2012; 
Deshaies & Joazeiro 2009). Replacement of the Cdc20 activator protein by Cdh1 in mitotic exit 
and G1 phase promotes the APC to target the Cdc20 itself, as well as, Aurora-A kinase and 
Cdc25 phosphatase. This leads to activation of important cell cycle regulators such as p21 and 
p27. Phosphorylation of the Cdh1 stimulates its dissociation from the APC complex and 
promotes cell cycle transition to S phase (Qiao et al. 2016; Metzger et al. 2012). The Cdc20 and 
Cdh1 activator proteins increase the APC/C activity by enhancing its interaction with the Ub 
charged E2 enzymes (Van Voorhis & Morgan 2014).  
 
   The polycomb repressive complex 1 (PRC1) is another RING domain E3 ligase complex. It is 
part of a family of multimeric complexes known as the polycomb group. Members of the 
polycomb group are involved in chromatin compaction and gene silencing and are essential for 
cell differentiation and development (Abdouh et al. 2016). The PRC1 complex is composed of 
RING1A, RING1B and BMI1 core proteins which together are involved in monoubiquitination 
of the histone H2A. The BMI1 RING finger protein is especially involved in heterochromatin 
formation in somatic cells, while RING1A/B perform ubiquitination of H2A (Lin et al. 2015). 
RING1B E3 ligase and its coactivator BMI1, recognize tri-methylated Lys27 on histone 3 (H3) 
and monoubiquitinate chromatin at H2A on Lys119. This leads to transcriptional silencing and 
has an established role in X chromosome inactivation (Vidal 2009).  
 
   The constitutive photomorphogenesis protein 1 (COP1) is a RING domain complex initially 
identified in Arabidopsis where it acts as a switch for plant growth underground in darkness 
versus growth under light exposure (Callis 2014). COP1 regulates plant’s response to the 
infrared, blue and ultraviolet lights by downregulating transcription factors that bind light-
responsive promoters (Callis 2014). In mammals, COP1 modulates glucose and lipid 
metabolism. Further, it regulates tumorigenesis through downregulation of substrates such as p53 
and c-Jun (Sanchez-Barcelo et al. 2016). The COP1 mediated downregulation of tumor 
suppressors, such as p53, p27 and 14-3-3σ, induces cell cycle progression and has been linked to 
tumorigenicity (Sanchez-Barcelo et al. 2016).  
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The HECT Domain E3 Ligases:  
 
   The HECT domain E3 ligases contain a 350-residue long conserved motif at their C-termini 
which resembles human E6AP enzyme’s C-terminus. The N-terminal extension of these 
enzymes contains different motifs or domains that mediate substrate specificity (Metzger et al. 
2012). The HECT domain itself contains two sections: The N-lobe that recruits the Ub-charged 
E2 enzymes and the C-lobe that contains a highly conserved cysteine residue required for 
intermediate thioester bond formation with ubiquitin. Structural studies have revealed that the 
two lobes of the HECT domain are flexible. Upon Ub-E2 docking on the N-lobe, conformational 
change brings the two lobes to close proximity to allow transfer of the ubiquitin from the N-lobe 
to the conserved cysteine on the C-lobe (Scheffner & Kumar 2014). The linkage type of 
ubiquitin chain assembled by the HECT domain solely depends on the C-lobe and is not affected 
by the E2 enzyme involved (Kim & Huibregtse 2009). Based on the N-terminal extensions of the 
HECT E3 ligases they are divided into three subfamilies: the Nedd4-like E3s, the HECT and 
RCC1-like domain E3s (HERC) and the “others” (Metzger et al. 2012). 
 
   The Nedd4-like E3 ligases include nine members with a characteristic N-terminal calcium-
dependent lipid binding domain (C2) followed by 2-4 WW domains (involved in protein-protein 
interaction) and a C-terminal E6AP homology domain (Scheffner & Kumar 2014). The Nedd4-
like E3s have a significant role in cancer development through regulation of trafficking and 
stability of proteins that are linked to tumorigenesis, such as SMAD, p53 and Jun families (Chen 
& Matesic 2007). Nedd4 (Neural precursor cell-expressed developmentally downregulated gene 
4) is the first member of this subfamily that was identified and is highly conserved and essential 
for viability among all eukaryotes. Nedd4 is mostly involved in the regulation of membrane 
proteins and promotes their endocytosis (Scheffner & Kumar 2014). It has been shown that viral 
matrix proteins expressed by Ebola virus, retrovirus and Epstein-Barr virus interact with Nedd4 
leading to their ubiquitination and recognition by the cellular ESCRT complex (endosomal 
sorting complex required for transport) which is important for their eventual budding from the 
host cell (Sette et al. 2013; Blot et al. 2004).  
   The human HERC E3 subfamily has six members (HERC1-6). These unusually large proteins, 
reaching up to 500 kDa, harbor one to three RLDs (RCC1-like domains) and one E6AP 
homology domain (Sanchez-Tena et al. 2016). RCC1 (Regulator of chromosome condensation 1) 
is a guanine nucleotide exchange factor (GEF) for small GTP-binding protein (also known as 
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Ran). The RLDs consist of seven repeats of a 50-70 residue motif and have dual functions as a 
GEF and E3 ubiquitin ligase. One end of the RCC1 functions as GEF and interacts with the small 
GTP-binding protein, while the other end contacts histones to allow interaction with the 
chromatin (Hochrainer et al. 2005). HERC1 is the first identified member of the HERC E3 
ligases. It’s a 530 kDa protein that acts as a GEF for ARF1 (ADP-ribosylation factor 1, a GTP 
binding protein) however, it does not ubiquitinate ARF1 suggesting that HERC1 has separate 
substrates for the GEF and E3 ligase activities (Sanchez-Tena et al. 2016; Diouf et al. 2011).  
 
   The “others” members of the HECT domain E3 ligases do not contain the C2-WW-HECT 
structure of the Nedd4-like E3s or the RCC1-like domain of the HERCs. The best example of 
such HECT E3 enzyme is E6AP, the first HECT domain E3 ligase that was identified in HPV 
infected cells associated with cervical cancer (Scheffner & Kumar 2014). The E6AP (expressed 
from UBE3A gene) was found as a binding partner with the HPV E6 oncoprotein. In HPV 
infected cells, the E6 viral protein induces interaction of the E6AP E3 ligase with proteins that 
are not its cellular substrates, such as p53, and leads to their ubiquitination and degradation, 
which contributes to HPV mediated cervical cancer (Mortensen et al. 2015). E6AP is known to 
function as both coactivator and downregulator of the steroid hormone receptors, such as 
estrogen, progesterone and androgen (Ramamoorthy et al. 2012). Mutations in the E6AP gene 
that cripple its activity have been linked to Angelman syndrome, a neurodevelopmental disorder 
(Margolis et al. 2015). 
 
E4 Ligase Enzymes: 
 
   A relatively new class of ubiquitin ligases known as E4, ubiquitin chain assembly factor, 
selectively interact with previously ubiquitinated proteins and catalyze elongation of the 
ubiquitin chain. These enzymes cannot ubiquitinate proteins that are not previously ubiquitinated 
by an E3 ligase enzyme (Micel et al. 2013). For instance, p300, an E4 enzyme, is involved in 
polyubiquitination of p53 following its mono or multi-monoubiquitination by Hdm2 (Crosas et 
al. 2006). Ufd2 is the first E4 ligase that was identified in yeast. Its human homologue, UBE4B 
(ubiquitin factor E4B), similar to the p300 is involved in polyubiquitination of p53 (Micel et al. 
2013). It acts as a cofactor for Hdm2 and catalyzes elongation of Ub chains on p53, which leads 
to p53 instability and inhibition of its transactivation. Overexpression of the UBE4B is observed 
in colon cancer, breast cancer, promyelocytic leukemia and medulloblastoma, whereas deletion 
of the UBE4B gene results in apoptosis of cancer cells (X.-F. Zhang et al. 2016; Li et al. 2003). 
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Ubiquitin-Like Proteins: 
 
   In recent years, a number of ubiquitin-related family of proteins have been identified that share 
the same beta-grasp structure. Ub-like proteins (Ubls) employ a pathway homologous to the 
ubiquitination for conjugation to their substrates. These three-step enzymatic cascades, similar to 
ubiquitination, utilize E1, E2 and E3 enzymes specific to each type of Ubl involved (Ronau et al. 
2016). Other than the Nedd8 the rest of the identified Ubls, such as SUMO, ISG15 and Fat10 do 
not show much sequence similarity to ubiquitin. SUMO (small ubiquitin-related modifier) is the 
most abundant Ubl in the cell after ubiquitin. Mixed linkages of SUMO-Ub have also been 
reported (Ronau et al. 2016). Nedd8 is highly related to the ubiquitin both in sequence and 
structure and similarly contains a conserved Ile44 hydrophobic patch, which is important for its 
protein-protein interaction (Soucy et al. 2009). Nedd8 interacts with the CRL (Cullin-RING 
ubiquitin ligase) enzyme complexes and facilities transfer of Ub to the substrate. Neddylation of 
the CRLs is essential for their enzymatic activity and substrate ubiquitination. In conjugation 
with the CRL enzymes, Nedd8 also regulates rate of substrate ubiquitination and degradation 
(Zhao & Sun 2013). Similar to the ubiquitination pathway Nedd8 is activated by Nedd8 
activating enzyme. Activated Nedd8 is then transferred to Nedd8 specific E2 enzymes, UBC12 
or UBE2F, through transthiolation. UBC12 or UBE2F process the transfer of Nedd8 to a 
conserved Lys residue at the C-terminal end of cullin protein of the CRL complex (Zhao & Sun 
2013). Nedd8 interaction with the CRL complex leads to conformational changes that are 
necessary for CRL interaction with the Ub-charged E2 enzymes (Micel et al. 2013; Soucy et al. 
2009).  
 
Functional Diversity in Ubiquitination Patterns: 
  
   Ubiquitin contains seven lysine residues including: Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 
and Lys63 and a signature glycine-glycine C-terminal end (Fig. 1-4) (Trempe 2011). Each of 
these lysines can form an isopeptide bond with another ubiquitin to form a Ub-Ub chain of 
uniform linkage (homotypic) with seven possible linkage types. Ubiquitin can also bind the N-
terminal amino group of another ubiquitin and form a Met-linked or linear linkage chain (Fujita 
et al. 2014; Trempe 2011; Dikic et al. 2009). Mixed-linkage (heterotypic) polyubiquitin chains 
have also been reported however, their significance is not well understood (Husnjak & Dikic 
2012; Dikic et al. 2009). Ub-Ub linkage types lead to the formation of chains that are structurally 
different and produce distinct signals. Lys48-linked ubiquitin chains, which are essential for 
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viability, are the most abundant linkage-type both in humans (52%) and yeast (29%) however, 
Lys63 at 38% is the second most abundant in humans, while Lys11 at 28% forms the second 
most abundant linkage in yeast followed by Lys63 at 16% (Trempe 2011). 
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Fig. 1-4: The ubiquitin structure. Ubiquitin contains seven lysine (Lys) residues (shown as 
sticks). Each of these lysine residues can form an isopeptide bond with another ubiquitin to 
produce a Ub-Ub chain with seven possible structurally different linkage types. The white 
surface representation refers to the hydrophobic Ile44 patch. The N and C-terminal domains have 
been identified. (Reprinted by permission from Elsevier: Current Opinion in Structural Biology, 
(Trempe 2011), copyright 2011). 
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   Monoubiquitination is the first step to start assembly of the polyubiquitin chain. On its own 
monoubiquitination in the majority of the known cases is implicated in protein localization, 
membrane receptor internalization, transcription regulation and DNA repair. For instance, 
RING1B component of the PRC1 E3 ligase complex monoubiquitinates histone H2A, which 
leads to chromatin compaction and gene silencing (Abdouh et al. 2016). Recent findings indicate 
that mono or multi-monoubiquitination of the substrate can also lead to proteasomal degradation. 
For instance, multi-monoubiquitination of cyclin B1 catalyzed by the APC complex along with 
the UBCH10, E2 ligase, results in its proteasomal degradation (Dimova et al. 2012). Further, it’s 
been reported that monoubiquitination of small proteins (about 20 residues long) on their N-
terminal α-amino group also leads to their rapid proteasomal degradation (Kravtsova-Ivantsiv & 
Ciechanover 2012). 
   
   Lys48-linked polyubiquitin chains of four or more ubiquitins are efficiently recognized by the 
26S proteasome and target proteins for proteolytic degradation (Varshavsky 2012). Under 
physiological conditions, the hydrophobic Ile44 patch on the ubiquitin mediates compact Lys48-
linked chain formation resulting in an intermolecular interface between the two joint ubiquitin 
molecules, which involves residues Leu8, Ile44 and Val70 of the hydrophobic patch (Fig. 1-
5)(Suryadinata et al. 2014; Kulathu & Komander 2012). NMR studies have revealed a less 
favorable conformation for Lys48 linkage under acidic conditions (pH6.8) which is formed 
through the interaction of the Ile44 hydrophobic patch of one ubiquitin with the Ile36 patch of 
another (Suryadinata et al. 2014). The hydrophobic patch on the ubiquitin surface not only is 
essential for Lys48 compact chain formation, but it is also important for the interaction of these 
chains with the 26S proteasome subunits (Husnjak & Dikic 2012). Further, proteins known as 
proteasome shuttling receptors, such as Rad23 in yeast (HR23B in humans), specifically 
recognize Lys48-linked Ub chains and shuttle tagged proteins to the proteasome (Shi et al. 
2016). 
   Lys63-linked Ub chains, both in humans and yeast, have non-proteolytic function and are 
implicated in DNA repair, intercellular protein trafficking, endocytosis and vacuolar 
protein sorting (Trempe 2011). Lys63 linkage has open conformation in which the two ubiquitin 
molecules are only connected through the linkage point (Fig. 1-5)(Kulathu & Komander 2012). 
Both Lys48 and Lys63 ubiquitinated proteins can bind pure proteasome with similar affinities in 
vitro however, Lys63 Ub chains do not affect the stability of the substrate proteins in vivo (Xu et 
al. 2009). Further, proteasome inhibition does not increase cellular levels of Lys63 linkage type, 
 22 
confirming the non-proteolytic function of these chains (Kim et al. 2011). It was shown that 
compared to the Lys48-linked polyubiquitin chains, Lys63 chains are much faster disassembled 
from the tagged proteins, which inhibits their recognition by the proteasome (Nathan et al. 2013). 
Also, several proteins and complexes such as ESCRT0 have been identified that specifically and 
tightly interact with the Lys63-linked Ub chains and block their interaction with the proteasome 
(Nathan et al. 2013).  
 
   Lys11-linked polyubiquitin chains are mostly involved in the endoplasmic reticulum (ER) 
associated degradation and mitophagy (Grice & Nathan 2016). In addition, Lys11 linkage 
catalyzed by the APC E3 ligase complex on the cell cycle proteins, such as cyclin B1 and 
securin, has been found important for cell cycle progression (Min & Lindon 2012). Lys11-
connected ubiquitins form a compact structure with an intermolecular interface mediated through 
the Ile36 patch (Fig. 1-5)(Kulathu & Komander 2012). It has been reported that the Ly11-linked 
Ubs do not efficiently lead to proteasomal degradation however, a recently identified heterotypic 
Ly11/Lys48 mixed chain catalyzed by the APC on the cell cycle proteins, such as cyclin A, is 
recognized by the proteasome and leads to downregulation of the tagged protein. Proteasome 
inhibition has led to the enrichment of the Lys11 chains indicating their proteolytic function 
(Swatek & Komander 2016; Ikeda & Dikic 2008). In contrast to steady levels of the Lys48 and 
Lys63 linkage types, cellular levels of the Lys11-linked Ub chains are cell cycle dependent and 
significantly increase following mitosis (Kulathu & Komander 2012).  
 
   Linear ubiquitin chains (also referred to as Met-linked) have open conformation in which 
Gly76 of one ubiquitin forms an isopeptide bond with the α-amino moiety of the methionine 
residue of another ubiquitin (Fig. 1-5) (Kulathu & Komander 2012). Linear ubiquitin chain 
assembly complex (LUBAC), an RBR E3 ligase, is the only identified E3 ligase that produces 
Met-linked polyubiquitin (Iwai 2011). The LUBAC mediated linear chains have been shown 
important in the regulation of the tumor necrosis factor (TNF) and activation of the nuclear 
factor κB (NF-κB) transcription factor. Linear-linked Ubs were identified on NEMO, a subunit 
of the Inhibitor-of-κB kinase (IKK), which further linked linear ubiquitination to the IKK 
degradation, NF-κB activation and cell death (Swatek & Komander 2016; Iwai et al. 2014). In 
addition, Met-linked polyubiquitination of certain proteins, such as PCNA (a replication clamp 
protein), NPL4 (nuclear protein localization4) and UFD1 (ubiquitin fusion degradation 1), 
efficiently promotes their proteasomal degradation (Kravtsova-Ivantsiv & Ciechanover 2012).  
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   Lys6-linked ubiquitin chains form a compact structure mediated through the Ile44 and the 
Ile36 patches of each ubiquitin (Fig. 1-5). Proteasomal inhibition does not lead to accumulation 
of the Ly6-linked chains indicating their non-proteolytic function (Swatek & Komander 2016). 
One study showed that Lys6 and Lys33-linked chains largely increase upon UV stress, 
associating Lys6 ubiquitination with the DNA damage response (Elia et al. 2015). The Lys6 
linkage has also been implicated in mitochondrial degradation. In fact, mutation of the 
ubiquitin’s Lys6 resulted in the delay in mitophagy (Ordureau et al. 2015). 
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Fig. 1-5: Crystal structure of the different ubiquitin linkage types. Surface representation of the 
diubiquitins in varying linkage types including: Lys48, Lys63, Met-linked (or linear linkage), 
Lys11 and Lys6 are shown (Protein Data Bank IDs: 2XK5, 3NOB, 1AAR, 2JF5 and 2W9N). 
The hydrophobic Ile44 (in blue) and Ile36 (in green) patches involved in the intermolecular 
interactions are indicated. (Reprinted by permission from Nature Publishing Group: Nature 
Reviews Molecular Cell Biology, (Kulathu & Komander 2012), copyright 2012). 
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   The other linkage types, Lys27, 29 and 33, have been detected in very low levels in the cell and 
their role in the proteasomal degradation is not well understood. Ring finger E3 ligase, RNF168, 
was shown to polyubiquitinate histone H2A with Lys27-linked ubiquitins, which was 
upregulated in response to DNA double-strand breaks. The Lys27 linkage is implicated in DNA 
damage response and leads to recruitment of DNA double-strand break response proteins such as 
p53 binding protein (53BP1) and breast cancer associated gene 1 (BRCA1) to DNA damage 
response foci (Gatti et al. 2015). Lys29-linked chains are assembled by UBE3C, a HECT domain 
E3 ligase, and have been linked to proteasomal degradation (Kristariyanto, Abdul Rehman, et al. 
2015). Lys33-linked Ub chains are assembled by AREL1, HECT E3 ligase, and are implicated in 
Golgi membrane trafficking (Yuan et al. 2014).  
 
 Modifications of the Ubiquitin:   
 
   It has been noted that Ub itself can be further phosphorylated, acetylated or modified by the 
other Ubls (Swatek & Komander 2016). For instance, ubiquitin is targeted for SUMOylation on 
Lys6, Lys11, Lys27, Lys48 and Lys63. Proteasome inhibition leads to upregulation of the Lys6 
and Lys27 SUMO-conjugated ubiquitins suggesting their role in protein degradation (Hendriks 
et al. 2014). Acetylation of the ubiquitin was readily detected on the Lys6 and Lys48. Even 
though acetylation did not interfere with the monoubiquitination, Lys11, Lys48 and Lys63 chain 
elongation of the Ac-Ub was interrupted. Histone H2B has been identified as a substrate for the 
Ac-Ub modification (Ohtake et al. 2015). PTEN induced protein kinase 1 (PINK1) 
phosphorylates ubiquitin on Ser65 as its main substrate. Phospho-ubiquitin is required for the 
optimal activation of Parkin, E3 ligase enzyme, and ubiquitination of the damaged mitochondria 
(Matsuda 2016). 
  
The 26S Proteasome: 
 
   The proteasome is a 2.5 MDa complex with 33 identified subunits and two major sub-
complexes:  The 20S core particle (CP) and the 19S regulatory particle (RP) (Grice & Nathan 
2016). The barrel-shaped CP contains two outer rings of subunits known as the alpha-rings (α1-
7) and two inner beta rings (ß1-7). CP subunits ß1, ß2 and ß5, which form the proteolytic active 
site, are threonine proteases with chymotrypsin, trypsin and caspase-like proteolytic activity 
(Grigoreva et al. 2015). The 19S RP is composed of 10 base subunits and 9 lid subunits that are 
involved in ubiquitinated substrate recognition, ubiquitin tag removal as well as unfolding and 
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translocation of the protein through the proteasome gate. The 19S RP base subunits anchor the 
19S RP to the alpha ring of the CP. The ATPase regulatory particles of the base subunits, Rpt1-6, 
form a heterohexameric ring that contacts the CP. They use ATP hydrolysis to unfold the 
substrate protein and transfer it through the open gate of the CP (Grigoreva et al. 2015; Finley 
2009). Other than the 6 ATPase subunits of the RP, the non-ATPase (Rpn) subunits are only 
conserved in eukaryotes and are suggested to have evolved mostly for ubiquitinated substrate 
recognition and processing (Finley et al. 2012). Rpn1, 2 and 13 along with the 6ATPase subunits 
form the RP base (Grigoreva et al. 2015). The 19S RP lid is consists of the Rpn3 and Rpn5-12, 
which are mainly involved in the removal of the ubiquitin tag from the substrate. Rpn11 is a 
metalloprotease deubiquitinating enzyme that efficiently removes Ub tags from the substrate 
before protein translocation into the CP. Rpn10 (S5a) and Rpn13 subunits are known as the 
ubiquitin receptors. They bind ubiquitin chains in an ATP dependent manner with a very high 
affinity (Fig. 1-6A)(Hamazaki et al. 2015). It has been shown that Lys48-linked Ub-chains on 
the tagged proteins interact with the proteasome by initially contacting Rpn10 and Rpn13 
subunits (Hamazaki et al. 2015). The 19S RP subunits also interact with the ubiquitin like 
domains of the shuttling proteins, such as Rad23 in yeast (hHR23A & B in humans), that contain 
Ubl-UBA (ubiquitin associating) domain. The Ubl domains of the shuttling receptors interact 
with the proteasome subunits, such as Rpn1 and Rpn13, while the UBA domain binds the 
ubiquitin chain on the substrate (Fig. 1-6B)(Grigoreva et al. 2015; Chen & Madura 2006).  
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Fig. 1-6: Schematic representation of the proteasome ubiquitin receptors. A) Rpn10 and Rpn13 
subunits of the 19S RP contact polyubiquitin chains on the substrate, specially Lys48-linked 
Ubs, with high affinity and in an ATP dependent manner. B) The Ubl domains of the shuttling 
receptors contact 19S RP subunits, such as Rpn1 and Rpn10, while their UBA domain binds 
ubiquitin chain on the substrate. (Reprinted by permission from Creative 
Commons (http://creativecommons.org/licenses/by/4.0/): Cellular and Molecular Life Sciences, 
(Grice & Nathan 2016), copyright 2016).  
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Deubiquitinating Enzymes: 
 
   Ubiquitin is a long-lived protein despite its covalent fusion to rapidly degrading substrates. 
This is due to the ubiquitin’s efficient removal from the Ub-tagged proteins and disassembly of 
the ubiquitin chains by deubiquitinating enzymes (DUBs). DUBs catalyze the hydrolysis of the 
isopeptide bond between the carboxyl terminal glycine (Gly76) of the ubiquitin and the lysine 
residue of a tagged substrate protein or another ubiquitin (Phillips & Corn 2015; Hershko 2005). 
A computational bioinformatics analysis has identified 84 potential deubiquitinating enzymes in 
the human genome (20 in yeast S. cerevisiae) (Ye et al. 2009). Based on their conserved catalytic 
domains DUBs are grouped into five major families of thiol and metalloprotease (Fig. 1-7) 
(Wolberger 2014; Nijman et al. 2005). Four of the DUB families including, ubiquitin specific 
proteases (USP), ubiquitin C-terminal hydrolases (UCH), ovarian tumor domain-containing 
proteases (OTU) and Machado Joseph disease domain (MJD) are thiol proteases. They have 
similar catalytic activity to papain enzyme, a cysteine isopeptidase. The fifth family of DUBs are 
ubiquitin specific metalloproteases that are related to the JAB1/ MPN/Mov34 (JAMM) domain 
metalloenzymes (Sahtoe & Sixma 2015). In addition, a new family of DUBs named MINDY 
(motif interacting with Ub-containing novel DUB family) has been recently described that 
belongs to the cysteine proteases superfamily (Abdul Rehman et al. 2016).  
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Fig. 1-7: Five families of the deubiquitinating enzymes (excluding MINDY DUBs). Proteases 
are shown in green and Ub molecule in blue. Active site Cys, Asn, Asp and His residues are 
shown as Van der Waals spheres (with carbon in gray, nitrogen in blue, oxygen in red, sulfur in 
orange and zinc ion in purple). USP, ubiquitin specific proteases (USP7 structure, 1nbf); OTU, 
ovarian tumor domain proteases (OTUB2 structure, 1tff); UCH, ubiquitin C-terminal hydrolases 
(UCH-L3 structure, 1xd3); MJD, Machado Joseph disease domain proteases (Ataxin-3 structure, 
1yzb); JAMM, JAB1/MPN/Mov34 domain metalloenzymes (AfJAMM structure, 1r5x). 
(Reprinted by permission from Elsevier: Cell, (Nijman et al. 2005), copyright 2005).  
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   The activity of the cysteine proteases relies on the function of a highly-conserved cysteine, 
histidine and aspartate/asparagine catalytic triad. Polarized aspartic acid/asparagine assists 
histidine to deprotonate the thiol group of the cysteine residue. Then deprotonated cysteine 
launches a nucleophilic attack on the substrate’s isopeptide carbonyl group carbon to form an 
intermediate thioester bond. Histidine then donates a hydrogen to the ε-amino group of the 
substrate’s leaving Lys residue and tetrahedral intermediate collapses. Remaining acyl-enzyme 
intermediate is then hydrolyzed to free the enzyme and form a carboxylic acid group on the 
remaining distal ubiquitin (Fig. 1-8) (Eletr & Wilkinson 2014; Clague et al. 2013; Katz et al. 
2010). 
 
   Metalloproteases coordinate a Zn2+ ion in their active site typically with the help of two 
histidines, an aspartic acid and a water molecule. The water molecule is bound to Zn2+ ion and a 
conserved glutamic acid. Glutamic acid deprotonates water and activates it into a potent 
nucleophile. Activated water molecule launches a nucleophilic attack on the substrate’s 
isopeptide carbonyl group carbon. Then glutamic acid acts as a proton donor and transfers a 
hydrogen to the ε-amino group of the leaving protein’s lysine residue. Tetrahedral intermediate 
collapses by forming a carboxylate group on the distal ubiquitin and releases the enzyme 
(Shrestha et al. 2014).  
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Fig. 1-8: Schematic representation of cysteine protease DUBs (USPs) mechanism in cleaving a 
diubiquitin chain. A) The catalytic triad residues, Asp, His and Cys, mediate cleavage of the 
isopeptide bond. B) Aspartic acid assists histidine to deprotonate the thiol group of the Cys, 
which in turn launches a nucleophilic attack on the substrate’s isopeptide carbonyl carbon. C) A 
negatively charged tetrahedral intermediate forms. Then histidine donates a proton to the ε-
amino group of the leaving Lys residue on the proximal ubiquitin. D) Tetrahedral intermediate 
collapses leading to the release of the proximal ubiquitin and leaving behind an acyl-enzyme 
intermediate. E-G) Acyl intermediate is hydrolyzed to free the enzyme and form a carboxylic 
acid group on the remaining substrate. Covalent bonds (in black), isopeptide bonds (in red) and 
noncovalent bonds (in yellow) are shown. (Reprinted by permission from APS Journals: 
Physiological Reviews, (Clague et al. 2013), copyright 2013).  
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Ubiquitin Specific Proteases (USP): 
 
   USPs (Ubps in yeast) represent the largest DUB subclass. Out of 84 DUBs identified in 
humans, 56 belong to the USP family (16 out of 20 DUBs in S. cerevisiae) (Davis & Simeonov 
2015; Nijman et al. 2005). USPs/Ubps share two highly conserved motifs known as His and Cys 
boxes that contain the catalytic triad residues in the active site pocket. Research on yeast and 
mammalian cells indicate that despite highly conserved sequences in the USPs’ catalytic 
domains, USPs/Ubps have diverse functions and show substrate specificity. This arises from 
different insertions in their catalytic domains and terminal extensions, which modulate their 
cellular localization and protein-protein interaction (Davis & Simeonov 2015). Resolved 
structures of the USP enzymes (except for CYLD, tumor suppressor protein) revealed a 
conserved extended right hand-like architecture consists of the thumb, palm and fingers 
subdomains (Sato et al. 2015). The active site is located in a cleft between the thumb and the 
palm structures and the fingers subdomain helps positon the ubiquitin C-terminal glycine within 
the active site (Reyes-Turcu et al. 2009). Some USP enzymes, such as USP7, have misaligned 
catalytic triad. Realignment of the catalytic resides is typically achieved through interaction with 
the ubiquitinated substrate or regulatory proteins (Faesen et al. 2012; Hu et al. 2002). 
 
Ubiquitin C-Terminal Hydrolases (UCH):  
 
   Four UCH domain DUBs have been identified in humans (one in yeast). UCH-L1 and UCH-
L3, which only consist of a catalytic domain (about 230 residues), are involved in the removal of 
short peptides from the C-termini of the ubiquitin precursors and cannot cleave polyubiquitin 
chains (Zhou et al. 2012). Also, UCH-L1 and UCH-L3 are implicated in the removal of 
accidental ubiquitin C-terminus thiol or amine adducts that are formed during the thioester 
intermediate bond formation (Clague et al. 2013). Large UCH enzymes, UCH37 and BRCA1-
associated protein 1 (BAP1) with 100 and 500 residues extension at their C-termini respectively, 
are able to cleave polyubiquitin chains (Zhou et al. 2012). It was shown that UCH37, a 
proteasome-associated DUB in humans, can hydrolyze Lys48-linked ubiquitins. The ability of 
these enzymes to catalyze the cleavage of Ub chains depends on the length of the loops that 
hover over the UCH domain active sites. UCH37 and BAP1 compared to UCH-L1 and UCH-L3 
have longer crossover loops (over 14 residues long), which provide more flexibility and larger 
access to the catalytic triad allowing them to cleave diubiquitins as well as polyubiquitin chains 
(Zhou et al. 2012). 
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Ovarian Tumor Related Proteases (OTU): 
 
   The OTU catalytic domain is about 150-350 residues long and resembles the ovarian tumor 
gene implicated in the development of fruit fly ovaries (Balakirev et al. 2003). Sixteen OTU 
DUBs have been identified in humans (two in yeast) which are further categorized into three 
classes: the OTUs, the Otubains and the A20-like OTUs. OTU DUB enzymes are typically 
involved in the regulation of the signaling pathways. For instance, A20, Cezanne and OTULIN 
regulate NF-κB signaling while OTUD5 regulates interferon signaling cascade (Mevissen et al. 
2013). Further, OTU domain DUBs show high specificity towards cleaving one or two types of 
Ub linkages. For instance, human OTUB1, A20 and yeast Otu1 specifically recognize Lys48-
linked Ub chains, while Cezanne cleaves Lys11-linked chains, TRABID recognizes Lys29 and 
Lys33 linkages and OTULIN hydrolyzes linear-linked Ubs (Mevissen et al. 2013).    
  
Machado Joseph Disease/Josephin Domain (MJD) Proteases:  
 
   Four DUBs in humans contain the ~180 residue-long MJD domain, including Ataxin-3, 
Ataxin-3L, Josephin-1 and Josephin-2 (Costa & Paulson 2012). MJD domain DUBs have been 
implicated in the Machado-Joseph disease, the most common spinocerebellar ataxia and fatal 
neurodegenerative disorder caused by polyglutamine expansion (beyond ~ 44 glutamines) in 
Ataxin-3 (Costa & Paulson 2012). MJD DUBs contain a catalytic domain at their N-termini and 
multiple ubiquitin interacting motifs (UIM) at their C-termini. For instance, Ataxin-3 contains a 
Josephin domain at its N-terminus and two UIMs followed by polyglutamine chain and a third 
UIM at its C-terminus (Clague et al. 2013).   
 
JAB1/ MPN/Mov34 Domain (JAMM) Proteases: 
 
   The JAMM domain DUBs are metalloproteases related to the MPN (Mpr1-Pad1-N-terminal) 
family of proteins, which are also conserved in prokaryotes (Eletr & Wilkinson 2014). Fourteen 
JAMM domain-containing proteins have been identified in humans, one in yeast (Rpn11) out of 
which only six have shown deubiquitinase activity, including BRCC36, Rpn11 (also known as 
POH1), CSN5, MYSM1, AMSH and AMSH-LP (AMSH-like protein) (Shrestha et al. 2014). 
The JAMM domain DUBs such as Rpn11, an essential proteasomal subunit, tend to cleave 
polyubiquitin chains in whole from the substrate and show a high preference for Lys63 linkage 
type. Also, they typically function as part of a large multisubunit complex (Clague et al. 2013). 
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For instance, Rpn11 is a subunit of the proteasome 19S RP, AMSH is a component of the 
ESCRT transport machinery, CSN5 functions as part of the COP9 signalosome (CSN), BRCC36 
is associated with the BRISC and BRCA1-RAP180 complexes (involved in DNA repair) and 
MYSM1 is a histone H2A deubiquitinating enzyme that functions as part of the p/CAF complex 
(p300/CBP- associated factors, a histone acetyltransferase complex) (Bueno et al. 2015; Le Guen 
et al. 2015; Patterson-Fortin et al. 2010). 
 
MINDY Domain Proteases: 
 
   MINDY is a recently described family of cysteine protease deubiquitinating enzymes with a 
high preference for Lys48-linked polyubiquitin chain hydrolysis. Its orthologues have been 
identified in humans as well as in plants and budding yeast (Abdul Rehman et al. 2016). Crystal 
structure of the MINDY-1 catalytic domain, a member of the MINDY DUBs, resembles a “light 
bulb”, consisting of the base of the bulb “stalk” and the “bulb” (Fig. 1-9) (Abdul Rehman et al. 
2016). The catalytic domain structure also revealed that catalytic Cys137 and His319 are not 
within the hydrogen bond distance and therefore are in an unproductive state. However, the 
structure of the MINDY-1 catalytic domain in complex with propargylated ubiquitin showed 
conformational change in a “Cys loop” that tends to occlude access to the active site and helped 
realign the active site residues into a productive conformation (Abdul Rehman et al. 2016). 
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Fig. 1-9: MINDY-1 catalytic domain structure. Structure resembles a light bulb with two 
subdomains consisting of “bulb” and “bulb stalk”. Catalytic Cys137 and His319 are identified. 
Blocking ß2- α1 loop (Cys loop) hovering over active site is shown in cyan. (Reprinted by 
permission from Creative Commons (Creative Commons Attribution License (CC BY)): 
Molecular Cell, (Abdul Rehman et al. 2016), copyright 2016).  
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Cellular Functions of DUBs: 
 
   The major role of the ubiquitin pathway is tagging proteins for proteolytic destruction 
therefore, deubiquitinating enzymes are essentially involved in protein stabilization. DUBs are 
important regulators of the ubiquitin-proteasome system. Prior to degradation of proteins by the 
26S proteasome, DUBs remove polyubiquitin chains and assist in the unfolding of the protein 
and its translocation into the proteasome CP chamber (Finley 2009). Recycling of the Ub chains 
from the tagged proteins is essential for preserving available ubiquitin pool for cellular functions 
(Hochstrasser & Amerik 2004). Further, DUBs are known to deubiquitinate and stabilize 
enzymes that are involved in the ubiquitin-proteasome pathway, such as auto-ubiquitinating E3 
ligases. In addition, ubiquitin is expressed with a C-terminal extension. Proper cleavage of the 
Ub precursors is essential for the production of functional ubiquitins (He et al. 2016). DUBs are 
also involved in nonproteolytic functions such as regulation of transcription through 
deubiquitination of histone H2A and H2B (Emre et al. 2005; Henry et al. 2003). Further, DUBs 
through the removal of Lys63-linked chains or single ubiquitin tags regulate cellular levels of 
proteins that are targeted for endocytosis and degradation in lysozymes (Dupre & Haguenauer-
Tsapis 2001). 
 
DUBs Associated with the Proteasomal Degradation: 
 
   Three DUBs are known to associate with the 26S proteasome in humans (two in yeast) 
including UCH37, USP14 (Ubp6 in yeast) and Rpn11 (also Rpn11 in yeast). UCH37 and USP14 
transiently interact with the proteasome, while Rpn11 is an essential subunit of the 19S RP lid 
(Eletr & Wilkinson 2014). 
 
   UCH37, a UCH domain DUB, interacts with the C-terminal domain of Rpn13/Adrm1 ubiquitin 
receptor subunit of the 19S RP lid (Jiao et al. 2014). It has been shown that the C-terminal 
domain of the UCH37 has an inhibitory effect on its deubiquitination activity. Interaction of the 
UCH37 with Rpn13 releases the inhibition and brings UCH37 enzyme to close proximity of the 
polyubiquitin tag on the substrate, allowing it to remove distal ubiquitins from the chain 
(VanderLinden et al. 2015). The decrease in the cellular levels of UCH37 leads to increase in 
degradation of the proteasomal substrates suggesting a role for UCH37 in the stabilization of the 
ubiquitin-tagged proteins (Wang et al. 2014; Al-Shami et al. 2010). 
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   USP14 and its yeast orthologue, Ubp6, are non-essential cysteine proteases. They contain a 
conserved Ubl domain in their N-termini which is necessary for their interaction with Rpn1 
subunit of the 19S RP. The Ubl domain interaction with the proteasome increases USP14/Ubp6 
ubiquitin-substrate hydrolysis activity by ~300-1000 folds (Selvaraju et al. 2015). USP14/Ubp6 
similar to UCH37 remove single ubiquitin moieties from the distal end of a polyubiquitin chain 
with a high preference for Lys48 linkage. Deletion of the USP14 gene in mice or UBP6 gene in 
yeast leads to depletion of the free cellular ubiquitin pool indicating their important role in 
recycling ubiquitin (M. J. Lee et al. 2011). Ubp6 was shown to interact with and catalytically 
oppose the function of Hul5 (KIAA10 in mammals), a proteasome-associated HECT domain E3 
ligase (Aviram & Kornitzer 2010). Knockdown of USP14 in human cells or deletion of Ubp6 in 
yeast increases proteolytic degradation of proteins (Bashore et al. 2016).  
 
   Rpn11/POH1, a metalloprotease, is essential for viability in yeast and cell growth in humans. 
RNA interference knockdown of Rpn11 leads to accumulation of ubiquitinated proteins and 
defect in proteasome function due to proteasomal instability and disruption its assembly (Saunier 
et al. 2013; Koulich et al. 2008). Rpn11 dependent deubiquitination activity requires ATP 
hydrolysis and an intact proteasome. Also, unlike UCH37 and USP14, Rpn11 acts as an 
endopeptidase and tends to cleave Ub-chains in whole from their proximal end. It was observed 
that Ubp6 interaction with the proteasome 19S RP strongly interferes with Rpn11 
deubiquitination activity and helps stabilize substrates (Bashore et al. 2016; Koulich et al. 2008). 
 
DUBs Associated with Endocytosis and Protein Trafficking: 
 
   Many membrane proteins, such as receptors (especially tyrosine kinases) and channels, are 
downregulated through endocytosis and trafficking to the lysosomes. Monoubiquitinated or 
Lys63-linked polyubiquitinated membrane proteins bind UBD of the ESCRT complex and form 
sorting endosomes which mature into multivesicular bodies (MVBs). MVBs fuse with the 
lysosome and release ubiquitinated proteins into the vacuole (Olmos & Carlton 2016; Carlton 
2010). Ubiquitin tags must be removed prior to fusion of the MVBs with the lysosome. The 
ESCRT complex, is composed of four major subcomplexes, including ESCRT-0, I, II and III, 
and similar to the proteasome it tends to associate with deubiquitinating enzymes (Olmos & 
Carlton 2016). AMSH, a metalloprotease, and USP8 associate with multiple components of the 
ESCRT-0 and ESCRT-III subcomplexes. They both contain microtubule interacting and 
trafficking domains which play a role in intracellular trafficking and endosomal localization 
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(Olmos & Carlton 2016; MacDonald et al. 2014). AMSH is a Lys-63 specific DUB. It interacts 
with a subunit of the ESCRT-III and is involved in proof reading and stabilizing receptors prior 
to their fusion with the lysosome (Birol & Echalier 2014). USP8, which cleaves most types of 
ubiquitin linkages, stabilizes Hrs and STAM subunits of ESCRT-0. Depletion of USP8 leads to 
enlarged endosomes due to the accumulation of ubiquitinated proteins (MacDonald et al. 2014; 
De Ceuninck et al. 2013). 
 
DUBs Involved in Activation and Stabilization of E3 Enzymes: 
 
   Many E3 ligase enzymes tend to undergo adventitious self-ubiquitination. Their interaction 
with a DUB is essential for their stabilization and rescue from proteasomal degradation (Ventii & 
Wilkinson 2008). For instance, Rho52, an oncoprotein and an E3 ligase, interacts closely with 
the USP4 deubiquitinating enzyme which helps stabilize Rho52 from self-ubiquitination in the 
absence of its substrates. Rho52 also tends to ubiquitinate USP4 however, USP4 is able to self 
deubiquitinate and stabilize itself (Wada & Kamitani 2006). Likewise, RING1B, E3 ligase 
subunit of the PRC1 complex, is targeted for degradation both by auto-ubiquitination and by 
E6AP, E6 associated E3 ligase. While E6AP forms Lys48-linked polyubiquitin chains on 
RING1B, its auto-ubiquitination leads to Lys6, Lys27 and Lys48 mixed and branched linkage 
types assembly. Interaction of RING1B with USP7 leads to removal of Ub chains and return of 
the protein to its native state (de Bie & Ciechanover 2011). DUBs can also alter or regulate E3 
ligase activity through induction of conformational changes. For instance, a conserved lysine 
residue in cullin subunit of the SCF E3 ligase complex is conjugated to Nedd8, a Ubl protein. 
This conjugation stabilizes the C-terminus of cullin and increases the efficiency of the RING 
domain to ubiquitinate substrates. CSN5, a JAMM domain DUB and subunit of the COP9 
signalosome (CSN), deneddylates cullin and removes Nedd8, which leads to conformational 
change, dissociation of Skp1 from the SCF complex and downregulation of the SCF activity 
(Mosadeghi et al. 2016; Enchev et al. 2012). 
 
DUBs Involved in Modulating the Activity of E2 Enzymes: 
 
   Deubiquitinating enzymes can block the interaction of the E2 enzymes with the ubiquitin or 
inhibit E2 mediated transfer of the Ub to the E3 ligases or substrates. For instance, Parkin is a 
Parkinson disease-associated RBR domain E3 ligase. UBCH7, Parkin’s cognate E2 enzyme, has 
to first transfer the ubiquitin intermediate to the active site of Parkin before Ub is transferred to 
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the substrate (Durcan et al. 2012). The ataxin-3 deubiquitinating enzyme is known to make a 
tight complex with Parkin and prevent the transfer of Ub from UBCH7 to the Parkin’s active site 
(Durcan et al. 2012). Another example is OTUB1, an OTU domain deubiquitinating enzyme. It 
directly interacts with the Ub conjugated E2 enzymes, such as UBE2D2 (Hdm2 cognate E2 
enzyme) and UBC13, and hinder their function (Sun & Dai 2014). Co-crystal structure of the 
OTUB1 with UBE2D2 revealed that OTUB1 binds this E2 enzyme through residues that are 
involved in interaction with Hdm2. Subsequently, OTUB1 inhibits Hdm2 mediated 
ubiquitination of p53 non-catalytically and leads to p53 stabilization (Sun & Dai 2014). 
Similarly, OTUB1/UBC13 structure revealed that OTUB1 binds UBC13 residues that are 
involved in the transfer of Ub to H2A through RNF168 E3 ligase (Wiener et al. 2012). 
DUBs Involved in Processing and Recycling of Ubiquitin: 
 
   In all eukaryotic cells genes that express ubiquitin either code for head to tail linked 
polyubiquitin chains with a small C-terminal extension (UBB and UBC genes in humans) or a 
single ubiquitin fused to the ribosomal subunits (UBA52 and RPS27A/UBA80 genes in humans). 
In humans UCH-L3, and to a lesser extent USP9X and USP7, are the deubiquitinating enzymes 
involved in the cleaving of the ubiquitin precursors that are fused to the ribosomal subunits (L40 
and S27A proteins) (Grou et al. 2015). In contrast, Otulin, an OTU domain DUB, displays 
remarkable preference for cleaving polyubiquitin chain precursors. Ub precursors are either 
expressed from the UBB gene, that codes for three ubiquitin monomers followed by a cysteine 
residue, or the UBC gene, that codes for nine ubiquitin monomers followed by a valine residue 
(Eletr & Wilkinson 2014). UCH-L3 complements Otulin function by removing amino acids or 
peptides from the C-terminus of the final ubiquitin in the poly Ub chain (Eletr & Wilkinson 
2014). Further, UCH-L1 and specially UCH-L3 are also implicated in the removal of the 
adventitious nucleophile thiol or amine adducts that get conjugated to the C-terminal glycine of 
the ubiquitin through thiolester intermediate bond formation (Bishop et al. 2016; Sekiguchi et al. 
2006). In humans at least two DUBs can act on one type of ubiquitin precursor indicating the 
importance of de novo free ubiquitin synthesis and robustness of this process (Grou et al. 2015). 
   To maintain cellular levels of the free ubiquitin pool polyubiquitin chains released from the 
protein substrates must be cleaved to single ubiquitins (Coyne & Wing 2016; Clague et al. 2013). 
USP5, also known as iso-peptidase T (Ubp14 in yeast), specifically recognizes and cleaves 
unanchored polyubiquitin chains (Grou et al. 2015). USP5 is a multidomain enzyme that can 
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hydrolyze varying Ub linkage types including Lys6, Lys29, Lys48, Lys63 and Met-linked 
ubiquitins. Full-length structure of the USP5 revealed four ubiquitin binding sites: two zinc 
finger ubiquitin-binding domains at its N-terminus and two UBA domains inserted within the 
catalytic domain (Avvakumov et al. 2012). Deletion of Ubp14 in yeast or knockdown of USP5 in 
human cells lead to accumulation of polyubiquitin chains, which interfere with proteasomal 
degradation of certain substrates (Grou et al. 2015).   
DUBs Associated with Chromatin Modification: 
  
   In humans, 10% of the histone H2A is ubiquitinated at Lys119 and about 1% of the histone 
H2B is ubiquitinated at Lys120 (Atanassov et al. 2011). Histone H2B ubiquitination is linked to 
transcription activation, while H2A ubiquitination generally leads to silencing (Du 2012). DUBs 
such as MYSM1, USP16, USP21, BAP1, BRCC3 and USP10 recognize and deubiquitinate 
histone H2A. MYSM1/2A-DUB is a JAMM domain DUB that deubiquitinates H2A and leads to 
transcription activation of androgen receptor-regulated genes (Gatzka et al. 2015). USP16, which 
colocalizes with RING1B E3 ligase component of the PRC1 complex, works in oppose to the 
PRC1 by globally deubiquitinating H2A and maintaining gene expression during mitosis 
(Frangini et al. 2013). USP21 deubiquitinates H2A on Lys119 in mice especially during liver 
regeneration (Pannu et al. 2015). BAP1, a UCH domain DUB, is a major tumor suppressor 
protein and chromatin remodeling factor (Murali et al. 2013). BAP1 deubiquitinates H2A at 
Lys119 in oppose to the PRC1 function and leads to repression of genes such as human HOX 
genes (39 conserved genes that code for transcription factors involved in embryonic anterior-
posterior patterning and development) (Yu et al. 2014). BRCC3, a JAMM domain 
metalloprotease with specificity for Lys63-linked Ub chains, antagonizes RNF8 mediated H2A 
ubiquitination during double-strand DNA breaks (Huang et al. 2015; Feng et al. 2010). USP10 
specifically recognizes histone H2A.Z variant which is involved in thermosensory response and 
regulation of transcription. Deubiquitination of H2A.Z by USP10 leads to transactivation of 
androgen receptor-regulated genes such as prostate-specific antigen (Draker et al. 2011).  
   USP3 and USP22 (Ubp8 in yeast) can deubiquitinate both H2A and H2B. USP3 interacts with 
ubiquitinated H2A, gamma-H2AX (H2A variant) and H2B through its zinc finger ubiquitin-
binding domains and opposes RNF168 E3 ligase activity (Sharma et al. 2014; Nicassio et al. 
2007). USP22 and its yeast homologue, Ubp8, are histone deubiquitinating subunits of SAGA 
(transcriptional co-activator histone acetylation complex) (Cole et al. 2015). USP22 
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deubiquitinates H2B on Lys120 and Ubp8 on Lys123 (Melo-Cardenas et al. 2016). Ubp8 activity 
leads to recruitment of C-terminal kinase 1 (CtK1) which in turn phosphorylates RNA-
polymerase II and initiates transcription (Wyce et al. 2007).  
 
   USP7, USP15, USP36 (Ubp10 in yeast), USP44 and USP49 are involved in deubiquitination of 
histone H2B. USP7 has been shown to interact with GMPS (guanosine 5’-monophosphate 
synthase), a metabolic enzyme involved in the final step of de novo guanine nucleotides 
synthesis. Together they are involved in H2B deubiquitination and act as transcriptional 
repressors. Depletion in the cellular levels of  GMPS or USP7 leads to increase in 
monoubiquitinated H2B (Reddy et al. 2014; van der Knaap et al. 2010). USP15 was reported to 
directly interact with the RNF20-RNF40 E3 ligase complex, which is involved in histone H2B 
monoubiquitination. Further, the USP15 N-terminal DUSP (domain present in USPs) and Ubl 
domains interact with SART3 (Squamous cell carcinoma antigen recognized by T-cells 3) 
component of the splicing machinery. SART3 recruits USP15 to the nucleus for deubiquitination 
of histone H2B (Q. Zhang et al. 2016; Long et al. 2014). USP36 deubiquitinates Ub-H2B in 
Drosophila stem cells and its overexpression in humans is linked to ovarian cancer. Its yeast 
homologue, Ubp10, localizes to silent chromatin and has established a role in telomeric 
silencing. Ubp10 deubiquitinating activity leads to low levels of histone H3 Lys4 and Lys79 
methylation which in turn leads to recruitment of Sir proteins and telomeric silencing (Reed et al. 
2015; J. Li et al. 2008). USP44 antagonizes RNF20 E3 ligase function by deubiquitinating 
histone H2B. It was shown that USP44 levels are significantly downregulated during embryonic 
stem cells differentiation, which is important for activation of genes involved in the 
developmental process, such as DAAM2 (dishevelled associated activator of morphogenesis 2) 
(Fuchs et al. 2012). Lastly, USP49 forms a complex with RuvB-like1 ATPase and 
deubiquitinates H2B. USP49 activity is important for efficient splicing of a large set of exons 
(Zhang et al. 2013). 
 
DUBs Involved in Signaling Cascades: 
 
   Reversible ubiquitination has a critical role in recruiting, activating and controlling stability of 
receptors and signal transducing proteins. Catalysis of the Lys63-linked Ub chains is important 
for recruiting signaling proteins such as kinases in a non-proteasome dependent manner, while 
Lys48-linked ubiquitination regulates the half-life of the signaling receptors and complexes 
(Clague et al. 2013). The best-studied signal transduction pathway dependent on the reversible 
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ubiquitination is that of nuclear factor κB (NF-κB) transcription factor which has well-
established roles in innate and adaptive immunity and cell growth (Won et al. 2016). In an 
unstressed cell a family of inhibitory proteins, IκB, associate with NF-κB in the cytoplasm and 
hinder its nuclear localization and transactivation (Won et al. 2016). Signal engagement by 
receptors, such as Tumor Necrosis Factor (TNF), leads to recruitment of TRAF2 or TRAF6 
(TNF receptor-associated factors), RING-type E3 ligases, and their Lys63 autoubiquitination and 
activation (Hoesel & Schmid 2013). TRAF E3s further catalyze Lys63-linked ubiquitin chains 
on the TNF complex components such as RIP1 and RIP2 (receptor interacting proteins). This 
acts as a signal to recruit TAK1-TAB2/3 kinase which in turn phosphorylates IκB Kinase (IKK) 
and leads to Lys63-linked ubiquitination of IKK regulatory subunit, NEMO (NF-κB essential 
modulator). Subsequently, activated IKK phosphorylates IκB on two N-terminal serine residues. 
The SCF E3 ligase complex (with a beta-transducing repeat-containing protein, ßTrCP) 
recognizes phosphorylated IκB and catalyzes its Lys48-linked ubiquitination and proteasomal 
degradation. IκB downregulation allows NF-κB to enter the nucleus and start its transactivation 
(Won et al. 2016; Hoesel & Schmid 2013). Two DUBs, A20 and CYLD, have been identified as 
downregulators of the NF-κB signaling pathway (Chen 2012). A20 is a novel enzyme with an 
OTU domain at its N-terminus and a zinc finger domain with E3 ligase activity at its C-terminus 
(Heyninck & Beyaert 2005). The A20 OTU domain specifically cleaves Lys63 Ub linkage. It 
hydrolyses Lys63-linked chains produced by TRAF E3 ligases on RIP1 and inhibits NF-κB 
signaling. Simultaneously A20 acts as an E3 ligase and catalyzes Lys48-linked ubiquitination of 
RIP1 which leads to its degradation. Mice with A20 deletion die shortly after birth due to 
continuous NF-κB signaling and organ inflammation (Won et al. 2016; Heyninck & Beyaert 
2005). CYLD, another DUB involved in the NF-κB signaling, is a tumor suppressor with a USP 
catalytic domain which shows preference for Lys63 and linear-linked Ub chains. It inhibits IKK 
activation by hydrolyzing Lys63 chains from TRAF2, TRAF6, RIP1 and NEMO (Kobayashi et 
al. 2015). CYLD depletion leads to increase in ubiquitinated RIP1 levels and activation of NF-
κB signaling (Chen 2012). Recently more DUBs have been implicated in NF-κB signaling such 
as Cezanne, USP21 and USP7. Cezanne (Cellular zinc finger anti-NF-κB) is an OTU domain 
DUB with a preference for Lys11 linkage hydrolysis. TNF signaling activates Cezanne and 
recruits it to TNF receptors (TNFR). In return, Cezanne cleaves Lys11-linked Ub chains from 
activated TNFR1 which suppresses ubiquitination of RIP1 and downregulates NF-κB signaling 
(Enesa et al. 2008). Likewise, USP21 is activated by TNF signaling. It downregulates NF-κB 
transactivation by associating with and deubiquitinating RIP1 (Xu et al. 2010). USP7 has also 
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been implicated as the negative regulator of the NF-κB pathway. It was shown that upon Toll-
like receptor (TLR) or TNFR signal engagement USP7 translocates to the cytoplasm. It leads to 
downregulation of the NF-κB dependent inflammatory cytokine response through 
deubiquitination of the Lys63-linked Ub chains on TRAF6 E3 ligase and NEMO component of 
the IKK complex (Li et al. 2014; Daubeuf et al. 2009). 
 
   Other noteworthy signaling cascades that are tightly regulated by reversible ubiquitination are 
the Wnt and TGF-ß pathways. Wnt/ ß-catenin signaling is highly conserved and has a critical 
role in the development and adult tissue homeostasis. Wnt proteins interact with Frizzled 
transmembrane receptors and lead to signal transduction through ß-catenin transcription 
coactivator (Yun et al. 2015). The USP8 deubiquitinating enzyme, which is involved in 
endosomal trafficking, was shown to recycle ubiquitin-tagged Frizzled receptors, suppress their 
lysosomal trafficking and upregulate Wnt signaling (Mukai et al. 2010). Further, USP4, USP34 
and TRABID (an OTU domain DUB) stabilize components of the Wnt signaling pathway such 
as ß-catenin, Axin and APC respectively and regulate Wnt signaling (Yun et al. 2015; Lui et al. 
2011; Tran et al. 2008). TGF-ß signaling cascade involves a variety of cytokines and regulates 
different biological functions. Activated TGF-ß receptor, in turn, phosphorylates receptor-
regulated SMAD proteins (R-SMADs) and leads to their transcription activation in association 
with SMAD4 (Juan Zhang et al. 2014). USP9X deubiquitinating enzyme (also known as FAM, 
fat facets) is recruited to this complex to activate SMAD4 by specifically removing 
monoubiquitin tags from SMAD4 Lys519. Monoubiquitinated SAMD4 cannot interact with R-
SMADs and remains inhibited in the cytoplasm (Dupont et al. 2009). USP15 and USP4 also 
upregulate TGF-ß levels by deubiquitinating and stabilizing TGF-ß type I receptors (TßRI) 
(Aggarwal & Massague 2012).  
 
DUBs Involved in the DNA Repair Pathways:   
 
   Many environmental factors, such as toxins, viruses and radiation, and cellular factors, such as 
metabolic byproducts and replication errors, can lead to DNA damage which is quite hazardous 
to the cell. DNA lesions caused by double-strand breaks, single-strand breaks (SSBs) and 
interstrand crosslinks activate the DNA repair pathways, which are crucial for preserving 
genomic integrity and health of the organism (Jasin & Haber 2016). DNA repair pathways are 
tightly associated with reversible ubiquitination. Effector proteins including E3 ligases are 
recruited to the DNA break lesions through the function of kinases, such as ATM, ATR, DNA-
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PK, Chk1 and Chk2 (Li & Xu 2016). Subsequently, Lys63-linked Ub chains get accumulated 
through enzymatic activity of RNF8 and RNF168, RING finger E3 ligases. This leads to 
recruitment of the genome caretaker proteins, such as 53BP1, Pax transactivation domain-
interacting protein (PTIP) and BRCA1 containing protein complex, which activate the DNA 
double-strand break pathway (Li & Xu 2016). RNF8 associates with HERC2, a large HECT 
domain E3 ligase, which helps RNF8 to specifically interact with UBC13 E2 ligase and form 
Lys63-linked Ub chains on histones at the site of the DNA damage. RNF8/HERC2 function 
further activates RNF168 which also with the help of UBC13 forms Lys63-linked polyubiquitin 
on histone H2A and H2AX (Jasin & Haber 2016; Bekker-Jensen & Mailand 2011). 
Deubiquitinating enzymes, USP3 and BRCC3, counteract the DNA repair signaling by cleavage 
of the Lys63-linked ubiquitins at the DNA break sites, while OTUB1 inhibits ubiquitination 
function of RNF168 by interacting with the UBC13 E2 ligase and blocking its interaction with 
E3 ligases (Nakada et al. 2010). Another DUB that has been identified as a major regulator of the 
DNA damage response is USP28. DNA double-strand breaks can lead to DNA damage induced 
apoptosis which in most cases is orchestrated through the Chk2 kinase-p53-PUMA pathway 
(Fong et al. 2016). In response to DNA damage, USP28 interacts with and stabilizes Chk2 kinase 
and other scaffolding proteins such as 53BP1, Claspin and mediator of DNA damage checkpoint 
1. Depletion of USP28 decreases cellular levels of these proteins, weakens DNA damage 
response and inhibits IR induced p53 mediated apoptosis (Fong et al. 2016; Gupta et al. 2014). 
USP28 is also implicated in G2 DNA damage response checkpoint. To allow cell cycle 
progression in unstressed cells G2 checkpoint is silenced through ubiquitination and 
destabilization of Claspin. Plk1, a mitotic kinase, phosphorylates Claspin and leads to its 
recognition and downregulation by the SCF E3 ligase complex (containing a ßTrCP F-box 
subunit) (Bassermann et al. 2008). In case of DNA damage, the APC/C E3 ligase complex (along 
with Cdh1 component) ubiquitinates and destabilizes Plk1 kinase and therefore prevents mitosis. 
(Bassermann et al. 2008).  
 
   Naturally occurring compounds, such as reactive aldehydes, and exogenous chemicals, such as 
chemotherapeutic drugs, can give rise to intrastrand crosslink which leads to covalent bonding of 
the two DNA strands and blocks essential processes such as DNA transcription and replication 
(Lopez-Martinez et al. 2016). PCNA, Fanconi anemia complementation group D2 (FANCD2) 
and Fanconi anemia complementation group I (FANCI) are involved in the interstrand crosslinks 
repair pathway. These proteins are activated through monoubiquitination and further promote 
activation of the Fanconi anemia (FA) signaling cascade. Monoubiquitination of FANCD2 
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FANCI heterocomplex is important for their localization at the DNA repair foci and their 
subsequent interaction with repair factors such as BRCA1 and RAD51 recombinase, which are 
implicated in DNA repair through activation of the homologous recombination (Lopez-Martinez 
et al. 2016). The USP1 deubiquitinating enzyme is one of the most important regulators of the 
FA signaling in response to DNA damage. In complex with its activator, USP1-associated factor 
1 (UAF1), USP1 deubiquitinates PCNA, FANCD2 and FANCI and suppresses FA signaling 
(Boisvert & Howlett 2014). UAF1, contains a WD40 domain at its N-terminus, which binds 
USP1, and two SUMO-like domains (SLDs) at its C-terminus, which interact with the highly 
conserved SUMO-like interacting motifs of FANCI (Yang et al. 2011). UAF1 SLD2 is also 
important for USP1 mediated deubiquitination of FANCD2-Ub and PCNA-Ub (Yang et al. 
2011). In response to DNA damage, UAF1 targets USP1 to the FANCD2-FANCI 
heterocomplex. USP1/UAF1 deubiquitination of FANCD2 and FANCI is crucial for proper 
function of the FA pathway and is especially important for exit from S phase and recycling of 
FANCD2 (Boisvert & Howlett 2014; Murai et al. 2011). Even though USP1/UAF1 complex 
dampens the FA signaling, USP1 gene deletion in mouse embryonic fibroblasts or DT40 chicken 
cells led to hypersensitivity to chemical cross-linking agents and defective homologous 
recombination repair (Boisvert & Howlett 2014). It was shown that USP1/UAF1 
deubiquitination function also suppresses the non-homologous end-joining pathway which 
further promotes activation of homologous recombination repair in DNA double-strand breaks 
(Murai et al. 2011). The activity of the USP1/UAF1 complex is highly regulated. Upon exposure 
to DNA damaging agents, such as radiation, USP1 transcription is inhibited by p21, a cyclin-
dependent kinase inhibitor, to allow accumulation of the monoubiquitinated FANCD2/FANCI 
and activation of the DNA damage response (Rego et al. 2012). At the same time USP1 
undergoes autocleavage at an internal Gly-Gly motif which leads to its dissociation from UAF1 
and eventual degradation (Huang et al. 2006).     
 
Regulation of DUBs Activities:  
 
   Reversible ubiquitination has a critical role in many complex cellular functions. Any 
derangement in the activity of enzymes involved in this pathway disrupts cell homeostasis and is 
linked to many human cancers, disease and neurological disorders (Hanpude et al. 2015; Shi & 
Grossman 2010). Majority of DUBs are implicated in multiple and varying cellular functions at 
the same time they show timely activation and substrate specificity regarding each particular 
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function. DUBs activity must be tightly regulated. To date, many mechanisms have been 
identified that govern DUBs function and substrate specificity.  
 
Regulation of DUBs Expression and Stability: 
 
   DUBs activity can be regulated by controlling their expression. For instance, repression effect 
of USP1 on the FA signaling pathway is downregulated upon DNA damage by inhibiting its 
transcription. Activated p21 terminates USP1 transcription and leads to its quick attenuation 
(Rego et al. 2012). Further, regulation of DUBs’ activity also occurs through downregulation of 
their cellular levels. For instance, upon exposure to DNA damaging radiation USP1 autocleaves 
itself which leads to its degradation and activation of the FA signaling pathway (Huang et al. 
2006). Another example is the case of A20, an OTU domain DUB, which itself is a substrate of 
mucosa-associated lymphoid tissue (MALT) protease (Martinez-Climent 2014). MALT cleaves 
A20 after Arg439 and suppresses its negative effect on the NF-κB pathway. Deletion or 
mutations in A20 or constitutively activated MALT leads to prolonged NF-κB signaling and is 
associated with MALT lymphoma (Martinez-Climent 2014; Du 2011). 
 
   Recently microRNAs (miRNAs) have also been implicated in the post-transcriptional 
regulation of DUBs’ expression. miRNAs lead to mRNA silencing and decay by base-paring 
with the complementary sequences within 3' untranslated region of the mRNA molecules. This 
recruits RISC (RNA-induced silencing complex) to the mRNA transcript and triggers its 
decapping and deadenylation (Bartel 2009). USP14, a proteasome bound DUB, is upregulated in 
multiple human cancers such as leukemia, colorectal cancer and non-small cell lung cancer (Wu 
et al. 2013). It was shown that upregulation of MiR-4782-3p miRNA correlates with a decrease 
in USP14 expression in patients with non-small cell lung cancer (Wu et al. 2014). MiR-4782-3p 
has been successfully used to target USP14, decrease its expression and inhibit cell proliferation 
(Wu et al. 2014).  
    
Substrate-Induced Regulation of DUBs Activities:  
 
   To avoid random and untimely hydrolysis of the substrates and as a safeguard mechanism, 
typically DUBs active site residues are in an inactive conformation. In case of the cysteine 
protease DUBs histidine must be within the hydrogen bond distance from cysteine (~3.8 Å) to 
deprotonate its thiol group (Jeffrey 1997). For instance, USP7 crystal structure revealed that 
catalytic residues are not in a productive state and that catalytic cysteine residue is about 10 Å 
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away from the catalytic histidine. Structure of the USP7 bound to ubiquitin aldehyde showed 
conformational change and realignment of the catalytic residues into an active conformation (Hu 
et al. 2002). Another example of active site realignment upon substrate interaction is seen in the 
case of the UCH-L1 enzyme. In the absence of the substrate catalytic histidine rotates about 7.7 
Å away from the catalytic cysteine rendering the active site unproductive (Boudreaux et al. 
2010). UCH-L1 bound to a suicide substrate, ubiquitin vinyl methyl ester, revealed two contact 
sites for ubiquitin. While the C-terminal glycine of ubiquitin contacts the active site, an N-
terminal ß-hairpin loop of Ub contacts a hydrophobic patch on UCH-L1 about 17 Å away from 
the active site (Boudreaux et al. 2010). Ubiquitin interaction with UCH-L1 distal site leads to 
rearrangement of the active site residues into an active conformation (Ronau et al. 2016; 
Boudreaux et al. 2010). Another case is OTULIN, an OTU domain DUB, specific for cleavage 
of the linear ubiquitin chains. Crystal structure of the OTULIN revealed that catalytic Cys-His-
Asn triad in the majority of the molecules is misaligned (Keusekotten et al. 2013). An Asp 
residue in the catalytic domain inhibits productive conformation by pulling active site histidine 
residue away from cysteine. However, in case of OTULIN’s interaction with the linear ubiquitin 
chains, catalytic histidine residue is forced back to a hydrogen bond distance with the catalytic 
cysteine (Keusekotten et al. 2013). It was shown that Glu16 residue of the linear-chained 
proximal ubiquitin releases the inhibitory effect of Asp on the active site histidine and allows 
rearrangement of the catalytic triad into a productive conformation. Only in linear-linked 
ubiquitin chains Glu16 can contact OTULIN’s Asp residue and release its inhibitory effect on the 
active site histidine, giving OTULIN its unique specificity (Elliott & Komander 2016; 
Keusekotten et al. 2013) 
 
Regulation of DUBs Activity and Specificity Through Internal Loops and Domains: 
 
   Other than misaligned catalytic triad in some DUBs’ internal loops crossing over or adjacent to 
the active site regulate ubiquitin access and catalytic activity. DUBs interaction with substrates 
or binding partners is important in relieving the obstruction. As mentioned before USP7 catalytic 
residues in the absence of ubiquitin are misaligned. It was shown that USP7’s five C-terminal 
Ubl domains can fold back towards the catalytic domain. This allows Ubl4 & 5 to interact with a 
so-called “switching loop” close to the catalytic triad which leads to a significant conformational 
change in the loop and helps realign the catalytic residues (Faesen et al. 2011). Another example 
is the case of CSN5, a JAMM domain metalloprotease and a subunit of the COP9 signalosome 
(CSN). CSN5 recognizes and cleaves NEDD8 from the CRL E3 ligase complex and 
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downregulates CRL activity (Cope et al. 2002). However, outside the CSN complex CSN5 is 
essentially an inactive enzyme and access to its active site is inhibited by an internal loop, 
referred to as Ins1 (insertion loop 1). Within the holoenzyme, CNS6 forms a heterodimer with 
CSN5 and simultaneously contacts CSN4 subunit through a conserved ß-hairpin loop (Ins2) 
(Lingaraju et al. 2014). Upon the CSN complex interaction with neddylated CRL E3 ligase, 
CSN4 subunit interacts with CRL and undergoes significant remodeling, which is sensed by the 
Ins2 loop of the CSN6 subunit. Conformational change in the CSN6 Ins2 leads to considerable 
movement in the CSN5 Ins1 and removes its inhibitory effect from the CSN5 active site 
(Lingaraju et al. 2014). Therefore, the inhibitory effect of the Ins1 assures that CSN5 can only 
function within the CSN complex and in response to neddylated CRLs (Lingaraju et al. 2014). In 
case of the USP14 (functional homologue of yeast Ubp6), its crystal structure revealed that 
catalytic triad is in an active position however, the catalytic domain alone showed low affinity 
for Ub-substrate cleavage (Hu et al. 2005). It was observed that within the catalytic domain two 
surface loops, blocking loops 1 and 2 (BL1 and BL2) which are also conserved in yeast, occlude 
the ubiquitin binding pocket (Hu et al. 2005). Cocrystal structure of the USP14 catalytic domain 
bound to ubiquitin aldehyde revealed a significant conformational change in the position of BL1 
and BL2 which leads to opening access to the active site (Hu et al. 2005). Further, the interaction 
of the yeast Ubp6 Ubl domain with Rpn1 subunit of the proteasome 19S RP results in 
considerable movement in BL1 and BL2 and removes their inhibitory effect from the Ubp6 
active site (Bashore et al. 2016).    
    
   All four members of the UCH domain DUBs incorporate crossover loops that block the 
catalytic active site by joining an α-helix to a β-strand across the active site pocket. These 
crossover loops have a varying length (11-21 amino acids long) and contribute to substrate 
specificity (Clague et al. 2013). UCH-L1, the most abundant protein in the brain, contains the 
shortest crossover loop with a rigid structure that restricts access to the active site. Accordingly, 
it is involved in the removal of short peptides from the C-terminus of the ubiquitin precursors 
and accidental Ub C-terminus thiol or amine adducts that are formed during thioester 
intermediate bond formations (Bishop et al. 2016). UCH-L3 crystal structure revealed a 20 
residue long crossover loop which was mostly disordered indicating its high flexibility (Misaghi 
et al. 2005). However, the steric constrain imposed by the crossover loop does not allow 
accommodation of large substrates. Therefore, UCH-L3 cannot cleave the isopeptide bond 
between two ubiquitins and instead shows a high preference for small ubiquitin C-terminal 
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leaving groups (Grou et al. 2015). It was shown that expansion of the UCH-L3 crossover loop by 
5-10 glycine residues allows hydrolysis of Lys48 and Lys63 linked Ub chains (Popp et al. 2009). 
 
Allosteric Regulation of DUBs Activity and Specificity: 
 
   Many deubiquitinating enzymes function as a subunit of a larger complex or through 
interaction with another binding partner. A global proteomic analysis of 75 DUBs identified 774 
proteins associated with these enzymes (Sowa et al. 2009). DUBs typically show a low affinity 
towards the ubiquitinated substrate and only achieve optimal function through interaction with 
other proteins. In some cases interacting partners downregulate DUBs’ activity or contribute to 
their substrate specificity (Reyes-Turcu et al. 2009). A notable example of the allosteric 
regulation is the case of USP1 and its coactivator UAF1, regulators of the FA DNA repair 
pathway. USP1 alone is essentially an inactive enzyme. Its interaction with UAF1 increases 
enzymatic activity (Kcat) by 35 folds while it does not affect ubiquitin binding (Villamil et al. 
2013). Probing active site amino acids revealed that UAF1 interaction modulates active site 
residues and leads to their conformational change. Further, it was shown that in the USP1/UAF1 
complex compared to the apoenzyme, pKa of the catalytic cysteine does not change however, 
upon UAF1 interaction pKa of the catalytic histidine decreases, which facilities its function as a 
general base (Villamil, Chen, et al. 2012; Cohn et al. 2007). Another example is the case of 
UCH37 (also known as UCH-L5) and BAP1. Similar to UCH-L1 and UCH-L3, UCH37 and 
BAP1 contain crossover loops that occlude the active site groove. However, in contrast to UCH-
L1 & 3 that cleave small leaving groups and peptides, UCH37 hydrolyzes Lys48-linked Ub 
chains and BAP1 deubiquitinates histone H2A (Morrow et al. 2013). It was shown that 
interaction of UCH37 with Rpn13, ubiquitin receptor of the 19S RP, and BAP1 with ASXL1 
(additional sex combs like 1) stimulates their catalytic activity (Ronau et al. 2016). Cocrystal 
structure of UCH37, Rpn13 and ubiquitin-propargyl (suicide inhibitor) revealed that upon 
UCH37 and Rpn13 interaction a segment of the crossover loop contacts Rpn13 and gets 
stabilized. Rpn13 also interacts with the C-terminal UCH37-like domain (ULD) of the UCH37 
and holds it in a favorable position for binding with the ubiquitin (Sahtoe et al. 2015; Misaghi et 
al. 2009). INO80G is another binding partner of UCH37 which recruits it to INO80 chromatin 
remodeling complex (VanderLinden et al. 2015). While Rpn13 activates UCH37, INO80G 
interaction with the ULD domain inhibits UCH37 enzymatic activity. Crystal structure of 
UCH37 in complex with the INO80G revealed that upon interaction INO80G forces C-terminal 
end of the ULD towards the UCH37 active site and blocks access to the ubiquitin-binding groove 
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(Sahtoe et al. 2015; VanderLinden et al. 2015).  
   Allosteric regulation of DUBs has also been noted in the endocytic and autophagy pathways. 
AMSH, a JAMM domain DUB, is recruited to endosomes by STAM, a subunit of the ESCRT 
complex, which also enhances AMSH hydrolysis activity (Davies et al. 2013). While the AMSH 
catalytic domain interacts with the distal ubiquitin in a Lys63-linked Ub chain, the STAM Ub 
interacting motif (UIM) binds the Ile44 patch of the proximal ubiquitin. STAM interaction with 
the proximal Ub stabilizes the chain and increases AMSH enzymatic activity (Davies et al. 
2013).  
 
Post-Translational Modification of DUBs: 
 
   Similar to many well-studied cellular processes DUBs’ activity is also fine-tuned through post-
translational modifications, such as phosphorylation, SUMOylation and even ubiquitination. For 
instance, Ser313 phosphorylation of USP1 by Cdk1 kinase is critical for recognition and 
activation by its cofactor, UAF1. Mutation of Ser313 to alanine suppresses USP1/UAF1 complex 
formation and renders USP1 inactive (Villamil, Liang, et al. 2012). Another example is OTULIN 
which negatively regulates the NF-κB pathway by antagonizing the linear Ub chain assembly 
complex, LUBAC. HOIP, E3 ligase subunit of the LUBAC, interacts with the OTULIN’s PUM 
interacting motif and recruits it to the LUBAC. It was shown that phosphorylation of the 
conserved Tyr56 within the PUM interacting motif of OTULIN abolishes its interaction with the 
LUBAC and inhibits its antagonizing effect on the NF-κB pathway (Schaeffer et al. 2014). 
Likewise, CYLD, tumor suppressor protein and a USP domain DUB, is regulated both through 
phosphorylation and SUMOylaltion. Retinoic acid induced SUMOylation of CYLD on Lys40 
inhibits its substrate cleavage activity and upregulates the NF-κB signaling (Kobayashi et al. 
2015). In addition, Ser418 phosphorylation of CYLD by IKKɛ (IκB kinase epsilon) oncoprotein 
inhibits its deubiquitination activity towards TRAF2 and is essential for IKKɛ mediated cell 
transformation (Hutti et al. 2009). DUBs’ function can also be modified through ubiquitination. 
For instance, ubiquitination of ataxin-3 on Lys117 in reaction to the unfolded protein response 
(UPR) leads to enhanced hydrolysis of polyubiquitin chains while it does not affect on ataxin-3 
preference for Lys63-linked ubiquitins (Tsou et al. 2013). Another example is the Josephin 
domain protein 1 (JosD1), a member of the JAM domain DUBs. JosD1 can hydrolyze Ub chains 
only after it is activated through monoubiquitination. Ubiquitination of JosD1 is also important 
for its plasma membrane localization and regulation of endocytosis (Seki et al. 2013).  
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   Post-translational modification of DUBs can alter their cellular localization without affecting 
catalytic activity. For instance, BAP1 is multi-monoubiquitinated by an E2/E3 hybrid enzyme, 
UBE2O, close to its nuclear localization motif (Mashtalir et al. 2014). Such modification leads to 
the cytoplasmic sequestration of BAP1 and restricts its access to the nuclear substrates 
(Mashtalir et al. 2014). Similarly, USP4 phosphorylation by AKT kinase at Ser445 leads to its 
translocation to the cytoplasm and localization to the membrane where it can stabilize TßRI 
receptor and upregulates the TGF-ß signaling (Zhang et al. 2012).  
 
   Further, it has been noted that catalytic cysteine of DUBs can be modified and temporarily 
inactivated by reactive oxygen species. Many DUBs from USP, UCH and OTU family can 
undergo reversible oxidation by reactive oxygen species such as superoxides, hydrogen 
peroxides and hydroxyl radicals (Lee et al. 2013). Oxidation of DUBs catalytic cysteine 
produces cysteine sulphenic acid or sulphene amide which inhibits isopeptide bond hydrolysis 
activity (Lee et al. 2013). For instance, inhibition of the USP1 enzymatic activity by oxidation is 
essential for the PCNA monoubiquitination and activation under oxidative stress (Lee et al. 
2013). USP1 is inactivated partly through oxidation of its catalytic cysteine residue, which leads 
to accumulation of the monoubiquitinated PCNA and activation of the translesion synthesis 
pathway (TLS). USP1 recovers from oxidative inhibition in a time-dependent manner and mostly 
through activation of the anti-oxidative genes (Lee et al. 2013). Another example is the case of 
A20 OTU domain deubiquitinating enzyme. High resolution structure of the A20 catalytic 
domain under different oxidation states (oxidation numbers) indicated that catalytic cysteine 
oxidizes into cysteine sulphenic acid which is stabilized by OTU catalytic center structure 
through hydrogen bond formation (Kulathu et al. 2013). It is suggested that cysteine 
modification to sulphenic acid intermediate may protect the active site from further oxidation 
(Kulathu et al. 2013).   
 
Human USP7: 
 
   Human ubiquitin specific protease 7 (USP7/HAUSP) is a well-characterized cysteine protease 
deubiquitinating enzyme involved in stabilization, activation and localization of its substrates. 
An ever-expanding list of proteins has been identified as USP7 substrates or binding partners. 
USP7 modulation of tumor suppressors and transcription factors such p53, PTEN (phosphatase 
and tensin homolog), FOXO4 (forkhead Box O4) and retinoblastoma-associated protein (Rb) 
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family is essential for normal cellular stress response and regulation of cell cycle progression. 
USP7 is also implicated in the regulation of the DNA repair pathways, epigenetics and immune 
response (Pfoh, Lacdao & Saridakis 2015; Nicholson & Suresh Kumar 2011). Therefore, it is not 
surprising that aberrations in the USP7 activity are linked to tumorigenesis and human disease.  
 
USP7 Domain Structure: 
 
   USP7 harbors a TRAF-like domain (Tumor necrosis factor receptor (TNFR) associated factor 
(TRAF)) in its N-terminus and five Ubl domains in its C-terminus (Fig. 1-10) (Sheng et al. 2006; 
Holowaty et al. 2003). A shallow groove on the surface of the USP7 N-terminus binds substrates 
or interacting proteins (E/P/A)XXS motifs where X stands for any amino acid with a higher 
preference for serine (Sarkari et al. 2010; Saridakis et al. 2005). All USP7 homologues in their 
TRAF-like domain binding pocket harbor a highly conserved 164DWGF167 motif where Asp164 
and Trp165 residues have been found essential for USP7-substrate interaction (Saridakis et al. 
2005). USP7 C-terminal Ubl domains are also involved in protein-protein interaction. USP7-
CTD structure revealed that the five Ubl domains are arranged in a 2-1-2 architecture where 
Ubl12 and Ubl45 form di-Ubls and Ubl3 shows limited contact (Faesen et al. 2011). USP7 C-
terminal interacting proteins such as GMPS, UHRF1 and ICP0 recognize a negatively charged 
758DELMDGD764 motif on Ubl2 through their KXXXK sequence where the two lysine residues 
have been found important for interaction with USP7 Asp762 and Asp764 (Pfoh et al. 2015).  
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Fig. 1-10: The domain arrangement of human USP7. USP7 contains an N-terminal substrate 
binding TRAF domain, a catalytic domain and a C-terminal domain that comprises five 
ubiquitin-like (Ubl) sub-domains. 
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   The USP7 catalytic domain resembles an extended right hand composed of the fingers, palm 
and thumb subdomains. The active site residues are located in a cleft between the thumb and 
palm structures while the finger subdomain helps position the ubiquitin C-terminal glycine 
within the active site cleft (Fig. 1-11) (Hu et al. 2002). USP7 crystal structure revealed that the 
catalytic Cys223 is about 9.7 Å away from the catalytic His464 rendering the active site 
unproductive (Hu et al. 2002). However, the USP7 catalytic domain structure bound to ubiquitin 
aldehyde showed conformational change and realignment of the catalytic cysteine to 3.6 Å 
distance from histidine (close to a hydrogen bond distance) (Hu et al. 2002). Further, it was 
noted that realignment of the catalytic triad is reinforced by the C-terminal Ubl4 and 5. The 
USP7 Ubl domains show considerable flexibility between Ubl123 and Ubl45 and can fold back 
towards the catalytic domain (Faesen et al. 2011). Consequently, a peptide extension beyond 
Ubl45 contacts the “switching loop” close to the catalytic triad and results in a significant 
conformational change in the loop. This leads to the realignment of the catalytic triad and 
increases catalytic activity by 100 fold (Faesen et al. 2011). 
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Fig. 1-11: USP7 catalytic domain structure depicting the fingers (in green), thumb (in red) and 
palm (in blue) subdomains. Cys and His boxes include the active site residues in a cleft between 
Thumb and Palm structure. (Reprinted by permission from Elsevier: Cell, (Hu et al. 2002), 
copyright 2002).  
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Regulation of the USP7 Activity and Stability: 
 
   The active conformation of the USP7 catalytic triad is further stabilized with the help of 
allosteric activator proteins such as GMPS and ABRO1(Abraxas brother 1). GMPS induces 
USP7 activation and is required for its histone H2B deubiquitination, while USP7 has no effect 
on GMPS stability or de novo GMP synthesis (van der Knaap et al. 2010). GMPS is typically 
sequestered in the cytoplasm owing to its monoubiquitination by TRIM21, an autoimmune 
associated RING domain E3 ligase (Reddy et al. 2014). Upon genomic stress TRIM21 
dissociates from GMPS, allowing unubiquitinated GMPS to localize in the nucleus where it 
allosterically activates USP7 and stabilizes USP7-p53 complex. Nuclear accumulation of GMPS 
is required for USP7 mediated stabilization and transactivation of p53 (Reddy et al. 2014). 
GMPS contacts USP7 C-terminal Ubl123 and specifically interacts with 758DELMDGD764 
sequence on Ubl2. It promotes compact confirmation of USP7 by forcing Ubl45 to reach the 
“switching loop” and therefore leads to realignment of the catalytic residues (Fig. 1-12)(Pfoh, 
Lacdao, Georges, et al. 2015; Faesen et al. 2011). ABRO1, another protein implicated in the 
USP7 activation, is a component of the BRISC complex which is a multisubunit DUB involved 
in Lys63-linked Ub hydrolysis (Jianhong Zhang et al. 2014). Upon oxidative stress or DNA 
damage signal, ABRO1 which is typically cytoplasmic localizes to the nucleus. It was shown 
that ABRO1 simultaneously interacts with the USP7 C-terminal domain and p53 and promotes 
formation of the ABRO1-USP7-p53 complex. ABRO1 enhances USP7 deubiquitination activity 
and mediates stability and transactivation of p53 in a USP7 dependent manner (Jianhong Zhang 
et al. 2014). Apart from USP7 activators there are cellular proteins that downregulate USP7 and 
inhibit its contact with cellular substrates. For instance, TSPYL5 (testis-specific protein, Y-
encoded-like 5) selectively binds the USP7 N-terminal TRAF domain, impairs USP7-p53 
interaction and leads to p53 instability (Yang et al. 2013; Epping et al. 2011).  
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Fig. 1-12: Schematic representation of USP7 activation by Ubl45. Upon folding of the USP7 C-
terminal Ubl domains a peptide extension beyond Ubl45 contacts the “switching loop” close to 
the catalytic active site and mediates realignment of the catalytic triad. The compact 
conformation of USP7 is further stabilized through the interaction of GMPS with USP7 Ubl123. 
(Reprinted by permission from Elsevier: Molecular Cell, (Faesen et al. 2011), copyright 2011). 
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   Other than allosteric regulation of its activity, USP7 stability is also regulated through post-
translational modifications. 60-70% of the cellular USP7 exists as a phosphorylated isoform 
(Khoronenkova et al. 2012). Under normal cellular conditions, CK2 kinase (Casein kinase II) 
phosphorylates USP7 on Ser18 and stabilizes it by inhibiting USP7 ubiquitination and 
proteasomal degradation (Khoronenkova et al. 2012). However, upon exposure to ionizing 
radiation ATM kinase phosphorylates and activates PPM1G phosphatase (protein phosphatase, 
Mg2+/Mn2+ dependent, 1G) which in turn dephosphorylates and downregulates USP7. The 
decrease in the cellular levels of phosphorylated USP7 was followed by Hdm2 downregulation 
and p53 transactivation (Khoronenkova et al. 2012). 
 
USP7 Regulation of the p53-Hdm2 Pathway: 
 
   One of the most extensively studied functions of USP7 is regulating the stability of p53 and its 
negative regulator, Hdm2. p53 provoked cell cycle arrest or apoptosis upon a variety of stress 
signals including, DNA damage, viral infection or oncogenic activation is crucial for DNA repair 
and tumor suppression (Shadfan et al. 2012). p53 and Hdm2 both interact with the USP7-NTD 
DWGF motif through their (P/A)XXS sequence, which is important for their deubiquitination 
and stabilization (Sheng et al. 2006). However, Hdm2 is the USP7 preferred substrate and makes 
more extensive contact with the N-terminal TRAF domain. It was noted that reduction in the 
cellular levels of USP7 leads to instability of p53 while its total removal results in destabilization 
of Hdm2 and in turn stabilizes p53. Therefore, under normal cellular homeostasis stabilized 
Hdm2 maintains p53 at low levels to allow cell cycle progression (Sheng et al. 2006; 
Meulmeester et al. 2005). Further, it was observed that despite deletion of the p53 TRAF binding 
sequence, USP7 was still able to stabilize it. Both p53 and Hdm2 also interact with the USP7 C-
terminal domain, which is sufficient for their deubiquitination and stabilization (Ma et al. 2010; 
Brooks et al. 2007). Hdmx, Hdm2 homologue, is another known USP7 substrate implicated in 
the p53-Hdm2 pathway. It interacts with the USP7 N-terminal domain (NTD) through its AHSS 
motif (Sarkari et al. 2010). Hdmx does not show E3 ligase activity however, it forms a 
heterodimer with Hdm2 through its RING domain and stabilizes Hdm2 by inhibiting its 
autoubiquitination. Under stress signal ATM kinase is activated through autophosphorylation 
and subsequently phosphorylates Hdm2, Hdmx and p53 (Chao 2015). These modifications lead 
to the inhibition of Hdm2-p53 interaction. Further, ATM mediated phosphorylation of Hdmx 
leads to its ubiquitination by Hdm2 and destabilization of the heterodimer. Activated ATM 
kinase also phosphorylates and activates PPM1G phosphatase which in turn dephosphorylates 
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and downregulates USP7 (Khoronenkova et al. 2012). Loss of Hdmx, instability of USP7 and 
increase autoubiquitination of Hdm2 results in stability and transactivation of p53 (Chao 2015).  
 
   DAXX, the death domain associated protein, is another USP7 substrate involved in the p53-
Hdm2 pathway. DAXX is a transcriptional co-repressor that localizes to the promyelocytic 
leukemia nuclear bodies (PML-NBs) (Hofmann et al., 2002). PML-NB components such as 
PML and DAXX are regulated by interferons and are involved in the antiviral response. It is well 
established that not only USP7 localizes to the PML-NBs, it also interacts with and stabilizes 
DAXX (Tang et al. 2006). In unstressed cells, DAXX interacts with USP7 and Hdm2 
simultaneously and secures USP7 mediated stabilization of Hdm2. Also, this interaction leads to 
USP7 mediated stabilization of DAXX itself from Hdm2 ubiquitination (Tang et al. 2010). Upon 
DNA damage ATM dependent phosphorylation of DAXX leads to its separation from Hdm2 and 
promotes Hdm2 destabilization and p53 transactivation (Tang et al. 2013). 
 
USP7 Regulation of Protein Localization: 
 
   Other than its crucial role in the regulation of the p53-Hdm2 pathway, USP7 is involved in 
many none p53 related cellular functions. For instance, the interaction of PTEN and FOXO4 
tumor suppressor proteins with USP7 lead to their subcellular translocation. PTEN has a well-
stablished role in downregulation of the highly oncogenic PI3K/AKT kinase pathway and plays 
an essential role in chronic myeloid leukemia (Morotti et al. 2015). PTEN is ubiquitinated on 
Lys289 which leads to its nuclear localization and activation of the apoptotic pathway (Song et 
al. 2008). In unstressed cells, USP7 deubiquitinates PTEN and leads to its nuclear exclusion. 
Upon stress signal PML nuclear bodies through adaptor protein DAXX oppose deubiquitination 
activity of USP7 on PTEN, which allows PTEN to enter the nucleus and activate its target genes 
(Song et al. 2008). Further, BCR-ABL, a chimeric oncogene and PTEN suppressor, was shown 
to physically interact with USP7 and upregulate its stability through phosphorylation (Morotti et 
al. 2015). Stabilized USP7 increases deubiquitination of PTEN and results in its nuclear 
exclusion. Constitutively active BCR-ABL tyrosine kinase has been identified in more than 90% 
of chronic myeloid leukemia cases (Morotti et al. 2015). Similar to PTEN nuclear localization of 
FOXO4 is induced by monoubiquitination. Upon oxidative stress c-Jun N-terminal kinase 
phosphorylates FOXO4 and leads to its multi-monoubiquitination and translocation to the 
nucleus (van der Horst et al. 2006). Hdm2 E3 ligase monoubiquitinates FOXO4 and mediates its 
nuclear localization, which in turn leads to transcription of the cyclin-dependent kinase inhibitors 
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p27 and p21 and cell cycle arrest (Coomans de Brachene & Demoulin 2016; Brenkman et al. 
2008a). In unstressed cells, USP7 deubiquitinates FOXO4 and promotes its cytoplasmic 
sequestration.  
 
USP7 Regulation of Genomic Stability and Cell Cycle Progression: 
 
   In response to DNA damage, the repair pathways activate cell cycle checkpoints to delay or 
arrest cell division. This provides enough time to repair DNA lesions and is essential for 
genomic stability. USP7 has a crucial role in the regulation of DNA damage response through 
stabilization or modulation of key proteins involved in the DNA break signaling pathways, such 
as Claspin, Chk1, Bub3, Rad18, ARF-BP1, PRC1, CHFR and Rb. DNA damage leads to ATR 
kinase dependent phosphorylation and activation of Chk1through Claspin, an adaptor protein, 
which itself is subject to ubiquitination and proteasomal degradation. USP7 through regulation of 
Claspin’s half-life controls the duration of Chk1 phosphorylation and response to DNA damage 
(Alonso-de Vega et al. 2014; Faustrup et al. 2009). USP7 is also implicated in cell cycle 
regulation through stabilization of retinoblastoma-associated protein (Rb). Rb, a major 
checkpoint protein, is implicated in both cell cycle progression and cell cycle inhibition which is 
mostly mediated through its interaction with, and inhibition of E2F transcription factor 
(Bhattacharya & Ghosh 2014). Upon genotoxic stress phosphorylation of Rb by p38, mitogen-
activated kinase, promotes its recognition and ubiquitination by Hdm2 E3 ligase, which leads to 
activation of E2F and apoptosis (Delston et al. 2011). In normal human cells, USP7 was shown 
to directly interact with Rb and stabilize it from Hdm2 mediated degradation (Bhattacharya & 
Ghosh 2014).  
 
   Further, USP7 depletion is correlated with mitotic abnormalities and genomic instability 
(Giovinazzi et al. 2014). Spindle assembly checkpoint monitors attachment of chromosomes to 
the mitotic spindle and prevents segregation errors. It’s been shown that USP7 interacts with and 
stabilizes Bub3, a mitotic checkpoint protein and a subunit of the spindle assembly checkpoint. 
Depletion of USP7 decreases cellular levels of Bub3 and leads to genomic instability (Giovinazzi 
et al. 2014; Maresca & Salmon 2010). USP7 is also implicated in the regulation of CHFR, a 
RING domain E3 ligase and a mitotic stress checkpoint protein. CHFR activation upon mitotic 
stress signal leads to ubiquitination and proteasomal degradation of mitotic kinases such as 
Aurora A and Plk1 (polo-like kinase1) and therefore delays entry into metaphase. USP7 interacts 
with CHFR and stabilize it from autoubiquitination (Oh et al. 2007).  
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   Furthermore, USP7 downregulation leads to impaired translesion synthesis (TLS) response and 
defective replication. Bulky DNA lesions block DNA polymerase and stall replication. Rad18, 
an E3 ligase enzyme and a substrate of USP7, along with Rad6 its cognate E2 conjugating 
enzyme monoubiquitinate PCNA which leads to recruitment of TLS DNA polymerases and 
activation of DNA replication through DNA lesions (Zlatanou et al. 2016). Upon DNA damage 
signal USP7 mediated deubiquitination of Rad18 protects it from degradation and leads to the 
activation of the TLS pathway (Zlatanou et al. 2016). USP7 is also implicated in the base 
excision repair (BER) pathway through regulation of ARF-BP1 (also known as Mule) E3 ligase 
enzyme. In unstressed cells, ARF-BP1 primary function is suppression of p53 and 
downregulation of the BER pathway by destabilizing DNA polymerase ß, the major BER 
polymerase (Parsons et al. 2009). Ser18 phosphorylated isoform of USP7 interacts with ARF-
BP1 and inhibits its autoubiquitination and proteasomal degradation (Khoronenkova & Dianov 
2013). Upon DNA damage USP7 is dephosphorylated and destabilized by PPM1G phosphatase. 
This leads to autoubiquitination of ARF-BP1 and its proteasomal degradation. Downregulation 
of ARF-BP1 is necessary for activation of p53 and cellular DNA damage response 
(Khoronenkova & Dianov 2013). 
 
USP7 Regulation of Transcription and Epigenetics:  
 
   USP7 has been implicated in epigenetics through direct deubiquitination of histone H2B and 
regulation of proteins that are involved in DNA modification. The GMPS/USP7 complex 
opposes BRE1 E3 ligase monoubiquitination of histone H2B on Lys120 and promotes 
transcriptional silencing. Mutational analysis revealed that loss of GMPS or USP7 leads to 
increase in ubiquitinated histone H2B levels (van der Knaap et al. 2005). Further, GMPS/USP7 
complex through stabilization of PRC1 promotes histone H2A ubiquitination on Lys119 and 
leads to transcriptional repression (de Bie et al. 2010). PRC1 is also implicated in the regulation 
of INK4b-ARF-INK4a tumor suppressor locus. USP7 and USP11 mediated stabilization of 
PRC1 subunits, RING1B, BMI1 and MEL18, represses tumor suppressors ARF and p16/INK4a 
expression, which suggests an oncogenic role for USP7 (Maertens et al. 2010; Lecona et al. 
2015). USP7 is also involved in the regulation of DNA methylation through interaction with 
UHRF1 (Ub like with PHD and RING finger domains 1) and DNMT1 (maintenance DNA 
methyltransferase 1) proteins. UHRF1 is a RING domain E3 ligase enzyme that strongly 
associates with the heterochromatin and has been shown essential for maintaining genomic 
methylation (Zhang et al. 2015). UHRF1 recruits DNMT1 to heterochromatin to maintain DNA 
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methylation on the newly synthesized DNA strands. USP7 forms a heterodimer with DNMT1 
which then associates with UHRF1 on the silenced methylated chromatin (Felle et al. 2011). 
USP7 interacts with DNMT1 through its C-terminal domain, stimulates DNMT1 enzymatic 
function and stabilizes it from UHRF1 negative regulation (Felle et al. 2011). UHRF1 interacts 
with the both N-terminal TRAF domain and C-terminal Ubl12 binding motif of USP7, which is 
important for is stabilization from autoubiquitination (Pfoh, Lacdao, Georges, et al. 2015). USP7 
also allosterically promotes UHRF1 chromatin association (Zhang et al. 2015).  
 
USP7 as a Target for Herpesviruses: 
 
Human Herpesviruses (HHVs):  
 
   Herpesviruses are members of the Herpesviridae, a large family of double stranded DNA 
viruses, which can establish latent infection in their respective hosts (Edelman 2005). Out of 
more than 100 identified herpesviruses only eight species are known to routinely infect humans, 
including herpes simplex virus types 1 and 2 (HSV-1 & HSV-2), varicella-zoster virus (VZV/ 
HHV-3), Epstein-Barr virus (EBV/ HHV-4), human cytomegalovirus (HCMV/ HHV-5), human 
herpesvirus 6A & 6B (HHV-6A & HHV-6B), human herpesvirus 7 (HHV-7) and Kaposi's 
sarcoma associated herpesvirus (KSHV/ HHV-8) (Alibek et al. 2014). Mammalian herpesviruses 
are further classified into α, β or γ subfamilies mainly based on their genetic properties and 
evolutionary relatedness (Edelman 2005). The alphaherpesvirinae have an extremely short 
reproductive cycle in host cells (about one hour), infect a wide range of tissues and are able to 
stablish latent infection in sensory nerve ganglia. HSV-1, HSV-2 and VZV are 
alphaherpesviruses (Edelman 2005). The betaherpesvirinae, including HCMV, HHV-6 and 
HHV-7, share a long reproductive cycle. They have restricted host range and stablish latency 
mostly in lymphocytes and secretory glands (Edelman 2005). The gammaherpesvirinae also 
show very restricted host range and stablish latency in lymphoid tissue which is generally 
restricted to T or B cells. EBV and KSHV belong to this subfamily (Edelman 2005). HHVs are 
extremely widespread and more than 90% of adults have been infected with at least one type of 
these viruses (Alibek et al. 2014; Edelman 2005). In the majority of cases, treatment of the 
infection symptoms does not clear the virus and the latent form of the virus persists during the 
lifetime of the host (Chisholm & Lopez 2011). To stablish latency, herpesviruses have to 
suppress host immune responses and evade the immune system (Wen & Damania 2010). HHVs 
have evolved various mechanisms for host immune evasion including inhibition of cellular 
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senescence and apoptosis as well as promoting cell proliferation (Alibek et al. 2014; Wen & 
Damania 2010). Considering the crucial role of USP7 in regulating multiple tumor suppressor 
proteins and the DNA damage response pathways, it is not surprising that several proteins 
expressed by HHVs directly interact with USP7 and deregulate its function.  
 
HHV Proteins Interaction with USP7: 
 
   Members of the herpesvirus family, such as HSV-1, EBV, KSHV and HCMV have evolved to 
interfere with the USP7 regulated pathways by competitively binding to USP7 and hindering its 
interaction with cellular substrates and binding proteins (Salsman et al. 2012; Lee et al. 2009; 
Saridakis et al. 2005; Everett et al. 1997). USP7, initially known as herpesvirus associated USP 
(HAUSP), was isolated as an interacting partner with HSV-1 ICP0 protein (Everett et al. 1997). 
ICP0 is a RING domain E3 ligase enzyme that promotes degradation of host PML-NBs 
associated proteins, such as PML and Sp100 (Lanfranca et al. 2014). PML proteins are primary 
components of PML-NBs which are mediators of crucial cellular functions such as p53 
activation, DNA damage response, apoptosis and inhibition of viral genome replication in the 
nucleus (Lanfranca et al. 2014). The ICP0 C-terminal KXXXK sequence tightly interacts with 
the USP7 758DELMDGD764 motif on Ubl2. USP7 stabilizes ICP0 from autoubiquitination while 
ICP0 ubiquitinates USP7 and downregulates its cellular levels (Pfoh, Lacdao, Georges, et al. 
2015). Further, ICP0 promotes translocation of USP7 to the cytoplasm where in complex with 
ICP0, USP7 deubiquitinates TRAF6 and NEMO Lys63-linked Ub chains and downregulates 
TLR mediated NF-κB activation and inflammatory cytokine response (Daubeuf et al. 2009) 
 
   Epstein-Barr virus, another USP7 interacting HHV, immortalizes B-lymphocytes during its 
latent infection and is implicated in multiple carcinomas and lymphomas. EBNA1, an EBV 
expressed latent protein, is involved in the maintenance of latent EBV genome, initiation of 
DNA replication and transcriptional activation of latent proteins (Frappier 2012; Pattle & Farrell 
2006). Structural analysis revealed that EBNA1 binds the USP7 TRAF domain DWGF binding 
pocket with much higher affinity than USP7 cellular substrates, such as p53 and Hdm2 (Sarkari 
et al. 2010). It decreases cellular levels of p53 and subsequently suppresses DNA damage 
mediated apoptosis. In addition, EBNA1 induces degradation of PML, tumor suppressor protein, 
through simultaneous interaction with USP7 and CK2 kinase. EBNA1 recruits USP7 and CK2 to 
PML-NBs and induces CK2 mediated phosphorylation of PML protein. This leads to 
ubiquitination and degradation of PML. USP7 further downregulates PMLs independent of its 
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catalytic activity and p53 stabilization. EBNA1 mediated degradation of PMLs is linked to EBV-
induced nasopharyngeal carcinoma (Sarkari et al. 2011; Sivachandran et al. 2010). 
   KSHV is the causative agent of Kaposi’s sarcoma and primary effusion lymphoma. Multiple 
KSHV expressed proteins have shown interaction with USP7. Viral interferon regulatory factors 
1 and 4 (vIRF1 & vIRF4), latency-associated nuclear antigen 1 (LANA) and ORF45 
competitively bind USP7-NTD at the same region as USP7 cellular substrates (Chavoshi et al. 
2016; Gillen et al. 2015; Jager et al. 2012; Lee et al. 2011; Sarkari et al. 2010; Lee et al. 2009; 
Saridakis et al. 2005). They block USP7-substrate interaction, cripple the cell’s interferon and 
innate immune response and suppress p53 mediated apoptosis (Lee et al. 2009; Saridakis et al. 
2005). Further, vIRF4 also directly interacts with Hdm2 and inhibits its autoubiquitination while 
vIRF1 interacts with p53 and inhibits its acetylation and transactivation by p300  (Nakamura et 
al. 2001). Therefore, multiple KSHV expressed proteins have evolved to target USP7 and other 
proteins in the p53-Hdm2 pathway to comprehensively suppress p53 activity. 
   UL35, an HCMV latent protein, is implicated in viral gene expression and replication. UL35 
gene codes for two proteins: UL35 and UL35a, both of which were shown to interact with USP7. 
UL35 but not UL35a was reported to effect USP7 subcellular localization and inhibit USP7 
nuclear body formation independent of their disruptive effect on PML-NBs (Salsman et al. 
2012). The function of USP7 nuclear bodies is currently unknown, however they are associated 
with PML-NBs formation (Salsman et al. 2012). 
 
X-ray Crystallography: 
 
   Three-dimensional structures of proteins can help identify common features, modes of 
regulation and protein interaction (Shapiro & Harris 2000). Atomic-level structural data provide 
crucial information, such as nature of the chemical bonds and chemical reaction mechanisms. In 
recent years, use of structural information has become an essential part of pharmaceutical drug 
discovery and optimization. Structural information on target proteins and their binding sites help 
optimize lead compounds and improve quality and selectivity of the drugs (Klebe 2000). To 
obtain the structure of a protein by crystallography, the initial steps include cloning, expression 
and purification of a soluble, highly pure and homogenous protein (Luna-Vargas et al. 2011). 
The subsequent step is a random and coarse screening using sparse matrix kits for conditions that 
would support crystal formation. In case of a successful hit, this step is followed by optimization 
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of the crystal quality. Crystals are then used for X-ray diffraction data collection and structure 
determination, which results in a three dimensional model of the protein (Blundell & Patel 2004). 
 
Protein Crystallization: 
 
   In aqueous solutions and under non-denaturing conditions, pure and homogenous soluble 
proteins undergo slow precipitation which can promote protein crystallization. Slow precipitation 
allows the formation of a crystalline lattice consisting of organized repeats of protein units that 
are held together by noncovalent bonds (Rhodes 2006). The first stage in protein crystallization 
is nucleation which leads to the formation of thermodynamically stable protein aggregate also 
known as the critical nucleus. The crystal growth stage follows when macromolecules diffuse to 
the surface of the critical nucleus. Then growth ceases as protein concertation in the solution 
depletes or the growing faces of the crystal gets interrupted by impurities (Rupp 2010). Crystal 
growth can be visualized using a two-dimensional phase diagram depicting the change in the 
protein concentration versus concentration of the precipitating agent. Two major zones can be 
identified in the graph: unsaturated and supersaturated (Fig. 1-13). The unsaturated zone never 
supports crystal formation (Krauss et al. 2013). As the protein concentration increases beyond its 
solubility limits, solution becomes saturated and supersaturated. The supersaturated zone can be 
further divided into two zones. In the precipitation zone, very high concentration of protein leads 
to amorphous protein aggregation. In the nucleation zone or labile zone, intermediate 
supersaturation leads to the critical nucleus formation, while at metastable zone (lower 
supersaturation) only crystal growth is supported. In optimal cases, few critical nuclei form in the 
nucleation zone and as crystals grow, decreases in the protein concentration in the solution shift 
the system to the metastable zone where only crystal growth is supported and there is no more 
nucleation (Fig. 1-13) (Krauss et al. 2013; Boistelle 1986). 
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Fig. 1-13: Protein solubility phase diagram as a function of protein concentration. (Reprinted 
from MDPI: Journal of Biological Sciences, (Krauss et al. 2013), copyright 2013). 
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   In practice, it is very difficult to find perfect conditions for crystal nucleation and growth and 
there are no systematic methods that would assure crystallization of macromolecules. Such 
conditions must be experimentally and individually developed for each protein. Furthermore, 
only 13-15% of soluble proteins that enter crystallization trials form crystals that are useful in 
structure determination (Wernimont & Edwards 2009). 
 
Crystallization Screening Methods: 
 
   The most common protein crystallization screening methods include vapor diffusion and 
microbatch. In the vapor diffusion method, a few microliters of the protein in precipitation buffer 
is exposed to a reservoir containing the same precipitation buffer (100-500 µL) with slightly 
higher concentration than the protein droplet. Then the well is sealed to achieve equilibrium. As 
the equilibrium forms over the protein droplet, water molecules evaporate from the protein until 
the concentration of the protein droplet and the reservoir reaches equilibrium. The slow increase 
in the concentration of the protein and precipitant in the droplet can help shift the solution to 
supersaturation zone (Benvenuti & Mangani 2007). If all the other parameters such as 
temperature, pH, ionic strength, type of precipitant, etc. are appropriate, a critical nucleus can 
form and crystal growth will follow. Vapor diffusion screens can be set up as sitting drops where 
a protein droplet is placed on a pedestal above the reservoir level or hanging drops where a 
protein droplet is placed on an inverted lid or coverslip over the reservoir (Fig. 1-14A & B). In 
both methods, the environment is sealed to achieve equilibrium. In sandwich drop vapor 
diffusion technique protein droplet is placed between two coverslips over the buffer reservoir 
(Fig. 1-14C) (Krauss et al. 2013; Benvenuti & Mangani 2007). Another screening method is 
micro-batch where a small volume of the protein mixed with precipitant is placed on a well in a 
plate and is then covered with paraffin oil to prevent evaporation. In this method concentration of 
the precipitant and volume of the drop remains unchanged. However, the formation of protein 
aggregates or crystals can change protein concentration (Fig. 1-14D) (Krauss et al. 2013; Rupp 
2010). 
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Fig. 1-14: Common crystallization screening methods. In vapor diffusion method, equilibrium is 
achieved in a sealed environment. Water molecules evaporate from less concentrated protein 
droplet and gradually increase protein concentration which can lead to crystal formation. A) 
Hanging drop vapor diffusion where protein droplet is placed on an inverted lid or coverslip over 
the reservoir. B) Sitting drop vapor diffusion where protein droplet is placed on a well above the 
reservoir level. C) Sandwich drop vapor diffusion technique where protein droplet is placed 
between two coverslips over the buffer reservoir. D) Microbatch method where a small volume 
of the protein mixed with precipitant is placed on a well in a plate and is then covered with 
paraffin oil to prevent evaporation. (Reprinted from MDPI: Journal of Biological Sciences, 
(Krauss et al. 2013), copyright 2013). 
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   Substances known to precipitate proteins including salts, organic solvents and polymers, are 
typically used in crystallization solutions. Formation of a protein crystal has a very low success 
rate and depends on a variety of factors, such as protein concentration and purity, pH, 
temperature, ionic strength, pressure and types of precipitants and additives used (Krauss et al. 
2013). Any substance that is added to the crystallization screen other than the compounds present 
in the precipitation buffer is considered an additive, such as cofactors, ligands, metal ions, salts, 
detergents, alcohols and amino acids (Krauss et al. 2013). Search for optimal conditions that can 
support nucleation and crystal growth is done through an initial random or coarse screening to 
identify crystalline conditions. These conditions are then optimized and refined using a 
systematic screening approach. The most common approach in screening is based on the sparse-
matrix screens where varying precipitants are made according to the literature and based on the 
conditions that have previously led to the formation of quality crystals (Wooh et al. 2003).  
 
X-ray Diffraction: 
 
   X-ray crystallography is a form of very high-resolution microscopy that is used to determine 
the three-dimensional structure of a protein. Chemical bonds between atoms in a molecule are 
about 1.5 angstrom (Å) apart; therefore, electromagnetic radiation such as X-rays with 
wavelengths in the angstrom range can be used to visualize them (Rhodes 2006). Ideally, the 
diffraction pattern from the crystal should be better than 4 Å resolution to distinguish secondary 
structure and better than 2.5 Å to distinguish hydrogen bonds (Munshi et al. 2012; Jeffrey 1997). 
Many ordered molecules in a crystal produce a strong and detectable diffraction pattern which 
appears as series of distinct spots referred to as reflections (Rupp 2010). The intensity of the 
spots, their amplitude and positions are measured by an optical scanner to produce an electron 
density map. Diffracted X-rays refer to the clouds of electrons and their distribution in the 
molecules, which is known as electron density. Using the protein’s known amino acid sequence, 
the electron density map is fitted with a molecular model that must contain appropriate bond 
lengths, bond angles, conformational angles and distance between adjacent groups (Rupp 2010; 
Rhodes 2006). 
 
Improvement of X-ray Diffraction Quality: 
 
   Techniques, such as microseeding with microcrystals are employed to promote either 
nucleation or formation of larger or better-quality crystals. Typically, a high level of 
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supersaturation is needed for nucleation to occur, which either is not achievable or can lead to a 
large number of nuclei formation and very small crystal growth (Oswald et al. 2008). A seed or 
nucleation agent provides a solid base for crystal growth by lowering the required energy for 
spontaneous nucleation (Oswald et al. 2008). Microseeding is done by transferring a microscopic 
crystal from a higher supersaturated solution to a lower supersaturated one (Oswald et al. 2008). 
Obtained crystals can be further soaked in ligands, inhibitors or heavy atoms to produce crystal 
ligand complex, or to improve crystalline lattice (Mizutani et al. 2014). Cross-linking reagents 
can be added to crystals to improve protein-protein docking, structural rigidity and handling of 
the crystals (Leitner et al. 2010). Annealing is another method used to increase the quality of X-
ray diffraction which includes warming up flashed-cooled crystals to room temperature followed 
by reflash-freezing. Annealing has shown success in decreasing static disorder and mosaicity of 
the crystals (Harp et al. 1998). Further, optimization methods are employed to screen for best 
cryo conditions and improve quality of cryo-protectants for each protein. Cryo-protectants are 
used to avoid freezing of protein crystals and ice formation when crystals are exposed to liquid 
nitrogen stream during X-ray exposure (Rupp 2010). Another method to improve quality of 
crystals is the removal of highly flexible regions of proteins, such as loops or N-terminal or C-
terminal unstructured regions. This is done by designing deletion mutant constructs or by partial 
proteolysis of the pure protein using proteolytic enzymes such as trypsin (Wernimont & Edwards 
2009). If a protein contains flexible domains each domain can be expressed and crystallized 
separately. Further, point mutation can be used to alter surface residues that interfere with the 
formation of a well-ordered crystal lattice (Malawski et al. 2006). 
  
Thesis Rationale and Outline: 
 
   Deubiquitinating enzymes negatively regulate ubiquitination and have crucial roles in many 
cellular processes such as regulation of protein stability, protein trafficking, cell cycle 
progression and DNA transcription and replication. Ubiquitin specific proteases, USPs in 
humans/ Ubps in yeast, are the largest family of deubiquitinating enzymes. USPs/Ubps 
involvement in many important pathways and cellular processes implicated in disease, disorder 
and cancer have made them an important subject of investigation. In the following chapters we 
have set out to investigate S. cerevisiae Ubp enzymes expression, function and structure and 
further shed light into the novel interaction of two human herpesviruses proteins with the human 
USP7 deubiquitinating enzyme. 
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   S. cerevisiae Ubps have shown significant conservation of sequence and function with their 
human homologues. Lack of intron in S. cerevisiae UBP genes and less complicated post-
translational modifications make them a much more convenient target for cloning, expression 
and purification and further functional studies compared to their human homologues. In chapter 
2, we explored the possibility of expressing soluble recombinant S. cerevisiae Ubp enzymes in E. 
coli for the purpose of crystallography and structure determination. Multiple optimization 
methods were employed to express soluble proteins in E. coli and further purify these proteins 
for crystallization trials and screening. In chapter 2 we also provide the three-dimensional 
structure of yeast Ubp6 catalytic domain and further investigate yeast Ubp15, USP7 homologue, 
mechanism of substrate interaction. 
 
   In order to stablish latency human herpesviruses (HHVs) have evolved various mechanisms for 
host immune evasion, such as inhibition of cellular senescence and apoptosis and promoting cell 
proliferation. Deregulation of proteins involved in growth control has led to the recognition of 
some HHVs as underlying agents of human cancer. Proteins expressed by some members of the 
HHV family have evolved to interfere with the USP7-p53-Hdm2 pathway. They competitively 
bind to USP7 and hinder its interaction with cellular substrates or binding proteins. They block 
USP7-substrate interaction and cripple the cell’s interferon and innate immune response and p53 
mediated apoptosis. In chapter 3, we identified vIRF1 protein expressed by Kaposi’s sarcoma-
associated herpesvirus (KSHV) as a novel interacting protein with human USP7 and 
characterized this interaction using structural analysis of USP7-NTD and vIRF1 peptide complex 
and a series of in vitro pull-down assays. Further, we confirmed this interaction in vivo and 
investigated the effect of vIRF1 expression on proteins involved in the USP7-p53-Hdm2 
pathway. 
 
   In chapter 4, we identified pp71 tegument transactivator protein expressed by human 
cytomegalovirus as a novel interacting protein with the human USP7 N-terminal domain and 
further characterized this interaction using complex crystal structure of the USP7 N-terminal 
domain with pp71 peptide and series of in vitro assays. The interaction was confirmed in vivo 
and effect of pp71 expression on the USP7-p53-Hdm2 pathway was analyzed. 
 
   Chapter 5 provides a summary of findings, future directions and concluding remarks.  
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Chapter 2: Investigating Expression and Purification of S. 
cerevisiae Ubps for Protein Crystallography; Crystal 
Structure of Ubp6 and Insight into the Interaction 
Mechanism of the Ubp15 N-Terminal Domain  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Fig. 2-4 (S. cerevisiae Ubp6 catalytic domain structure) Dr. Saridakis supervised the 
experiment and collected crystal diffraction data. Dr. Roland Pfoh refined the diffraction data. I 
set up and performed the experiments and produced the final figures. In Fig. 2-9 (Superimposed 
15N HSQC spectra of Ubp15-NTD before and after titration with (E/P/A)XXS containing 
peptides) Dr. Saridakis and Dr. Sheng supervised the experiment. Procedure was done with the 
help of Sahar Farhadi and I analyzed the data and produced the figures. I performed all other 
experiments in this chapter.  
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Introduction: 
 
Ubiquitination: 
 
   Eukaryotic proteins undergo a variety of post-translational modifications, which help regulate 
and extend their functional diversity. One such modification is protein ubiquitination, where a 
multistep enzymatic process results in the addition of ubiquitin (Ub) moieties to specific 
substrate proteins. A covalent isopeptide bond forms between the carboxyl-terminal glycine of a 
ubiquitin molecule and either the amino-terminal or amino group of lysine residues of the 
specific substrate protein (Callis 2014; Varshavsky 2012; Hershko 2005). Up to 20% of yeast 
proteins under standard growth conditions have been found conjugated to ubiquitin (Peng et al. 
2003). Ubiquitin itself possesses seven lysine residues including: Lys6, Lys11, Lys27, Lys29, 
Lys33, Lys48 and Lys63, which all can participate in the assembly of polyubiquitin chains. This 
leads to variety of modifications ranging from mono to poly ubiquitination of the substrate 
protein and results in varying Ub-Ub linkages, which dictate the fate of the tagged protein 
(Faggiano et al. 2016; Trempe 2011). Polyubiquitination of a substrate with Lys48 linked 
ubiquitins provides a strong signal for recognition and degradation by the 26S proteasome and 
forms the most abundant type of ubiquitination. Mono or multi-monoubiquitination in most cases 
is linked to protein trafficking and proteasomal independent degradation (Callis 2014; Kulathu & 
Komander 2012). Apart from protein degradation, ubiquitination is implicated in other cellular 
functions such as DNA repair, DNA transcription, cell cycle progression and signal transduction. 
For instance, Lys11-linked ubiquitin chains, the second most abundant Ub linkage in yeast, are 
involved in both cell cycle control and proteasomal degradation, while Lys63-linked Ub chains 
regulate the NF-kb and the DNA repair signaling pathways (Finley et al. 2012; Trempe 2011; Xu 
et al. 2009).  
 
Deubiquitinating Enzymes: 
 
   The ubiquitination process is reversible. Deubiquitinating enzymes (DUBs) reverse 
ubiquitination by hydrolyzing the isopeptide bond between the C-terminal glycine (Gly76) of Ub 
and lysine residue of the substrate or another ubiquitin (Varshavsky 2012; Nijman et al. 2005). 
DUBs belong to the cysteine or metalloprotease families. Hydrolysis of the isopeptide bond by 
cysteine/thiol proteases relies on the function of three conserved cysteine, histidine and aspartate 
residues in their active site. A polarized aspartic acid assists histidine to deprotonate the thiol 
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group of the cysteine. Then deprotonated cysteine launches a nucleophilic attack on the 
substrate’s carbonyl group carbon to form an intermediate thioester bond, which is then 
hydrolyzed to free the enzyme and form a carboxylic acid group on the remaining substrate 
(Eletr & Wilkinson 2014; Katz et al. 2010). Metalloproteases coordinate a Zn2+ ion in their 
active site typically with the help of two histidine residues, an aspartic acid and a water 
molecule, which is required for hydrolysis (Shrestha et al. 2014). 
 
   Cysteine protease DUBs are further divided into four subclasses based on the structure of their 
catalytic domain: ubiquitin-specific proteases (USP), ubiquitin C-terminal hydrolases (UCH), 
ovarian tumor domain proteases (OTU) and Machado Joseph disease proteases (MJD) (Sahtoe & 
Sixma 2015; Nijman et al. 2005). Recently a new family of cysteine proteases has been 
described, referred to as MINDY (motif interacting with Ub-containing novel DUB family), with 
members identified in yeast as well as mammals (Abdul Rehman et al. 2016).  
 
Cellular Functions of DUBs: 
 
   DUBs are important regulators of the ubiquitin-proteasome system. Prior to degradation of 
substrate proteins by the 26S proteasome, DUBs remove polyubiquitin chains and assist in 
unfolding and translocation of proteins into the proteasome chamber (Finley 2009). Efficient 
removal of ubiquitin from substrate proteins prior to their rapid proteolysis inhibits inappropriate 
degradation of the ubiquitin tag along with the doomed protein and is crucial for maintaining 
available cellular ubiquitin pool for protein modifications (Eletr & Wilkinson 2014). Several 
DUBs have been found associated with the proteasome, such as yeast Ubp4, Ubp6 (USP14 in 
mammals) and Rpn11 (a metalloprotease) (Lee et al. 2011). In the absence of the proteasome 
associating Ubps, ubiquitin is very unstable and has a short half-life of 2 hours (Hanna et al. 
2003). Furthermore, DUBs, through removal of the Lys63-linked Ub chains or single ubiquitin 
tags regulate cellular levels of proteins that are targeted for endocytosis and degradation in 
lysozymes (Piper et al. 2014; Dupre & Haguenauer-Tsapis 2001). Monoubiquitination of yeast 
endocytic and plasma membrane proteins were previously reported which suggests a role for 
DUBs in the regulation of membrane-bound proteins half-life (Clague et al. 2012; Polo et al. 
2002). Deubiquitinating enzymes also remove ubiquitin tags from inappropriately tagged 
proteins involved in the ubiquitin-proteasome pathway and stabilize them, such as E3 ligases 
(Komander et al. 2009). Further, DUBs are involved in disassembly of the ubiquitin chains after 
their removal from tagged proteins. Excessive accumulation of ubiquitin chains competes with 
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the polyubiquitinated substrates for the 26S proteasome and inhibits proteasomal degradation.  
Deubiquitinating enzymes are also involved in non-proteolytic functions such as regulation of 
transcription and DNA damage response through deubiquitination of histone H2A and H2B (Cao 
& Yan 2012; Emre et al. 2005; Henry et al. 2003). Further, all ubiquitins are expressed with a C-
terminal extension beyond the Gly76. These precursors are either expressed as ubiquitin fused to 
ribosomal proteins or as ubiquitin multimers linked through their first and last residues. Proper 
cleavage of Ub precursors is essential for generation of functional ubiquitins. Many DUBs in 
yeast have shown Ub precursor cleaving activity (Clague et al. 2012; Hochstrasser & Amerik 
2004).   
 
Yeast S. cerevisiae Ubp Enzymes: 
 
   A large number of DUBs belong to the USP subclass, which is known as Ubps in yeast. 
USPs/Ubps share well-conserved sequences known as His and Cys boxes that include the 
catalytic residues (Tencer et al. 2016; Nijman et al. 2005). The catalytic domains of Ubps vary 
greatly in size which indicates different modes of regulation, function and substrate interaction. 
Ubps have also shown substrate specificity. This is achieved through different extensions in their 
structure which modulates their cellular localization and protein-protein interaction. Ubps also 
gain specificity through recognition of specific Ub linkages, mono or poly Ub chains, free or 
bound polyubiquitin chains and affinity for certain substrates (Katz et al. 2010). Removal of Ub 
tags from specific substrates has crucial physiological impact on cellular processes. For instance, 
deletion of yeast Ubp3 leads to transcriptional silencing at the telomeres, whereas deletion of 
yeast Ubp10, which works in contrast to Ubp3, significantly reduces levels of Sir4, a protein 
involved in silencing of the heterochromatin (Emre et al. 2005; Kahana & Gottschling 1999). 
 
   Saccharomyces cerevisiae (S. cerevisiae) expresses 16 Ubp enzymes, which are involved in 
differentially regulating various cellular processes, such as protein degradation and transport and 
chromosomal modification. Under standard growth conditions deletion of S. cerevisiae Ubps 
indicated that they are non-essential for growth, suggesting overlapping functions (Reyes-Turcu 
et al. 2009). 
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Project Rationale: 
 
   Proteins function correlates with their three-dimensional fold. Structural studies can help 
identify common and evolutionary conserved features and provide clues to proteins specificity, 
function and interaction (Shapiro & Harris 2000). Generation of soluble proteins with high purity 
is essential for protein crystallography as well as assays, biochemical characterizations and 
industrial use (Hoi et al. 2015; Luna-Vargas et al. 2011). S. cerevisiae Ubps have shown 
significant conservation of sequence and function with their human homologues. Lack of introns 
in S.c. UBP genes and less complicated post-translational modifications make them much more 
convenient targets for cloning, expression and purification and further functional studies as 
compared to their human homologues. The first step towards structural studies is the production 
of soluble and pure proteins. The ability to express and purify large quantities of recombinant 
proteins from Escherichia coli and availability of a variety of molecular tools has made it an 
attractive choice for protein expression, despite its lack of post-translational modifications 
(Rosano & Ceccarelli 2014). To investigate expression of soluble S. cerevisiae Ubps from E. coli 
for protein crystallography and structure determination, 127 constructs encompassing full-length 
or selected domains of all 16 Ubps and Sad1 and Pan2 proteins (catalytically inactive Ubps) 
were designed.  
 
   Further, both S. cerevisiae Ubp15 and its well-studied human homologue, USP7, harbor a 
highly conserved DWGF motif in their N-terminal domains (NTD) (Bozza & Zhuang 2011; 
Sheng et al. 2006). The DWGF motif in USP7-NTD is efficiently recognized by its cellular 
substrates and interacting proteins through their (P/A/E)XXS sequence, where X stands for any 
amino acids (Sheng et al. 2006; Saridakis et al. 2005). To gain insight into the S. cerevisiae 
Ubp15 mode of protein interaction, we analyzed binding affinity of Ubp15-NTD for the 
(E/P/A)XXS motifs using fluorescence polarization binding assays and NMR titrations.  
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Material and Methods: 
 
Primer Design and Construct Amplification: 
 
Prior to primer design for polymerase chain reaction (PCR) amplification of the S. cerevisiae 
Ubp constructs, primary amino acid sequences and secondary predicted structures were analyzed 
by Phyre2 web portal for protein modeling (Kelley et al. 2015). Primers were designed for 
ligation independent infusion based cloning with p15TV-L vector (GenBank ID: EF456736.1). 
(5’ TTG TAT TTC CAG GGC 3’) and (5’ CAA GCT TCG TCA TCA 3’) inserts, which are 
required for homologous recombination with the vector, were added to the 5’ ends of the forward 
and reverse primers respectively (Appendix A). To clone Ubp3 constructs into the pET-28b 
expression vector (Novagen #69865-3), restriction enzymes cut sites of NcoI (5’ GCG CCC 
ATG GGC 3’) and XhoI (5’ GCG CTC GAG 3’) were added to the 5’ ends of the forward and 
reverse pET-28b primers respectively (Appendix A).  
To amplify Ubp constructs, S. cerevisiae cells were grown overnight in yeast growth media 
(BioShop), followed by genomic DNA extraction using MasterPure™ yeast DNA purification 
kit (Epicentre, #MPY80200), according to the manufacturer’s protocol. PCR reactions were set 
up in 50 µL reaction volumes using 0.1 µL Pfu high-fidelity DNA polymerase (gift from Dr. 
Dinesh Christendat, University of Toronto), 1xPfu buffer (200 mM Tris-HCl pH 8.8, 100 mM 
(NH4)2SO4, 100 mM KCl, 1 % (v/v) Triton X-100, 1 mg/mL BSA), 250 µM dNTP (Fermentas), 
300 ng S. cerevisiae genomic DNA (measured using Thermo Scientific NanoDrop 2000), 1 µM 
of each forward and reverse primer and 250 µM MgSO4. PCR reactions were set up using 
standard protocols at annealing temperatures 5-7ºC lower than primers melting point in a Hybaid 
Px2 Thermal Cycler (Thermo Scientific). Amplified fragments were purified using GFX™ PCR 
DNA purification kit (GE Healthcare) as outlined by the manufacturer. 
Cloning of the Constructs: 
 
All vectors were initially transformed into chemically competent DH5α E. coli following a 
standard chemical transformation protocol (Yoshida & Sato 2009). Plasmids were amplified and 
retrieved via a DNA plasmid miniprep kit (Qiagen). p15TV-L vector was linearized with BseRI 
restriction enzyme (New England BioLabs, #R0581S) for 1 hour at 37°C and purified with a 
GFX™ PCR DNA purification kit (GE Healthcare) according to the manufacturer’s protocol and 
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eluted in 40 µL dH2O to achieve DNA concentration of ~100 ng/ µL (measured using a Thermo 
Scientific NanoDrop). For ligation independent cloning 1 µL of vector and insert were annealed 
using an In-Fusion HD cloning kit (Clontech) in p15TV-L according to the manufacturers 
protocol. 1 µL of annealing reaction was transformed into 25 µL of electrocompetent DH5α E. 
coli cells following a standard electroporation protocol (Yoshida & Sato 2009). Cells were 
grown on Luria-Bertani (LB) agar (Bioshop) plates, supplemented 100 µg/mL ampicillin (for 
selection of p15TV-L vector), at 37°C overnight.  
 
For cloning into pET-28b, the vector and the inserts were digested with NcoI and XhoI 
restriction enzymes (New England BioLabs) for 15 min at 37ºC and purified as mentioned 
above. Digested vector was further treated with calf intestinal alkaline phosphatase (New 
England BioLabs) for 15 min at 37ºC, purified and eluted in 40 µL dH2O to achieve DNA 
concentration of ~100 ng/ µL. 1 µL of digested vector and insert were ligated with T4 DNA 
ligase (New England BioLabs) in 10 µL reaction volume at 16ºC overnight according to the 
manufacturer’s protocol. 1 µL of the ligated mixture was electroporated into 25 µL 
electrocompetent DH5α E. coli and incubated on LB agar plates supplemented with 50 µg/mL 
kanamycin (for selection of pET-28b vector) at 37°C overnight. All positive transformants were 
validated by PCR and further screened by sequencing using T7 forward and reverse primers. 
 
Protein Expression: 
All positive recombinant p15TV-L vectors were heat shock transformed into E. coli BL21 (DE3) 
mgk cells, which harbor a Kanamycin resistant plasmid coding for 3 rare E. coli tRNAs 
including two arginines (AGG and AGA) and one Ile (ATA) (gift from Dr. Dinesh Christendat, 
University of Toronto). The recombinant pET-28b vectors were transformed into either BL21 
DE3 or Rosetta Blue cells (Novagen, 71-059-3). Cells were grown in varying volumes of Terrific 
Broth (Bioshop) and the appropriate antibiotics at 37ºC. At OD600 nm of 1.2, expression was 
induced with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and was carried out at 16ºC 
overnight. For co-expression with trigger factor (Tig) chaperone (TaKaRa Chaperone Plasmid 
Set), pg-Tf2 plasmid was transformed into BL21 mgk cells prior to re-transformation with 
p15TV-L plasmid. BL21 mgk cells were cultured in TB broth with 20 µg/mL chloramphenicol, 
along with 100 µg/mL ampicillin and 50 µg/mL kanamycin for the selection of the transformed 
clones. Expression of the Tig chaperone was induced by addition of 0.5 mg/ml of L-arabinose 
prior to the recombinant protein induction with IPTG. For NMR titration, uniformly labeled 15N-
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labeled 6xHis-tagged Ubp15-NTD (residues 1-204) was expressed from p15TV-L vector in 
BL21 mgk cells in M9 media enriched with 0.7 g/L 15NH4Cl as the sole nitrogen source. 
Protein Purification: 
 
Cells were harvested at 7,446 x g for 20 minutes at 4ºC and lysed by sonication at 30% 
amplitude in binding buffer (50 mM Tris pH 7.5, 150-500 mM NaCl, 5 mM Imidazole, 1x 
protease inhibitor cocktail [1 mM Benzamidine and 0.5 mM PMSF] and 1x Protease inhibitor 
tablet [Roche cOmplete ULTRA Tablets]). Lysates were clarified by centrifugation for 1 hour at 
41,287 x g for 30 minutes at 4ºC. Supernatants were allowed to interact with nickel-
nitrilotriacetic acid (Ni-NTA) beads (Qiagen) for 1 hour on a nutator at 4ºC. Beads were washed 
extensively with wash buffer (50 mM Tris pH 7.5, 150-500 mM NaCl and 20 mM Imidazole). 
Proteins were eluted by addition of elution buffer (50 mM Tris pH 7.5, 150-500 mM NaCl and 
250 mM Imidazole). Protein expression was verified by resolving samples on 12% SDS-
polyacrylamide gels followed by Coomassie blue staining or silver staining (Bio-Rad, Silver 
stain plus kit). All recombinant proteins were further purified by size exclusion chromatography 
using a HiLoad 16/60 Superdex 200 (GE Healthcare) on an ÄKTApurifier 10 UPC system (GE 
Healthcare) in 150, 300 or 500 mM NaCl and 20 mM Tris or Hepes pH 7.5. To remove fusion 
tags from the recombinant proteins expressed from p15TV-L or pET28-b vectors, proteins were 
incubated with tobacco etch virus (TEV) or thrombin proteases respectively, at 4ºC overnight, 
prior to size exclusion chromatography.  
 
Protein Crystal Screening and Optimization: 
 
Initial protein crystallization screening trials were set up using the vapor diffusion method in 96-
well sitting drop plates (Axygem, CP-AXYGEM-96-10) with sparse matrix crystallization suites 
including: JCSG I-IV, JCSG +, PEGs II, PACT and Classics II (Qiagen). 1 µL of purified protein 
was mixed with 1 µL of precipitant buffer against 100 µL reservoir solution followed by 
incubation at either 4ºC or 22ºC. Positive hits were further optimized in 15-well hanging drop 
vapor diffusion crystallization plates (EasyXtal 15-well Tools, Qiagen) by mixing 1 µL of 
varying purified protein concentration with 1 µL of precipitant buffer against 500 µL reservoir 
solution containing varying pH or precipitant concentrations. Additive screens (Hampton) for 
positive hits were also set up in 15-well hanging drop plates by mixing 1 µL of purified protein 
with 0.8 µL of reservoir buffer and 0.2 µL of provided additive. Plates were incubated at either 
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4ºC or 22ºC. Positive hits were further optimized by crystal seeding using Seed Bead Kit 
(Hampton) following manufacturers protocol.  
 
Partial proteolysis of recombinant proteins was performed by mixing trypsin (Sigma-Aldrich) 
and recombinant protein in a range of 1/100-1/10000 w/w ratio prior to crystallization screening 
according to (Wernimont & Edwards 2009).   
X-ray Data Collection and Structure Determination: 
 
X-ray data were collected at 100K on a Rigaku MicroMax007 rotating anode diffractometer with 
a 944+ charge-coupled device detector. Diffraction data were integrated and scaled using 
HKL2000 software. The Ubp6 structure was determined by molecular replacement method 
employing Ubp6 catalytic domain structure (Protein Data Bank ID 1VJV) as the search model 
using CNS 1.3 (Brunger 2007). The electron density was visualized and the Ubp6 protein model 
was built using Coot (Emsley & Cowtan 2004). REFMAC through PHENIX program suite was 
used for refinement and water picking at 2.5 Å resolution. The data collection and refinement 
statistics are shown in Table 2-2. Figures were prepared using PyMOL (Schrödinger 2010).  
 
Peptide Synthesis and Preparation:  
 
Peptides used in NMR studies, including wild-type (44SPGEGPSGTG53) and mutant 
(44SPGEGPAGTG53) vIRF1, wild-type (394FLDLAHSSE402) and mutant (394FLDLAHSAE402) 
HdmX, wild-type (152RVSPSTSYT160) and mutant (152RVSPSTAYT160) MCMBP and wild-type 
(395SQPSTSS401) and mutant (395SQPSTAS401) Hdm2, were synthesized by CanPeptide Inc. 
(Montreal, Canada) with both N-terminal acetylation and C-terminal amidation to mimic the 
native peptides. N-terminal fluorescein isothiocyanate (FITC) labeled wild-type 
(44SPGEGPSGTG53) and mutant (44SPGEGPAGTG53) vIRF1 and wild-type 
(400GGLPSSSKLA409) FOXO4 peptides used in fluorescent polarization assays were also 
synthesized by CanPeptide Inc. (Montreal, Canada).  
 
Fluorescence Polarization Binding Assay: 
 
N-terminal 6xHis-tagged USP7-NTD (residues 54-205) was expressed from the pET-15b vector 
and purified as described previously (Sheng et al. 2006). N-terminal 6xhis-tagged Ubp15-NTD 
and USP7-NTD were further purified by size-exclusion chromatography using a HiLoad 16/60 
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Superdex 200 (GE Healthcare) on an ÄKTApurifier 10 UPC system (GE Healthcare) in 150 mM 
NaCl and 50 mM Tris pH 8.0. FITC labeled wild-type (44SPGEGPSGTG53) and mutant 
(44SPGEGPAGTG53) vIRF1 and wild-type FOXO4 (400GGLPSSSKLA409) peptides were initially 
dissolved in dimethyl sulfoxide to a final concentration of 10 mM. Then 400 nM working stock 
of each peptide was prepared in assay buffer (150 mM salt, 50 mM Tris pH 8.0, 5% glycerol and 
0.01% Triton X-100). 795 µM of Ubp15-NTD and 500 µM concentration of USP7-NTD were 
serially diluted and shortly incubated with 40 nM fixed concentration of each peptide. 10 µl of 
the above dilutions were transferred into a 384 well plate (Corning) and fluorescence 
polarization was measured on a Synergy H4 microplate reader (BioTek, USA) with λex = 485 nm 
and λem = 520 nm. To obtain the equilibrium dissociation constant (Kd), polarization values were 
analyzed by Graphpad Prism 5.0 using a one-site binding model. Data were calculated based on 
three individual experiments and the standard deviation was calculated. 
 
NMR Spectroscopy: 
 
Uniformly 15N-labeled 6xhis-tagged Ubp15-NTD was incubated with TEV protease to cleave the 
6xHis fusion tag followed by dialysis into NMR buffer (200 mM NaCl, 25 mM Na phosphate pH 
7.0 and 10 mM DTT). Interaction of Ubp15-NTD with wild-type (44SPGEGPSGTG53) and 
mutant (44SPGEGPAGTG53) vIRF1, wild-type (394FLDLAHSSE402) and mutant 
(394FLDLAHSAE402) HdmX, wild-type (152RVSPSTSYT160) and mutant (152RVSPSTAYT160) 
MCMBP and wild-type (395SQPSTSS401) and mutant (395SQPSTAS401) Hdm2 peptides was 
monitored by analyzing 1H-15N HSQC spectra. Briefly, up to 0.4 mM of each unlabeled peptide 
was titrated in 0.2 mM of 15N-labeled Ubp15 (containing 10% D2O) up to 2:1 peptide:Ubp15 
molar ratio. NMR data were recorded at 25ºC using a triple resonance cryoprobe-equipped 
Bruker 700 MHz NMR spectrometer. Spectra were processed with Topspin 3.2 and analyzed 
with SPARKY program (Ye et al. 2012; Holowaty et al. 2003). 
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Results: 
 
Construct Design and Recombinant Protein Expression for Crystallization 
Trials: 
   It is well established that differences of a few amino acids can significantly improve the 
solubility of recombinant proteins or their ability to crystallize (Malawski et al. 2006). To 
identify soluble and purifiable S. cerevisiae Ubp proteins, 127 constructs with varying N and C 
termini were designed, coding for 16 Ubps, Sad1 and Pan2 proteins or their domains (Table 2-1). 
113 constructs that were successfully PCR amplified were inserted in p15TV-L vector via 
ligation independent cloning and expressed in E. coli BL21 (DE3) mgk cells as the first choice of 
expression vehicle. Expression of the Ubp3 constructs was also attempted from the pET-28b 
vector as shown in Table 2-1. Recombinant protein expression and solubility were screened by 
metal affinity chromatography via 6xHis fusion tags. All soluble recombinant proteins were 
further purified by size exclusion chromatography. Seventeen constructs failed to express any 
detectable levels of recombinant protein. Ten constructs expressed soluble proteins including 
Ubp1 (aa 92-741), Ubp3 (aa 1-912 and 189-912), Ubp3 catalytic domain (aa 449-912), Ubp6 (aa 
1-499), Ubp12 N-terminal domain (aa 1-361, 90-361 and 98-345) and Ubp15 N-terminal and C-
terminal domains (aa 1-204 and 538-1230).  
   Many optimizations and screening methods were routinely performed when attempting to 
crystallize soluble proteins. Initial protein crystallization screens were set up both at 4ºC and 
room temperature (22ºC) using recombinant proteins with the 6xHis fusion tag intact or cleaved. 
Also, partial in situ proteolysis of the purified proteins with trypsin was attempt to remove 
flexible surface loops that could interfere with protein crystallization (Wernimont & Edwards 
2009). 
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Table 2-1: S. cerevisiae Ubp Constructs PCR Amplification, Cloning and Expression Outcome: 
UBP Domain Residues PCR Expression  UBP Domain Residues PCR Expression 
1 
FL 1-809 ⎯ ⎯  
4 
NTD 1-323  Insoluble 
CD 92-741  Soluble  NTD 1-330 ⎯ ⎯ 
CD 92-809 ⎯ ⎯  NTD 1-561  Insoluble 
CD 93-753  None  NTD 2-315  Insoluble 
CD 97-741  Insoluble  NTD 324-561  None 
CD 97-809 ⎯ ⎯  CD 545-926  Insoluble 
CD 101-739  Insoluble  CD 551-926  Insoluble 
2 
NTD 1-735   Insoluble  CD 556-926  Insoluble 
NTD 434-832  Insoluble  CD 562-924   Insoluble 
CD 724-1271  None  
5 
NTD 1-280   Insoluble 
CD 725-1271  Insoluble  NTD 1-289  None 
CD 725-1259  Insoluble  NTD 1-445  Insoluble 
CD 731-1271 ⎯ ⎯  NTD 3-270  Insoluble 
CD 731-1259  Insoluble  NTD 3-280  Insoluble 
CD 736-1259   None  NTD 281-445  Insoluble 
3 
FL 1-912   Soluble 
  
CD 431-805  Insoluble 
NTD+CD 148-912  None CD 434-805  Insoluble 
NTD+CD 189-912   Soluble CD 440-805  Insoluble 
FL 1-912  Insoluble  CD 446-805   Insoluble 
NTD 1-459  Insoluble  6 FL 1-499   Soluble 
NTD+CD 50-912  None  CD 109-488  Insoluble 
NTD+CD 104-912  None  
7 
NTD 1-460   Insoluble 
NTD+CD 148-912  None  NTD 1-608  Insoluble 
NTD+CD 189-912  Insoluble  CD 593-1071  Insoluble 
CD 412-912  Insoluble  CD 598-1070  Insoluble 
CD 426-909  Insoluble  CD 598-1071  Insoluble 
CD 426-912  Insoluble  CD 603-1070  Insoluble 
CD 429-909  None  CD 603-1071  Insoluble 
CD 429-912  Insoluble  CD 608-1070  Insoluble 
CD 445-909  Insoluble  8 NTD 1-136   Insoluble 
CD 445-912  Insoluble  CD 137-469   Insoluble 
CD 447-909  Insoluble       
CD 447-912  Insoluble       
CD 449-909  Insoluble       
CD 449-912  Soluble       
CD 454-912  Insoluble       
CD 459-912   Insoluble       
Cloned in 
pET-28b 
vector 
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UBP Domain Residues PCR Expression  UBP Domain Residues PCR Expression 
9 
FL 1-754   None  
13 
FL 1-747   Insoluble 
CD 122-671  Insoluble  CD 139-669  Insoluble 
CD 122-707  None  CD 129-673 ⎯ ⎯ 
CD 124-674 ⎯ ⎯  CD 129-682 ⎯ ⎯ 
CD 128-671  Insoluble  CD 134-673  Insoluble 
CD 128-707 ⎯ ⎯  CD 134-682  Insoluble 
CD 134-668  Insoluble  CD 329-669   Insoluble 
CD 311-668   Insoluble  
14 
FL 1-781   None 
10 
NTD 1-361   Insoluble  NTD 1-322  Soluble  
CD 336-746  Soluble  NTD 40-277  Insoluble 
CD 351-734  Insoluble  CD 312-781  None 
CD 351-746  Insoluble  CD 316-781  None 
CD 356-734 ⎯ ⎯  CD 317-781  Insoluble 
CD 356-746 ⎯ ⎯  CD 322-781   Soluble 
CD 362-734  Insoluble  
15 
CD 215-537   Insoluble 
11 
NTD 1-297   Insoluble  NTD 1-204  Soluble 
NTD 1-135  Insoluble  CTD 538-1230   Soluble 
CD 297-710  Insoluble  
16 
CD 41-497   Insoluble 
CD 283-713  Insoluble  CD 46-499  Insoluble 
CD 287-717 ⎯ ⎯  CD 47-497  Insoluble 
CD 291-717   Insoluble  CD 53-499   Insoluble 
12 
FL 1-1123 ⎯ ⎯  SAD
1 
NTD 1-149   Insoluble 
NTD 1-345  Insoluble  CD 44-448  Insoluble 
NTD 1-361  Soluble  CD 150-448  Insoluble 
NTD 1-367  None  
PAN
2 
NTD 1-504   Insoluble 
NTD 90-361  Soluble  CD 493-826  Insoluble 
NTD 98-345  Soluble  CD 505-846  Insoluble 
NTD 98-361  Insoluble  CTD 847-1115   Insoluble 
NTD+CD 90-1123  Insoluble       
NTD+CD 98-1123  Insoluble       
NTD+CD 101-1119  None       
CD 353-1123  Insoluble       
CD 358-1123  Insoluble       
CD 362-1119 ⎯ ⎯       
 
FL: full-length, CD: catalytic domain, NTD: N-terminal domain, CTD: C-terminal domain, (-): 
failed PCR outcome. 
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Expression and Crystallization of S. cerevisiae Ubp1: 
    
   Ubp1, a 92 kDa protein, localizes to the ER membrane via an N-terminal transmembrane 
region, encompassing residues 34-51 (Wojtowicz et al. 2005). In efforts to express soluble Ubp1 
from E. coli, we designed constructs to bypass the transmembrane region. Initial expression in 
BL21 mgk or Rosetta Blue E. coli strains did not lead to any detectable levels of soluble protein. 
However, expression and solubility were optimized through co-expression of Ubp1 (residues 92-
741) with Tig chaperone in Bl21 mgk cells at 16ºC overnight, as opposed to an induction 
temperature of 25-37ºC reported previously (Wojtowicz et al. 2005) (Fig. 2-1A). Large quantities 
of soluble and stable Ubp1 was purified from E. coli in 500 mM NaCl and 20 mM Tris pH 7.5 
via metal affinity chromatography and was subjected to further size exclusion chromatography 
(Fig. 2-1B). Purified protein was used to set up crystallization screening trials. Crystals appeared 
in Ubp1 concentrations ranging from 12 to 30 mg/ml in 0.2 M Na or K thiocyanate, 20% w/v 
PEG 3350 and pH 7.0-7.8. Additives including 0.1 M KCl, 0.1 M LiCl and 0.2 M NaCl helped 
obtain larger crystals with improved morphology (Fig. 2-1C & D). However, despite 
optimization of crystallization and cryo conditions and use of post-crystallization treatments, 
such as dehydration, annealing and cross-linking of protein crystals to improve diffraction 
quality, Ubp1 crystals diffracted poorly upon exposure to X rays. 
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Fig. 2-1: Expression, purification and crystallization of S. cerevisiae Ubp1. A) Initially, Ubp1 
(residues 92-741) did not express soluble in BL21 mgk or Rosetta Blue E. coli strains. Soluble 
expression in BL21 mgk E. coli was optimized through co-expression with trigger factor (Tig) 
chaperone. S, soluble lysate fraction; In, insoluble fraction. B) Soluble Ubp1 purification from 
BL21 mgk cells by metal affinity chromatography via 6xHis fusion tag on a Ni-NTA resin. L, 
lysate; F/T, resin flow through; B, binding buffer flow through; W, wash buffer flow through; E, 
elution. C) Ubp1 crystals appeared in 12 mg/ml protein concentration in 0.2 M Na or K 
thiocyanate, 20% PEG 3350 and pH 7.0. D) Optimized Ubp1 crystals, grown with either 0.1 M 
KCl or 0.1 M LiCl or 0.2 M NaCl additives, appeared in 30 mg/ml protein concentration and 0.2 
M Na thiocyanate, 20% w/v PEG 3350, pH 7.4-7.8. 
 
 
 
Ubp1(92-741) 
 
  S      In               S      In               S      In 
-74 kDa 
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 87 
Expression of Soluble S. cerevisiae Ubp3: 
 
   S. cerevisiae Ubp3 (human USP10 homologue) is a 912-residue long protein with a C-terminal 
UCH catalytic domain. Ubp3 forms a heterotetramer complex with Bre5, its essential cofactor 
for DUB activity, via amino acids 186-272 (Li et al. 2007). In our efforts to express soluble 
Ubp3 catalytic domain, 13 constructs with varying N and C termini were cloned in p15TV-L 
vector and expressed in E. coli BL21 mgk. One construct coding for the catalytic domain 
residues 449-912 expressed a significant amount of soluble protein, which was stably purified in 
500 mM NaCl and 20 mM Tris pH 7.5. (Fig. 2-2). Despite screening of numerous crystallization 
conditions at varying incubation temperatures, pH and protein and precipitant concentrations, 
crystalline condition were not identified. Considering that Ubp3 residues 186-272 are essential 
for interaction with Bre5, we designed constructs to include both the catalytic domain and the N-
terminal region required for interaction with Bre5 (Table 2-1). Other than p15TV-L, constructs 
were also cloned into the pET-28b vector, which adds a 6xHis fusion tag to the C-terminus of the 
recombinant protein. Full-length Ubp3 residues 1-912 and 189-912 expressed soluble from pET-
28b vector in Rosetta Blue (DE3) cells (Fig. 2-2); however, crystallization trials did not produce 
a crystalline outcome. 
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Fig. 2-2: Expression and purification of soluble Ubp3 constructs from E. coli. 6xhis-tagged Ubp3 
catalytic domain (residues 449-912) expressed soluble from the p15TV-L vector in BL21 mgk E. 
coli cells. Ubp3 constructs containing residues 1-912 and 189-912 with a C-terminal 6xHis 
fusion tag expressed soluble from the pET-28b vector in Rosetta Blue E. coli cells. All proteins 
were purified by metal affinity chromatography via 6xHis fusion tag on a Ni-NTA resin. L, 
lysate; B, binding buffer flow through; W, wash buffer flow through; E, elution. 
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S. cerevisiae Ubp6 Expression and Crystallization: 
 
   S. cerevisiae  Ubp6 consists of a ubiquitin-like domain (Ubl) at its N-terminus (residues 6-76) 
followed by a USP catalytic domain (residues 108-494) at its C-terminus (Wyndham et al. 1999). 
Ubp6 was shown to stably interact with the non-ATPase Rpn1 subunit of the proteasome 19S 
regulatory particle (RP) through its N-terminal Ubl domain (Bashore et al. 2016; Guterman & 
Glickman 2004; Park et al. 1997). Even though the Ubl domain is not essential for Ubp6 activity 
or its nuclear localization, it is involved in targeting Ubp6 to the proteasome (Crosas et al. 2006; 
Chernova et al. 2003). Interaction of the Ubp6 Ubl domain with the 19S RP Rpn1 subunit was 
shown to increase Ub-substrate hydrolysis activity by 300 fold (Hu et al. 2005; Leggett et al. 
2002). 
   To date structural data available for Ubp6 or its human homologue, USP14, only represent the 
catalytic domain. In our efforts to obtain the crystal structure of the full-length Ubp6, residues 1-
499 were expressed from the p15TV-L vector in BL21 mgk cells. 6xhis-tagged Ubp6 was 
purified to homogeneity using metal affinity chromatography on a Ni-NTA resin column 
followed by size exclusion chromatography (Fig. 2-3A). Protein purified in 150 mM NaCl and 
20 mM Tris pH 7.5 crystallized at 4ºC in 20% w/v PEG 3350 and 0.2 M MgCl2.6H2O. 
Crystallization conditions were further refined by the addition of organic and inorganic additive 
compounds. Ubp6 crystals appeared at 60 mg/mL protein concentration and were optimized by 
the addition of 30% v/v 2-propanol as an additive. These crystals diffracted to 2.5 Å resolution 
and a complete data set was collected (Fig. 2-3B). The diffraction data was integrated, the 
structure was determined using molecular replacement and refined. A summary of data 
collection and refinement statistics is presented in (Table 2-2). The resulting model based on 
interpretation of the electron density only contained information for the Ubp6 catalytic domain; 
there was no density corresponding to the N-terminal Ubl domain. Examining the Ubp6 crystals 
by silver staining indicated that crystallized protein was indeed full-length Ubp6 (Fig. 2-3C). It 
seems that the Ubl domain is flexible and cannot produce an interpretable electron density. In an 
attempt to stabilize the Ubl domain, we tried co-crystallizing Ubp6 with single ubiquitin 
molecules in 1:1, 1:2 and 1:5 molar ratios however, crystals were never obtained. 
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Fig. 2-3: Expression, purification and crystallization of Ubp6. A) 6xhis-tagged full-length Ubp6 
was expressed from the p15TV-L vector in BL21 mgk cells. Proteins were purified by metal 
affinity chromatography via 6xHis fusion tag on a Ni-NTA resin. L, lysate; F/T, resin flow 
through; B, binding buffer flow through; W, wash buffer flow through; E, elution. B) Ubp6 
native crystals and their diffraction pattern. Crystals appeared in 20% w/v PEG 3350 and 0.2 M 
MgCl2.6H2O and 30% v/v 2-propanol additive at 4ºC, using 60 mg/mL of the protein. Ubp6 
crystals diffracted to 2.5 Å resolution. C) Silver staining of the Ubp6 protein crystals. Prior to 
silver staining, Ubp6 crystals were washed in crystallization buffer and boiled in protein loading 
dye for 5 minutes. Lanes 1&2, positive controls for the Ubp6 catalytic domain (CD) (residues 
109-499) and full-length respectively; Lanes 3&4, samples from the first and second wash of the 
crystals in crystallization buffer; Lane 5, Ubp6 crystals. 
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Table 2-2: Ubp6 X-Ray Data Collection and Refinement Parameters. 
 
              Native Ubp6 
X-Ray Data  
Space Group C121 
Resolution (Å) 27.64 – 2.50 
Unit Cell Axes (Å3, °) a=220.94, b= 49.20, c=110.04 
ß=114.45 
Molecules / AU 2 
Total Observations (#) 103736 
Unique Reflections (#) 36144 
Intensity (I/s<I>) 4.1 (1.2) 
Completeness (%) 95.9 (90.9) 
aRmerge 0.152 (0.536) 
Refinement  
Rwork 0.261 
Rfree 0.297 
Protein Atoms (#) 6395 
Water Molecules (#) 112 
rmsd bonds (Å) 
rmsd angles (°) 
0.014 
1.60 
rmsd dihedrals (°) 34.9 
rmsd improper (°) 0.84 
thermal factors (Å2) 43.0 
Ramachandran Plot  
Most Favoured 732 (94.33%) 
Additionally Allowed 
Out Lier  
32 (4.12%) 
12 (1.55%) 
Numbers in brackets refer to the highest resolution shell, 2.59 Å 
to 2.5 Å. aRsym = S |I-<I>| /SI where I is the observed intensity and 
<I> is the average intensity from multiple observations of 
symmetry-related reflections. 
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Ubp6 Crystal Structure: 
 
   We were able to identify two Ubp6 molecules per asymmetric unit in the 2.5 Å electron density 
which were superimposable, therefore, only one of the molecules is used for results presentation. 
Three-dimensional structure of the Ubp6 catalytic domain, residues 103-499, similar to human 
USP14, is analogous to an extended right hand with the subdomains that represent thumb, fingers 
and palm (Fig. 2-4A) (Hu et al. 2005; Hu et al. 2002). The previous comparison of the known 
human USP catalytic domain structures suggested that the extended right-hand architecture is 
conserved among USPs (Hu et al. 2002). The hand-like structure produces a binding pocket with 
the catalytic residues in the palm subdomain and is suggested to fit the 8 kDa ubiquitin molecule 
between the fingers and the palm-thumb frameworks (Hu et al. 2002). Two larger alpha helices 4 
and 5 and two smaller helices 3 and 6 form the thumb subdomain, while beta strands 1, 2, 4 and 
5 form the fingers (Fig. 2-4B & C). Catalytic triad C118, H447 and N465 are located in the palm 
subdomain.  
 
   USP14, the human homologue of Ubp6, has 32% sequence similarity and high structural 
conservation with Ubp6 and can compensate for the loss of Ubp6 in knockout S. cerevisiae  (Hu 
et al. 2005). As shown in Fig. 2-4D, the catalytic domain structures of USP14 and Ubp6 are 
superimposable and very similar (global and local RMSD= 1.285 Å) (Maiti et al. 2004). Further, 
USP14 blocking loops 1 and 2 (BL1 and BL2), which hover over the catalytic residues in the 
predicated ubiquitin binding pocket, are also conserved in S. cerevisiae Ubp6 and superimpose 
well (Hu et al. 2005). However, compared to USP14 a-helix 8, Ubp6 contains two extended a-
helices 11 and 12 (Fig. 2-4D). In the case of USP14, it was observed that the catalytic Cys114 is 
about 3.3 Å away from the catalytic histidine (His435) and also the Asp451 forms a hydrogen 
bond with the His435, indicating that the catalytic site is in an active conformation (Hu et al. 
2005). The Ubp6 catalytic domain structure also revealed that the catalytic triad is in an active 
conformation. Nitrogen d atom of the catalytic His447 is within a hydrogen bond distance (3.1 
Å) from the Cys118 thiol side chain and the Asn465 accepts a hydrogen bond from the nitrogen 
e of the His447 and stabilize it (Fig. 2-4E).  
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Fig. 2-4: Ubp6 catalytic domain structure. A&B) Catalytic domain of Ubp6 (residues 103-499) 
in surface and ribbon representation depicting the extended right-hand structure with the fingers, 
thumb and palm subdomains. Blocking loops 1 and 2 (BL1 and BL2) are shown in green and 
active site residues are shown in red. Predicted ubiquitin binding site is between the fingers and 
the palm-thumb structures. C) Ribbon representation of the Ubp6 catalytic domain showing BL1 
and BL2 in green, hovering over the catalytic residues. D) Superimposition of the Ubp6 (in 
brown) and USP14 (in cyan) catalytic domains (global and local RMSD= 1.285 Å). E) The 
catalytic site of Ubp6. The catalytic triads, C118, H447 and N465, are oriented in an active 
conformation. The cysteine thiol side chain is shown in yellow, amino groups are shown in blue 
and carbonyl groups are shown in red. Blocking loop 2 is shown in green hovering closely over 
catalytic triad. Blue dashed-line represents hydrogen bond. 
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Expression and Crystallization of S. cerevisiae Ubp12-NTD: 
 
   S. cerevisiae Ubp12, a 143 kDa protein, contains a domain specific for USPs (DUSP) at its N-
terminus (residues 97-199) and a USP catalytic domain at its C-terminus (residues 364-1110). 
The DUSP domain is conserved in Ubp12 orthologues in human USP4 and USP15 (Elliott et al. 
2011). In attempts to obtain the Ubp12 DUSP domain structure, we designed 10 constructs for 
the Ubp12 N-terminal domain expression in E. coli. 6xhis-tagged constructs coding for residues 
1-361, 90-361 and 98-345 expressed soluble from the p15TV-L vector in BL21 mgk E. coli cells. 
Proteins were purified by metal affinity chromatography on a Ni-NTA resin column via 6xHis 
fusion tag (Fig. 2-5A). Ubp12 (1-361) purified in 300 mM NaCl and 20 mM Hepes pH 7.5, 
crystallized at 4ºC at 12.5 mg/mL in 0.17 M NH4OAc and 20% w/v PEG 3350 pH 7.5 (Fig. 2-
5B). The diffraction resolution of the crystals were optimized from 5 Å to 3.4 Å using 
microseeding technique. However, despite extensive screening and optimization of the 
crystallization conditions, diffraction with a higher resolution was not achieved. Ubp12 (90-361), 
purified in 500 mM NaCl and 20 mM Tris pH 7.5, crystallized at room temperature in protein 
concentrations ranging from 30-40 mg/ml in three different conditions: 0.2 M NH4CH3CO2, 20% 
w/v PEG 4000 pH 7.5; 0.2 M NH4F, 20% w/v PEG 3350 pH 7.5 and 0.2 M Mg(HCOO)2, 20% 
w/v PEG 3350 pH 7.5. Crystals formed in magnesium formate had the best diffraction resolution 
of 4-6 Å which was optimized to 3.5 Å (Fig. 2-5C). Ubp12 (98-345), purified in 500 mM NaCl 
and 20 mM Tris pH 7.5 at the concentration of 20 mg/ml, crystallized at 4ºC in 0.1 M NH4OAc 
and 25% w/v PEG 3350 pH 7.5 crystallization buffer (Fig. 2-5D). Crystal size and morphology 
were significantly optimized by one round of microseeding using Ubp12 (98-345) crystals 
formed in the same condition. The best diffraction resolution obtained was 3.5 Å which is not 
adequate for detecting the amino acids side chains in the electron density map therefore structure 
determination was not pursued (Smyth 2000). 
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Fig. 2-5: Expression, purification and crystallization of the Ubp12 DUSP domain. A) Three 
constructs expressing 6xHis Ubp12 DUSP domain residues 1-361, 90-361 and 98-345 were 
expressed in soluble form in E. coli from the p15TV-L vector. Proteins were purified to 
homogeneity by metal affinity chromatography on a Ni-NTA resin column via 6xHis fusion tag. 
L, lysate; F/T, resin flow through; B, binding buffer flow through; W, wash buffer flow through; 
E, elution. B) Ubp12 (1-361) purified in 300 mM NaCl and 20 mM Hepes pH 7.5 crystallized at 
4ºC at 12.5 mg/mL in 0.17 M NH4OAc and 20% w/v PEG 3350 pH 7.5. C) Ubp12 (90-361) 
purified in 500 mM NaCl and 20 mM Tris pH 7.5 crystallized at room temperature at 30 mg/ml 
of protein concentration in 0.2 M Mg(HCOO)2 and 20% w/v PEG 3350 pH 7.5. D) Ubp12 (98-
345) purified in 500 mM NaCl and 20 mM Tris pH7.5 crystallized at 4ºC at 20 mg/ml in 0.1 M 
NH4OAc and 25% w/v PEG 3350 pH 7.5. 
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Expression of S. cerevisiae Ubp15 N- and C-Terminal Domains: 
 
   The Ubp15-NTD residues 1-204 and C-terminal domain residues 538-1230 were expressed in 
soluble form from the p15TV-L vector in E. coli BL21 mgk cells. Proteins were purified by 
metal affinity chromatography on a Ni-NTA resin column via their 6xHis fusion tag (Fig. 2-6). 
6xhis-tagged Ubp15-NTD despite many refinements and optimizations did not crystallize. 6xHis 
Ubp15-CTD purified in 500 mM NaCl and 20 mM Tris pH 7.5 formed microcrystals in 0.2 M 
Mg(CH3COO)2 and 20% w/v PEG 3350 (crystallized by Ira Lacdao). However, refinement of 
the crystallization conditions did not improve size and morphology of the protein crystals.  
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Fig. 2-6: Expression of the soluble Ubp15 N and C terminal domains in E. coli. 6xhis-tagged 
Ubp15-NTD residues 1-204 and Ubp15-CTD residues 538-1230 were expressed soluble from 
the p15TVL vector in BL21 mgk cells. Proteins were purified using metal affinity 
chromatography on a Ni-NTA resin column via 6xHis fusion tag. L, lysate; B, binding buffer 
flow through; W, wash buffer flow through; E, elution. 
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Binding Affinity of S. cerevisiae Ubp15-NTD for (E/P/A)XXS Motifs: 
 
    S. cerevisiae Ubp15 and its well-studied human homologue, USP7, contain a TRAF-like 
domain (Tumor necrosis factor receptor (TNFR) associated factors (TRAFs)) in their N-termini 
and five Ubl domains in their C-termini (Fig. 2-7A) (Bozza & Zhuang 2011; Sheng et al. 2006). 
Both USP7 and Ubp15 harbor a highly conserved DWGF motif within the binding pocket of 
their N-terminal TRAF-like domain. Aspartic acid and Trp residues have been found essential 
for USP7 substrate/protein interaction (Sheng et al. 2006). The DWGF motif in USP7-NTD is 
efficiently recognized by its cellular substrates and interacting proteins through their 
(P/A/E)XXS sequences, where X stands for any amino acid and S is essential for this interaction 
(Sheng et al. 2006; Saridakis et al. 2005). The N-terminal DWGF motif is conserved in all 
Ubp15/USP7 homologues (Fig. 2-7B). 
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Fig. 2-7: Schematic representation of human USP7 and S. cerevisiae Ubp15 domain structure. A) 
Both USP7 and Ubp15 harbor a TRAF-like domain in their N-termini and five Ubl domains in 
their C-termini. B) The N-terminal TRAF domain contains a DWGF motif which is highly 
conserved among all Ubp15/USP7 homologues. Asterisks represent conserved residues, and the 
period represents semi-conserved substitution. Sequence alignment employed the program 
ClustalW. Entries shown are from the National Center for Biotechnology Information Database 
(Resource 2016): USP7 sequence ID: (H. Sapiens, CAA96580.1); (M. musculus, 
NP_001003918.2); (D. rerio, XP_009297739.1); (G. gallus, NP_001334941.1); (X. laevis, 
NP_001121282.1); (A. gambiae, XP_316911.4); (A. thaliana, NP_001119179.1); (G. max, 
XP_006575589.1); (C. elegans, NP_001024012.1); (S. cerevisiae, ONH78017.1).       
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M. musculus 149 KSFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKG----FIDDDKVTFEVFVQA-DAPHG  203
D. rerio 146 KSFSRRISHLFFHKENDWGFSNFMSWSDVTDPERG----FVEDDKVTFEVYVQA-DAPHG  200
G. gallus 148 KSFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKG----FIEEDKVTFEVYVQA-DAPHG  202
X. laevis 150 KFFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKG----FVEDDKVTFEVYVQA-DAPHG  204
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A. thaliana 136 YSIRKETQHQFNARESDWGFTSFMPLSELYEPTRG----YLVNDTVLIEAEV-------- 179
G. max 134 YSIRKDSQHQFNARESDWGFINFMPLAELYDPARG----YLVNDTCVVE----------- 180
C. elegans 259 PSIQKKIHHSFHNTEVDWGFSNYDQYDTLCNPKDG----YVVNDTIKLRCRFTA-DVPTG  309
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: .   * *   : **** .      : .*  *    :: :..  . 
H. Sapiens        49  KSFSR ISHLFFH FMAWSEVTDPEKG----FI DDKVTFEVFVQ -DAPHG  103 
M. musculus       149 KSFS KENDWGFSNFMAWSEVTDPEKG --FIDDDKVT EVFVQA-DAPHG  203 
D. rerio          146 KSFSRRISHLFFHKENDWGFSNFMSW DVTDPERG- FVED KVTFE HG  2 0 
G. gallus         148 KSFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKG- FIE DKVT APHG  202 
X. laevis         150 KFFSRRISHLFFHKENDWGFSNFMAWSEVTDPEKG- FVE QA-DAPHG  204 
A. gambiae        163 EPFIRRIRHTFCMQENDWGFSSFMNWQEILDPANG- FIENDTIT PPRG  217 
A. thaliana       136 YSIRKETQHQFNARESDWGFTSFMPLSELYEPTRG- --Y AEV- -  179 
G. max            134 YSIRKD QHQFNARESDWGFINFMPLAELYDPARG--- YLVNDTCVVE-- ---   180 
C. elegans        259 PSIQKKIHHSF NTEVDWGFSNYDQYDTLCNPKDG- YV NDTIK VPTG  309 
S. cerevisiae     128 INLINKSHHRFNALDTDWGFANLID RPLSFLNEGTLNITAYVRILKDPTG  187 
                        : .   * * : **** .    : .* *  :: :..            
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   To investigate the interaction mechanism of Ubp15-NTD and its affinity for the (E/P/A)XXS 
motifs, we performed fluorescence polarization binding assays using FITC tagged EGPS 
containing vIRF1 (viral interferon regulatory factor 1, expressed by human Kaposi sarcoma 
herpesvirus; KSHV) and PSSS containing FOXO4 (human Forkhead box O transcription factor) 
peptides. Both proteins have previously shown high affinity for interaction with the human USP7 
N-terminal domain (Chavoshi et al. 2016; van der Horst et al. 2006). 40 nM fixed concentration 
of FITC labeled vIRF1 wild-type (44SPGEGPSGTG53) and mutant (44SPGEGPAGTG53) peptides 
were titrated in increasing concentrations of Ubp15-NTD (0-795 µM). Complex formation was 
measured by detecting changes in the polarization values. A dissociation constant (Kd) of 757.1 ± 
134 µM was obtained for wild-type vIRF1, while mutant vIRF1 peptide did not show any 
interaction (Fig. 2-8A). Mutation of serine to alanine of EGPS motif disrupts the binding, 
indicating the importance of the serine residue for this interaction. The experiment was repeated 
to test the interaction of PSSS containing (400GGLPSSSKLA409) human FOXO4 peptide with the 
Ubp15 N-terminal domain. A Kd of 48.2 ± 4.5 µM was obtained (Fig. 2-8B). In a similar 
experiment titration of 40 nM fixed concentration of FITC labeled FOXO4 peptide in increasing 
concentrations of USP7-NTD (0-500 µM) resulted in a Kd of 6.7 ± 0.6 µM (Fig. 2-8C). Our 
observations indicate that S. cerevisiae Ubp15-NTD has binding affinity for PSSS motif. 
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Fig. 2-8: Binding affinity of the Ubp15 N-terminal domain for (E/P/A)XXS motifs as determined 
by FITC fluorescence polarization assay. A) The assay was performed using FITC labeled EGPS 
containing vIRF1 wild-type (44SPGEGPSGTG53 in black) or mutant (44SPGEGPAGTG53 in red) 
peptides. The table represents dissociation constant (Kd) for Ubp15-NTD interaction with FITC 
labeled wild-type and mutant vIRF1 peptides. B&C) Fluorescence polarization assay was 
performed using FITC labeled PSSS containing FOXO4 peptide (400GGLPSSSKLA409) and 
increasing concentration of Ubp15-NTD or USP7-NTD respectively. The table represents 
dissociation constants (Kd) for Ubp15-NTD and USP7-NTD for interaction with FITC labeled 
FOXO4 peptide. mP, milipolarization. Error bars indicate standard error. Average values with 
standard deviation for three or more experiments are shown. 
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NMR 2D HSQC Detection of Ubp15-NTD Interaction with (E/P/A)XXS 
Motifs:  
 
   To investigate Ubp15-NTD interaction with (E/P/A)XXS motifs, we further monitored 1H-15N 
HSQC resonances of the uniformly 15N-labeled Ubp15-NTD in the presence and absence of 
unlabeled protein peptides that have previously shown a strong affinity for the human USP7-
NTD. 0.2 mM of the 15N-labeled Ubp15-NTD was titrated with 0.4 mM of each peptide (2:1 
peptide to Ubp15-NTD ratio). Fig. 2-9A represents superimposition of the 15N-labeled Ubp15-
NTD spectra before and after titration with the wild-type (44SPGEGPSGTG53) or mutant 
(44SPGEGPAGTG53) EGPS containing vIRF1 peptides. Strong disturbances were observed in 
the Ubp15-NTD chemical shift spectra after addition of the wild-type vIRF1 peptide. Mutation 
of Ser50 to alanine in the vIRF1 EGPS motif significantly reduced chemical shift disturbances of 
the Ubp15-NTD spectra, indicating the importance of serine residue for this interaction.  
 
   Further, the affinity of the Ubp15 N-terminal domain for AXXS motifs was analyzed. We 
monitored the effect of an AHSS containing HdmX peptide titration on the 15N-labeled Ubp15-
NTD 2D HSQC spectra (Meulmeester et al. 2005). The spectra were monitored before and after 
titration with the wild-type (394FLDLAHSSE402) or mutant (394FLDLAHSAE402) HdmX peptides. 
The Ubp15 N-terminal domain spectra showed disturbances upon titration with the HdmX 
peptide indicating that Ubp15 has binding affinity for AXXS motif (Fig. 2-9B) (Sarkari et al. 
2010).  
 
   In addition, we tested the effect of PSTS containing peptides on the 15N-labeled Ubp15-NTD 
spectra. 2D HSQC spectra of the Ubp15-NTD was analyzed before and after titration with wild-
type (152RVSPSTSYT160) and mutant (152RVSPSTAYT160) MCMBP (minichromosome 
maintenance complex) and wild-type (395SQPSTSS401) and mutant (395SQPSTAS401) Hdm2 
peptides (Fig. 2-9C & D). Both MCMBP and Hdm2 are substrates of USP7 and specifically 
interact with its N-terminal domain (Jagannathan et al. 2014; Sheng et al. 2006). Disturbances in 
the Ubp15-NTD chemical shift spectra indicated interaction of the Ubp15 N-terminal domain 
with MCMBP and Hdm2 peptides. Ser158 to alanine mutation of the PSTS motif in MCMBP 
peptide decreased disturbances in the Ubp15-NTD spectra, while Ser400 to alanine mutation of 
the PSTS motif in Hdm2 peptide did not have a strong effect. Our data suggest that Hdm2 
peptide that contains two serine residues (PXXSS) still holds interaction with the Ubp15 N-
terminal domain even after mutation of one of the serine residues to alanine.  
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Fig. 2-9: Superimposed 15N HSQC spectra of Ubp15-NTD before and after titration with 
(E/P/A)XXS containing peptides. For all NMR titration experiments the 15N-labeled Ubp15-NTD 
was titrated with 2:1 molar ratio of wild-type (WT) or mutant (Mut) peptides. A): 15N-labeled 
Ubp15-NTD spectra (in black) was titrated with EGPS containing wild-type (44SPGEGPSGTG53 
in red) or mutant (44SPGEGPAGTG53 in blue) vIRF1 peptides. B): 15N-labeled Ubp15-NTD 
spectra (in black) was titrated with AHSS containing HdmX wild-type (394FLDLAHSSE402 in 
red) or mutant (394FLDLAHSAE402 in blue) peptides. C) 15N-labeled Ubp15-NTD spectra (in 
black) was titrated with PSTS motif containing MCMBP wild-type (152RVSPSTSYT160 in red) or 
mutant (152RVSPSTAYT160 in blue) peptides. D) 15N-labeled Ubp15-NTD spectra (in black) was 
titrated with PSTS motif containing Hdm2 wild-type (395SQPSTSS401 in red) or mutant 
(395SQPSTAS401 in blue) peptides. Arrows indicate residues that were largely affected by the 
peptide interaction.  
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Discussion: 
 
   Conservation of the cellular pathways and genetic material from yeast to human has allowed a 
better understanding of the molecular mechanisms of different human diseases through research 
on yeast (Tencer et al. 2016; Botstein & Fink 2011). In most cases, human orthologues of yeast 
proteins have shown conservation in amino acid sequence, structure and function and can 
complement yeast deletion mutants (Mohammadi et al. 2015; Heinicke et al. 2007). The 
involvement of ubiquitin-specific proteases (USPs; Ubps in yeast) in various cellular pathways 
and processes, which are implicated in development and diseases such as cancer, have made 
them an important subject of investigation (D’Arcy et al. 2015; Kowalski & Juo 2012).  
   In this chapter, we have examined the expression of soluble S. cerevisiae Ubp enzymes in E. 
coli for protein crystallography. Generation of soluble and high purity proteins is essential for 
structural studies as well as biochemical characterization and industrial protein and enzyme 
expression (Luna-Vargas et al. 2011). Despite many advantages in using E. coli as an expression 
host for eukaryotic proteins, we had to face many setbacks. Lack of protein chaperones and post-
translational modifications in E. coli contributes to incorrect protein folding and the formation of 
protein aggregates and inclusion bodies (Rosano & Ceccarelli 2014). In fact, it is reported that 
only about 10% of recombinant eukaryotic proteins expressed in E. coli are soluble and 
functional (Finley et al. 2004). There are many recommendations for optimal approaches to 
construct design, expression and purification of recombinant proteins in E. coli, however, since 
every protein has different characteristics, the success rate of such approaches should be tested 
experimentally. In our efforts to express S. cerevisiae Ubps or their domains in E. coli, 127 
constructs for 16 Ubps and Sad1 and Pan2 (catalytically inactive Ubps) were designed and 
cloned in the p15TV-L vector. BL21 (DE3) mgk E. coli was used as the first choice of 
expression vehicle since it enhances the expression level by encoding for arginine (AGG and 
AGA) and Ile (ATA) tRNA codons that are rare in E. coli but common in eukaryotes (Rosano & 
Ceccarelli 2014). Further, we carried out the expression at 16ºC overnight as opposed to 37ºC. 
Expression at low temperature optimizes protein folding and decreases the rate of protein 
synthesis which helps reduce protein aggregation (Vera et al. 2007; Schellman 1997). Also, to 
improve yield or solubility of the recombinant proteins, we tried their co-expression with E. coli 
Tig chaperone (Martinez-Hackert & Hendrickson 2009). Extensive optimization of the 
constructs design and expression conditions, led to the successful expression of 10 soluble 
proteins including Ubp1 (aa 92-741), Ubp3 (aa 1-912 and 189-912), Ubp3 catalytic domain (aa 
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449-912), Ubp6 (aa 1-499), Ubp12 N-terminal domain (aa 1-361, 90-361 and 98-345) and 
Ubp15 N-terminal and C-terminal domains (aa 1-204 and 538-1230). S. cerevisiae Ubp1, Ubp6 
and the Ubp12 N-terminal domain were successfully crystallized. Ubp6 protein crystal was used 
to determine the three-dimensional structure of its catalytic domain. 
   Despite the availability of bioinformatics techniques that aim to predict the secondary 
structures of proteins, it is not possible to predict which specific N and C-terminal boundaries 
have a higher potential for soluble protein expression. Therefore, the creation of multiple 
constructs of varying N or C-termini can increase the chance of generating a soluble recombinant 
protein (Graslund et al. 2008). For instance, after preparation of thirteen constructs for the Ubp3 
catalytic domain, we were able to achieve soluble expression for one construct (residues 449-
912) (Table 2-1). In case of Ubp12 DUSP domain, out of six constructs, three expressed in 
soluble form in E. coli which were all successfully crystallized (Fig. 2-5). Further, even though 
the N-terminal fusion tags have higher success rate for optimal protein expression, soluble 
expression of the full-length Ubp3 (residues 1-912) and Ubp3 residues 189-912 was only 
achieved from the pET-28b vector, which adds a 6xHis fusion tag to the C-terminus of the 
expressed protein (Fig. 2-2) (Anon 2008; Dyson et al. 2004). Recombinant Ubp1 construct 
(residues 92-741), which was designed to bypass a previously reported N-terminal 
transmembrane region, expressed in soluble form when co-expressed with E. coli Tig chaperone 
(Fig. 2-1A). Previously reported soluble expression of Ubp1 was achieved after extensive codon 
optimization of arginine and leucine residues and a point mutation of Glu754 to leucine 
(Wojtowicz et al. 2005). Here we showed that through co-expression with Tig chaperone it is 
possible to achieve efficient soluble expression of the yeast Ubp1 in E. coli without the need for 
codon optimization. Ubp1 (residues 92-741) successfully crystallized however, despite repeated 
optimization attempts, crystals diffracted very poorly. Crystal size, morphology and X-ray 
diffraction resolution of the Ubp12 DUSP domain, Ubp1 and Ubp6 proteins were significantly 
optimized by addition of organic or inorganic additives to the crystallization conditions and use 
of microseeding techniques. However, a diffraction resolution adequate for detecting the amino 
acids side chains in the electron density map was only achieved for the Ubp6 catalytic domain. 
This outcome indicates the benefit of microseeding and use of additive compounds in optimizing 
protein crystals, while at the same time reveals their limited potential. 
   Full-length Ubp6 successfully crystallized and diffracted at 2.5 Å resolution (Fig. 2-3). Even 
though the full-length protein was crystallized, the resulting electron density map only contained 
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information for the catalytic domain, suggesting that the Ubl domain is mobile and does not 
produce interpretable electron density. The model of Ubp6 was composed of residues 103-499 
which was superimposable with the Ubp6 structure that was previously deposited in the protein 
data bank (accession code 1VJV). The Ubp6 catalytic domain revealed an extended right-hand 
architecture, which produces a binding pocket with the catalytic residues in the palm subdomain 
(Fig. 2-4). This binding pocket is suggested to fit the 8 kDa ubiquitin molecule between the 
fingers and the palm-thumb frameworks (Hu et al. 2002). Our structure indicated that the three 
catalytic residues are in an active conformation since the His447 is within hydrogen bond (3.1 Å) 
distance from the Cys118 thiol side chain and the Asn465 accepts a hydrogen bond from the 
His447 and stabilize it (Fig. 2-4E). Superimposition of human USP14 and yeast Ubp6 structures 
revealed that they are very similar and that the two blocking loops (BL1 and BL2) are also 
conserved in yeast and take similar positions (Fig. 2-4D). Even though catalytic triad of 
USP14/Ubp6 are aligned productively, the catalytic domain has a low binding affinity for Ub-
substrate, possibly because BL1 and BL2 block Ub carboxyl terminal access to the active site’s 
binding groove and decrease enzymatic activity (Hu et al. 2005). Previously it was shown that 
interaction of the Ubl domain of Ubp6 with the proteasome’s 19S RP increases Ub-substrate 
hydrolysis activity by 300 folds (Leggett et al. 2002). Further, reconstruction of the Ubp6-
proteasome complex using electron microscopy indicated that upon binding of the Ubp6 Ubl 
domain with Rpn1 subunit, Ubp6 surface loops make contact with the N-terminal domain of 
Rpt1, an ATPase subunit of the 19S RP (Bashore et al. 2016). This observation suggests that 
interaction of the Ubp6 Ubl domain with the 19S RP leads to BL1 and BL2 conformational 
change and makes active site residues accessible to the ubiquitin C-terminus. Superimposition of 
USP14 and Ubp6 also revealed that compared to USP14 a-helix 8, Ubp6 contains two extended 
a-helices 11 and 12 in the palm subdomain (Fig. 2-4D). The reconstructed model of Ubp6 bound 
to the 26S proteasome showed that interaction of the Ubl domain with Rpn1 subunit allows the 
two C-terminal helices of Ubp6 to contact the AAA+ domain of Rpt1 (Bashore et al. 2016). This 
suggests a function for the extended a-helices 11 and 12 in stabilizing and docking Ubp6 
catalytic domain in the 19S RP. 
   Further, we were able to express Ubp15 N-terminal and C-terminal domains in soluble form in 
E. coli (Fig. 2-7). To gain insight into the Ubp15-NTD mode of protein interaction, we analyzed 
binding affinity of Ubp15-NTD for the (E/P/A)XXS motifs that have previously shown 
interaction with human USP7. Initially, using fluorescence polarization binding assay, we 
measured the affinity of the Ubp15 N-terminal domain for EGPS containing vIRF1 (of KSHV) 
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peptide. FITC labeled wild-type vIRF1 peptide (44SPGEGPSGTG53) revealed a Kd of 757.1 µM, 
while Ser50 to alanine mutant vIRF1 peptide did not show any interaction. Further, our 1H-15N 
HSQC 2D NMR titration of Ubp15-NTD with wild-type vIRF1 peptide revealed disturbances in 
Ubp15-NTD chemical shift spectra which decreased upon titration with the mutant vIRF1 
peptide. This observation suggests that EGPS motif has a low binding affinity for Ubp15-NTD 
compared to that of USP7-NTD, which showed a Kd of 2 µM for interaction with vIRF1 peptide 
(Chavoshi et al. 2016). Also, mutation of serine to alanine of the EGPS motif disrupted this 
interaction, suggesting a similar mode of protein binding for Ubp15-NTD as compared to the 
USP7 N-terminal domain where serine residue is found essential for (E/P/A)XXS motifs 
interaction with USP7-NTD (Sarkari et al. 2010). Despite the high Kd of 757.1 µM, EGPS 
containing vIRF1peptide still led to strong disturbances of the Ubp15-NTD chemical shift 
spectra upon titration. It is important to note that for the FITC assay, a peptide concentration of 
40 nM was used while for NMR titration, the peptide concentration was 200 nM. The higher 
concentration of vIRF1 peptide can be attributed to the strong disturbances observe in the 
Ubp15-NTD spectra. Further, observed data from NMR titration assays only confirm the binding 
affinity of the motifs for Ubp15-NTD and do not provide any quantitative information on the 
strength of these interactions.  
 
   We also measured the affinity of the Ubp15-NTD for PSSS containing FOXO4 peptide 
(400GGLPSSSKLA409) using FITC assay. Our data revealed a much stronger Kd of 48.2 µM, 
compared to that of EGPS motif, for interaction with the Ubp15 N-terminal domain. FITC 
analysis of human USP7-NTD interaction with FOXO4 peptide resulted in a Kd of 6.7 µM. 
These observations indicate that Ubp15 has binding affinity for PSSS sequence. It is interesting 
to note that Cdh1, S. cerevisiae protein that has shown strong binding with Ubp15-NTD, 
contains a PSSS motif at its N-terminus (residues 13-16), which is conserved among yeast 
(Bozza & Zhuang 2011).  
 
   Further, using NMR titration assays Ubp15-NTD interactions were monitored with peptides 
from human HdmX, Hdm2 and MCMBP proteins that have previously shown a strong affinity 
for the USP7 N-terminal domain (Jagannathan et al. 2014; Sheng et al. 2006; Meulmeester et al. 
2005). Titration of the Ubp15 N-terminal domain with AHSS containing HdmX peptides led to 
disturbances of Ubp15-NTD spectra suggesting that Ubp15 interacts with AXXS sequences.  
Previously, Ecm30 was shown to interact with Ubp15 (Costanzo et al. 2010). Unpublished spot 
array analysis experiments from our lab indicated that AXXS motifs of Ecm30 including 
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(665SYNAAMSLLY674), (951KLSALRSDIL960) and (646KKSASPSAAT655) are involved in this 
interaction (Mandawe 2010, unpublished data). Furthermore, NMR 1H–15N HSQC resonances of 
15N-labeled Ubp15-NTD was monitored after titration with PSTS containing wild-type and 
mutant MCMBP and Hdm2 peptides. Addition of both peptides led to disturbances in the 
Ubp15-NTD spectra, indicating their interaction with the Ubp15 N-terminal domain. However, 
although mutation of serine to alanine in MCMBP peptide decreased the disturbances in the 
Ubp15-NTD spectra, mutant Hdm2 peptide still showed the same binding affinity as the wild-
type Hdm2 peptide. The Hdm2 peptide contains two serine residues (PXXSS) which might hold 
interaction with the Ubp15 N-terminal domain even after mutation of one of the serine residues 
to alanine. In fact, intrinsic fluorescence assay had shown that PSTSSS containing Hdm2 peptide 
(394YSQPSTSSSI476) has the strongest affinity for the USP7 N-terminal domain as compared to 
other Hdm2 binding sites (Sarkari et al. 2010). Further, mutation of Hdm2 PSTSSS motif to 
PSTASS decreased its binding with the USP7 N-terminal domain but did not abolish the 
interaction (Sarkari et al. 2010). This observation suggests that PSTSS motif has a similar mode 
of interaction with the Ubp15 N-terminal domain as compared to that of the USP7 N-terminal 
domain.  
 
   In summary, we have examined the expression of 127 Saccharomyces cerevisiae constructs 
encompassing full-length or domains of Ubp enzymes in BL21 mgk E. coli cells.  
Despite optimizations of the constructs design and protein expression and purification 
conditions, only 10 constructs expressed in soluble form. Soluble proteins were purified to 
homogeneity and used in protein crystallization trials. Three proteins crystallized including 
Ubp1, Ubp6 and the Ubp12 N-terminal domain. Ubp6 crystals led to a three-dimensional 
structure determination of its catalytic domain. Further, to analyze the yeast Ubp15 N-terminal 
domain protein interaction mechanism, using FITC assay and NMR titration, we showed that 
Ubp15 similar to its human homologue, USP7, interacts with AXXS and PXXS motifs. 
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(KSHV) vIRF1 Protein as a Novel Interaction Partner of 
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procedures, analyzed the data and produced the figures. In Fig. 3-6 (NMR titration of USP7-
NTD with WT or mutant vIRF1 peptides) Dr. Saridakis and Dr. Sheng supervised the 
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produced the figures. In Fig. 3-7 (Crystal structure of the UPS7-NTD:vIRF1 peptide complex) 
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rest of the figures. Fig. 3-10, schematic representation, was prepared by Ira Lacdao. 
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Introduction: 
 
Human Herpesviruses: 
 
   Human herpes viruses (HHV) are double-stranded DNA viruses, classified into α, β or γ 
subfamilies (Edelman 2005). To establish latency HHVs have to suppress host immune response 
and evade the immune system (Wen & Damania 2010). In the latent state, herpes viruses are 
dormant and remain in the nucleus by integrating their genome into the host chromosome and 
express only a small number of proteins essential for suppressing the host immune system (Wen 
& Damania 2010). HHVs have evolved various mechanisms for host immune evasion including 
inhibition of cellular senescence and apoptosis as well as promoting cell proliferation (Alibek et 
al. 2014). Another strategy to evade host immune surveillance is through expression of viral 
homologues of genes that are the host’s first line of defense against viral infection, such as 
interferons and interferon regulatory factors (IRFs), and therefore sabotage the function and 
regulation of these cellular proteins (Jacobs & Damania 2011). Such deregulation of proteins 
involved in growth control has led to the recognition of some HHVs as underlying agents of 
human cancer (Alibek et al. 2014; Chang et al. 1994). 
 
Karposi's Sarcoma Herpesvirus: 
 
   Karposi's sarcoma herpesvirus (KSHV), HHV-8, is the causative agent of Kaposi’s sarcoma, 
primary effusion lymphoma and multicentric Castleman’s disease which are especially prevalent 
in immunocompromised patients (Jacobs & Damania 2011; Angeletti et al. 2008). KSHV vIRF1 
(viral interferon regulatory factor 1) protein is encoded by ORF K9 and is believed to have been 
acquired through molecular piracy (Moore & Chang 1998). vIRF1 contains two domains, an N-
terminal DNA binding domain and a C-terminal IRF interaction domain (Fig. 3-1) (Hew et al. 
2013). vIRF1 DNA binding domain has approximately 40% sequence similarity to the DBDs of 
human IRF3 and IRF7 and contains a helix-turn-helix motif which is common in IRFs and DNA 
binding proteins (Hew et al. 2013). vIRF1 mediated deregulation of IRF3 and IRF7 leads to 
disruption of cellular antiviral activity. 
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Fig. 3-1: Domain arrangement of KSHV vIRF1 protein. vIRF1 contains a DNA binding domain 
(DBD) and an interferon association domain (IAD). 
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   vIRF1 is a potent inhibitor of the histone acetyltransferase activity of p300. It leads to 
hypoacetylation of histones and alteration of the chromatin structure, thereby reducing 
expression of IFNs  (Li et al. 2000). vIRF1 also directly interacts with p53 and inhibits its 
acetylation by p300  (Nakamura et al. 2001). Furthermore, vIRF1 has shown an inhibitory effect 
on Ataxia Telangiectasia-Mutated (ATM) kinase (Shin et al. 2006). ATM activation leads to 
phosphorylation of Ser15 and Ser20 on p53 which are close to Hdm2 binding pocket. In 
addition, activated ATM phosphorylates Hdm2 on Ser395, which inhibits Hdm2 mediated 
nuclear export of p53 into the cytoplasm, where it is degraded. ATM function results in reduced 
Hdm2 affinity for p53, leading to p53 stabilization (Shin et al. 2006; Chehab et al. 1999). Also, 
phosphorylation of Ser15 is a signal for p300 acetylation of p53, which is  important for its 
stability and activation (Lambert et al. 1998). Inhibition of ATM activity by vIRF1 increases 
ubiquitination and degradation of p53 by Hdm2 (Shin et al. 2006).  
 
Human USP7: 
 
   Human Ubiquitin Specific Protease 7 (USP7) also known as Herpes Associated Ubiquitin 
Specific Protease (HAUSP) is a well characterized deubiquitinating enzyme (DUB) originally 
identified as an interacting protein with HSV-1 immediate early protein, ICP0 (Everett et al. 
1997). USP7 harbors a TRAF-like domain in its N-terminus (USP7-NTD), a central catalytic 
domain and five Ubl folds in its C-terminus (Fig. 3-2) (Faesen et al. 2011; Sheng et al. 2006; 
Saridakis et al. 2005; Hu et al. 2002). The USP7-NTD recognizes and binds interacting proteins 
containing a (E/P/A)XXS motif (Sheng et al. 2006). All USP7 homologues harbor the highly 
conserved DWGF motif in their N-terminal domain, where the aspartic acid and Trp residues 
have been shown essential for protein interaction (Sarkari et al. 2010; Sheng et al. 2006). 
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Fig. 3-2: Domain arrangement of human USP7. USP7 contains an N-terminal substrate binding 
TRAF domain, a catalytic domain and a C-terminal domain that is comprised of five ubiquitin-
like (Ubl) sub-domains. 
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   USP7 is involved in maintaining cellular levels of the p53 tumor suppressor protein which is 
essential for normal cellular stress response (Li et al. 2002). p53 and its negative regulator, the 
E3 ligase, Hdm2, interact with the 164DWGF167 motif of USP7-NTD through their (P/A)XXS 
motifs, which leads to their deubiquitination and stabilization (Hu et al. 2006; Sheng et al. 2006). 
Since Hdm2 has a higher affinity for USP7 than p53, reduction in cellular levels of USP7 leads 
to instability of p53 while its removal results in destabilization of Hdm2, which in turn stabilizes 
p53 (Meulmeester et al. 2005; Cummins et al. 2004). USP7 also regulates the stability of Hdmx, 
a homolog of Hdm2. USP7 is an essential component of the p53-Hdm2-Hdmx pathway that 
maintains balance in the cellular levels of these proteins (Shadfan et al. 2012).  
 
HHVs Interaction with USP7: 
 
   Members of the herpesviruses family such as Epstein-Barr virus (EBV), Kaposi’s sarcoma 
associated herpesvirus (KSHV) and Herpes Simplex Virus type 1 (HSV-1) have evolved to 
interfere with the USP7-p53 pathway by competitively binding to USP7 and hindering its 
interaction with cellular substrates (Lee et al. 2009; Saridakis et al. 2005; Everett et al. 1997). 
ICP0 protein expressed by HSV-1 is an E3 ubiquitin ligase that ubiquitinates and destabilizes 
host proteins. Its interaction with USP7 leads to its rescue from self-ubiquitination and 
proteasomal degradation (Boutell et al. 2005). Epstein-Barr nuclear antigen 1 (EBNA1) 
expressed by EBV; viral interferon regulatory factor 4 (vIRF4), latency-associated nuclear 
antigen 1 (LANA) and ORF45 expressed by KSHV bind USP7-NTD at the same region as p53, 
Hdm2 and Hdmx (Gillen et al. 2015; Jager et al. 2012; Lee et al. 2011; Sarkari et al. 2010; Lee et 
al. 2009; Saridakis et al. 2005). They block USP7 substrate interaction and cripple the cell’s 
interferon and innate immune response and p53 mediated apoptosis (Lee et al. 2009; Saridakis et 
al. 2005).  
 
   vIRF4 residues spanning Ser202-Met216 contain the well-conserved ASTS sequence which 
forms an extended interaction with the USP7 N-terminal domain resulting in a dissociation 
constant (Kd) significantly lower than those obtained for USP7 cellular substrates, such as p53 
and Hdm2 (Lee et al. 2011). Furthermore, vIRF4 directly interacts with Hdm2 and inhibits its 
auto-ubiquitination which leads to Hdm2 survival and p53 instability (Lee et al. 2011). Likewise, 
LANA interacts with USP7-NTD through its 977PGPS980 motif (Jager et al. 2012). 
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    EBNA1 protein is involved in the initiation of DNA replication and transcriptional activation 
of EBV latent proteins (Pattle & Farrell 2006). Interaction of EBNA1 with the USP7 N-terminal 
DWGF motif occurs through EBNA1’s EGPS sequence, which does not match the previously 
reported (P/A)XXS motif or other known sequences required for binding to TRAF domains 
(Saridakis et al. 2005). A newly identified KSHV protein, ORF45, also interacts with USP7-
NTD through an EGPS motif (Gillen et al. 2015). 
 
Project Rationale: 
 
   We identified a 45PGEGPS50 consensus sequence in vIRF1 that is identical to the motif 
reported in EBNA1 and ORF45 (of KSHV) responsible for mediating their interaction with 
USP7-NTD (Gillen et al. 2015; Saridakis et al. 2005). It is already well established that HHVs 
target members of the USP7-p53-Hdm2 pathway. Multiple proteins expressed by KSHV, such as 
vIRF4, LANA and ORF45, have shown high-affinity binding with USP7, p53, Hdm2 and other 
proteins involved in regulation of p53 activity, such as ATM kinase and p300. vIRF1, expressed 
by KSHV, was previously reported to interact with p53 directly and inhibit its transactivity by 
blocking p300 acetylation of p53. This led us to investigate whether vIRF1 interacts with USP7. 
We characterized the interaction between USP7-NTD and KSHV vIRF1 using GST pull-down 
and fluorescence polarization assays, and further mapped the binding interface by 2D NMR 
HSQC. We also determined the crystal structure of a vIRF1 peptide with USP7-NTD. We 
confirmed that these two proteins interact in vivo and determined that expression of wild-type 
vIRF1 but not deletion mutant vIRF1 decreased cellular levels of p53 but not Hdm2 or ATM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
Material and Methods: 
 
Protein Expression: 
 
N-terminal 6xHis tagged wild-type (WT) and D164A/W165A mutant USP7-NTD were 
expressed from the pET15b vector as described previously (Sheng et al. 2006). His-tagged 
USP7-CTD was expressed from p15TV-L vector. Full-length His-USP7 in pFastBac was 
expressed in Spodoptera frugiperda (Sf9) cells as described previously (Pfoh et al. 2015). Full-
length vIRF1 was synthesized by GenScript (NJ, USA). ΔvIRF1 (deletion of residues 
45PGEGPS50) was made by ACGT Corporation (Toronto, Canada). The N-terminal GST fusion 
constructs were generated by PCR amplification corresponding to residues 1-90 of WT or 
ΔvIRF1 and inserted between the BamHI and NdeI sites of the pGEX2-TK vector. 
 
Protein Purification:  
 
For NMR titrations, uniformly labeled 15N 6xHis N-terminal tagged USP7-NTD was expressed 
in M9 media enriched with 0.7 g/L 15NH4Cl as the sole nitrogen source. All constructs were 
expressed in E. coli BL21 mgk cells in TB (Terrific broth, Bioshop) (except 15N His-USP7 
which was expressed in M9 media) with overnight 0.4 mM Isopropyl β-D-1-
thiogalactopyranoside induction at 16°C. The cells were harvested, resuspended in 50 mM Tris 
pH7.5, 500 or 150 mM NaCl, 5 mM Imidazole, 1x protease inhibitor cocktail (1mM 
Benzamidine and 0.5 mM PMSF) and 1x protease inhibitor tablet (Roche cOmplete ULTRA 
Tablets) and lysed using sonication. The lysate was cleared and allowed to interact with nickel-
NTA beads (Qiagen) for 1 hour. Beads were washed extensively with 50 mM Tris pH 7.5, 500 or 
150 mM NaCl and 20 mM imidazole. Proteins were eluted with the addition of 50 mM Tris 
pH7.5, 500 or 150 mM NaCl and 250 mM imidazole. 
 
Peptide Synthesis:  
 
Wild-type (44SPGEGPSGTG53) and mutant (44SPGEGPAGTG53) vIRF1 peptides were 
synthesized by CanPeptide Inc. (Montreal, Canada) with both N-terminal acetylation and C-
terminal amidation to mimic the native peptides. FITC labeled WT (FITC-Acp-SPGEGPSGTG-
NH2) and mutant (FITC-Acp-SPGEGPAGTG-NH2) vIRF1 peptides were also synthesized by 
CanPeptide Inc. (Montreal, Canada). 
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Fluorescence Polarization Binding Assay: 
 
Both wild-type and mutant USP7-NTD were further purified by size-exclusion chromatography 
using a HiLoad 16/60 Superdex 200 (GE Healthcare) on an ÄKTApurifier 10 UPC system (GE 
Healthcare) in 150 mM NaCl and 50 mM Tris pH 8.0. FITC labeled WT (FITC-Acp-
SPGEGPSGTG-NH2) and mutant (FITC-Acp-SPGEGPAGTG-NH2) vIRF1 peptides were 
initially dissolved in dimethyl sulfoxide to a final concentration of 10 mM. A 400 nM working 
stock of each peptide was prepared in assay buffer (50 mM Tris pH 8.0, 150 mM NaCl and 
0.01% Triton X-100). 500 µM of each protein was serially diluted and incubated with 40 nM of 
each peptide. 10µl of the above mixtures were transferred into a 384 well plate (Corning) and 
fluorescence polarization was measured on a Synergy H4 microplate reader (BioTek, USA) with 
λex=485nm and λem=520nm. Polarization values were analyzed by Graphpad Prism 5.0 using a 
one-site binding model to obtain the equilibrium dissociation constant (Kd). Data were calculated 
based on four individual experiments and the standard deviation was calculated. 
 
NMR Spectroscopy:  
 
NMR spectra were acquired at 25˚C on a Bruker 700 MHz NMR spectrometer equipped with a 
triple resonance cryo probe. Interaction of USP7-NTD with WT (44SPGEGPSGTG53) and mutant 
(44SPGEGPAGTG53) vIRF1 peptides was monitored by analyzing 1H-15N HSQC spectra. 
Briefly, 15N-labeled USP7-NTD was incubated with thrombin to cleave the 6xHis fusion tag 
followed by dialysis into NMR buffer (200 mM NaCl, 25 mM Na phosphate pH 7.0 and 10 mM 
DTT). Up to 0.4 mM unlabeled wild-type or mutant vIRF1 peptide was titrated in 0.2 mM of 
15N-labeled USP7 (containing 10% D2O) up to 2:1 peptide:USP7 molar ratio. Spectra were 
processed with Topspin 3.2 and analyzed with SPARKY program (Ye et al. 2012; Holowaty et 
al. 2003). 
 
GST Pull-Down Assay:  
 
Cells expressing GST fusion tagged proteins were lysed using sonication in 50 mM Tris pH 7.5, 
150 mM NaCl, 1x protease inhibitor cocktail (1 mM benzamidine and 0.5 mM PMSF) and 1x 
protease inhibitor tablet (Roche cOmplete ULTRA Tablets). Lysate was cleared and allowed to 
interact with glutathione-sepharose beads (GE Healthcare) for 1 hour. The beads were washed 
extensively with 50 mM Tris pH7.5 and 150 mM NaCl. GST tagged WT and deletion mutant 
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vIRF11-90 were kept bound to the glutathione-sepharose beads. Prior to the GST pull-down 
assays, USP7 proteins were dialyzed against 100 mM NaCl, 50 mM Tris pH 8.0, 5% glycerol, 5 
mM β-ME and 1x Protease inhibitor tablet. 30 µl of GST-tagged wild-type and deletion mutant 
vIRF11-90 bound to glutathione-sepharose resin were incubated with 150 µg of purified full-
length USP7, wild-type and mutant USP7-NTD and USP7-CTD for 2 hours at 4˚C. 1 nmole of 
GST alone bound to glutathione-sepharose beads was used as a negative control. The mixtures 
were then transferred to micro columns and washed extensively with assay buffer. The bound 
proteins were eluted with 20 mM reduced glutathione and detected by Coomassie Blue staining 
following sodium dodecyl sulfate-polyacrylamide gel electrophoresis.  
 
Crystallization:  
 
Prior to setting up crystal trials purified USP7-NTD was incubated with thrombin to remove the 
6xHis N-terminal fusion tag. USP7-NTD was further purified by size-exclusion chromatography 
using a HiLoad 26/60 Superdex 75 (GE Healthcare) on an ÄKTApurifier 10 UPC (GE 
Healthcare) in 500 mM NaCl and 20 mM Hepes pH 7.5. USP7-NTD (100 mg/ml) was co-
crystallized with at least five-fold molar excess of vIRF1 (44SPGEGPSGTG53) peptide at 4˚C 
using the hanging-drop vapor-diffusion method. Rod shape crystals appeared after 4 days 
following one round of micro-seeding using USP7-NTD:CHFR peptide crystal seeds in 30% 
PEG 4000, 0.1 M Tris pH 8.5 and 0.2 M LiSO4. 
 
X-ray Data Collection and Structure Determination:  
 
X-ray data was collected at the Advanced Photon Source. Diffraction data was integrated and 
scaled using autoPROC software (Monleon et al. 2002). The structure was determined by 
molecular replacement employing USP7-NTD (Protein Data Bank ID 1YY6) as search model 
without the EBNA1 peptide using CNS (version 1.3) and was refined also using CNS at 1.5 Å 
resolution (Sarkari et al. 2013). The electron density was visualized and the vIRF1 peptide model 
was built using Coot (Vonrhein et al. 2011). CNS 1.3 was used for refinement and 2Fo-Fc and Fo-
Fc maps were inspected for further refinement and model rebuilding in Coot. Water molecules 
were picked using CNS 1.3. Figure 3-7 was prepared using Pymol (Schrödinger 2010). 
 
Structure Deposition:  
 
Coordinates and structure factors for USP7-NTD:vIRF1 have been deposited in the RCSB under 
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Protein Data Bank ID 4YSI. 
 
Cell Culture and Antibodies:  
Human osteosarcoma U2OS cells were grown in McCoy’s medium supplemented with 10% FBS 
and 1 mg/ml Penicillin-Streptomycin. The antibodies were rabbit polyclonal against USP7 
(Bethyl Laboratories, A300-033A), mouse monoclonal against USP7 (Millipore, 05-1946), 
mouse monoclonal against Myc (Millipore 05-724), rabbit polyclonal against FLAG tag (Bethyl 
Laboratories, A190-102A), mouse monoclonal against FLAG tag (Sigma, F3165), mouse 
monoclonal against p53 (Santa Cruz, sc-126), rabbit polyclonal against phospho-p53 (Ser15) 
(Cell Signaling, #9284), rabbit monoclonal against ATM (#2873), rabbit monoclonal against 
phospho-ATM (Ser1981) (Cell Signaling, #5883), mouse monoclonal against MDM2 (Santa 
Cruz, sc-965), rabbit polyclonal against phospho-MDM2 (Ser166) (#3521) and mouse 
monoclonal against GAPDH (Santa Cruz, sc-47724). To detect proteins of interest HRP-
conjugated anti-mouse IgG (Jackson ImmunoResearch 115-035-166) and anti-rabbit IgG 
(Jackson ImmunoResearch 111-035-003) antibodies were used. 
Co-immunoprecipitation: 
 
Cells were transfected with pCMV/N-Myc USP7 and pcDNA3.1/FLAG vIRF1 (wild-type or 
EGPS deletion mutant) vectors (total of 10 µg of DNA per 15 cm tissue culture plate) using 
PolyJet transfection reagent according to the manufacturer’s protocol (SignaGen Laboratories). 
Cells were harvested 48 hours post-transfection and lysed in radioimmunoprecipitation buffer 
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 20% glycerol, 1X protease 
inhibitor cocktail (Roche)) followed by 2 sec sonication at 10% amplitude. Cell lysates were 
incubated with either mouse monoclonal anti-Myc primary antibody or rabbit polyclonal anti-
FLAG primary antibody overnight at 4 ˚C followed by the addition of pre-cleared protein A/G 
Plus-Agarose beads (Santa Cruz, sc-2003) for 1 hour. Immunoprecipitates were washed with 
radioimmunoprecipitation buffer five times and then boiled in SDS sample buffer for 5 minutes 
at 95 ˚C. Samples were resolved on 10% SDS-polyacrylamide gels and immunoblotted using 
antibodies described above. Co-immunoprecipitation experiment for endogenous USP7 was 
carried out following the same protocol using rabbit polyclonal anti-USP7 antibody. 
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Results: 
 
Identification of an EGPS Sequence in KSHV vIRF1:  
 
   It is well established that many USP7 substrates including Hdm2, p53 and Hdmx contain 
(P/A)XXS motifs for interaction with USP7-NTD through the highly conserved 164DWGF167 
motif with dissociation constant (Kd) values ranging from 10-45 µM (Sarkari et al. 2010; Hu et 
al. 2006; Sheng et al. 2006). KSHV proteins including vIRF4 and LANA interact with the USP7-
NTD 164DWGF167 motif through (P/A)XXS sequences (Jager et al. 2012; Lee et al. 2011). EBV 
EBNA1 also interacts with USP7-NTD however, with an unusual motif, EGPS, instead of 
(P/A)XXS (Saridakis et al. 2005). A recent study revealed that ORF45, a KSHV immediate early 
protein, also interacts with USP7-NTD through an EGPS sequence (Gillen et al. 2015).  
 
   We utilized SCAN Prosite to search for viral proteins containing the DPGEGPST sequence of 
EBNA1 and identified 44SPGEGPSG51 from KSHV vIRF1 (de Castro et al. 2006). Alignment of 
EBV EBNA1, KSHV ORF45 and KSHV vIRF1 proteins showed conservation of the EGPS 
interaction motif, and therefore we hypothesized that vIRF1 may interact with USP7-NTD (Fig. 
3-3). 
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Fig. 3-3: Alignment of the USP7 binding motif of vIRF1 with the previously identified USP7 
binding motifs of EBV EBNA1 and KSHV ORF45. “*” represents conserved residues and “.” 
represents semi-conserved substitution. 
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USP7-NTD and vIRF1 Interact in Vitro:  
 
   To test the binary interaction between vIRF1 and USP7, a series of GST pull-down assays 
were performed using GST-tagged vIRF11-90. GST-vIRF11-90 interacted with both full-length 
USP7 and USP7-NTD but not USP7-CTD confirming that vIRF1 binding is mediated through 
USP7-NTD (Fig. 3-4). Neither full-length USP7 nor USP7-NTD were retained by GST alone, 
indicating that the interaction with GST- vIRF11-90 was specific. Deletion of residues 
45PGEGPS50 (GST-ΔvIRF11-90) abolished its interaction with both full-length USP7 and USP7-
NTD confirming that vIRF1 interacts with USP7-NTD through its EGPS sequence, which is 
similar to the USP7 binding motif found in EBNA1. We also performed GST pull-downs using 
USP7-NTDDW, a double mutant containing alanine mutations at residues D164 and W165 within 
the 164DWGF167 motif. As expected, USP7-NTDDW did not interact with vIRF1. These pull-down 
assays demonstrated that USP7-NTD interacts specifically with vIRF1 in vitro. 
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Fig. 3-4: USP7 and vIRF1 GST pull-down assay. GST pull-down assay with GST-vIRF11-90, 
GST-ΔvIRF11-90 (deletion of 45PGEGPS50) or GST alone as negative control. Full-length USP7, 
USP7-NTD, USP7-CTD and USP7-NTDDW were used as prey. L, load; E, elution.   
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Binding Affinity of vIRF1 and USP7-NTD:  
 
   Fluorescence polarization was used to determine the dissociation constant between USP7-NTD 
and vIRF1. FITC labeled wild-type (WT) (44SPGEGPSGTG53) and mutant (Mut) 
(44SPGEGPAGTG53) vIRF1 peptides containing the potential USP7 interaction site were used in 
these assays. A fixed concentration of 40 nM FITC labeled vIRF1 peptide was titrated with 
increasing concentrations of USP7-NTD (up to 500 µM) to detect the fluorescence polarization 
changes during formation of the protein-peptide complex. The dissociation constant of WT 
vIRF1 peptide was calculated to be 2.0 ± 0.1 µM while Kd for the mutant peptide was calculated 
to be 46.1 ± 4 µM (Fig. 3-5A & B). Interaction was not observed between USP7-NTDDW and 
either WT or mutant vIRF1 peptides. The Kd value of 2µM for the interaction between vIRF1 
and USP7 compares well with that of EBNA1 and implies that KSHV vIRF1 interacts with 
USP7-NTD. 
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Fig. 3-5: Binding curve of vIRF1 and USP7. A) Fluorescence polarization of FITC labeled wild-
type (44SPGEGPSGTG53 in black) or mutant (44SPGEGPAGTG53 in red) vIRF1 peptides with 
USP7-NTD and USP7-NTDDW. B) Dissociation constants (Kd values) for the USP7-NTD 
interaction with FITC-labeled vIRF1 peptides. mP, milliPolarization. Error bars indicate means ± 
S.D. Average values with standard deviation for three or more experiments are shown. 
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NMR Analysis of the USP7-NTD and vIRF1 Peptide Interaction:  
 
   To further investigate the interaction between USP7-NTD and the vIRF1 peptide, 2D NMR 
HSQC spectra of 15N labeled USP7-NTD was analyzed in the presence of unlabeled WT 
(44SPGEGPSGTG53) or mutant (44SPGEGPAGTG53) vIRF1 peptides. Figure 3-6A displays the 
overlay of USP7-NTD 1H-15N HSQC spectra for USP7-NTD alone (in black) and USP7-NTD 
titrated with 0.4 mM of wild-type (in red) or mutant (in blue) vIRF1 peptides (2:1 peptide:USP7-
NTD ratio). Strong perturbations were observed in the USP7-NTD resonances in the presence of 
WT vIRF1 peptide while these disturbances were notably decreased in the presence of mutant 
vIRF1 peptide. Using previously assigned USP7-NTD spectra (Saridakis et al. 2005) (Biological 
Magnetic Resonance Data Bank Entry 6939) we were able to observe that upon vIRF1 binding, 
disturbances in USP7-NTD spectra were mostly in β-strand 7 residues such as D164, W165 
(shift was observed in indole side chain), G166, F167, S168 and Met171 (Fig. 3-6B). 
Resonances of a few residues from β3, β4 and β6 were also affected including Met100, F118 and 
S155. These observations are very similar to those of EBNA1/USP7-NTD interaction. However, 
in contrast to EBNA1, spectra of residues such as N169 and F170 from β7 and residues Met102 
and F117 did not show any change upon addition of vIRF1 peptide suggesting slightly different 
mode of interaction with USP7-NTD. 
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Fig. 3-6: NMR titration of USP7-NTD with WT or mutant vIRF1 peptides. Overlay of 2D 1H-
15N HSQC correlation spectra of 15N labeled USP7-NTD (black) titrated with 1:2 molar ratio of 
unlabeled wild-type (44SPGEGPSGTG53 in red) or mutant (44SPGEGPAGTG53 in cyan) vIRF1 
peptides. (D) Individual residues from USP7-NTD ß strand 7 and M100 from ß strand 3 that 
showed the largest shifts are identified. 
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Crystal Structure of the USP7-NTD and vIRF1 Peptide Complex:  
 
   To elucidate the molecular basis of this interaction in vitro we co-crystallized USP7-NTD with 
the following vIRF1 peptide (44SPGEGPSGTG53). The structure of the USP7-NTD:vIRF1 
peptide complex was determined using molecular replacement and refined to 1.5Å resolution. X-
ray data collection and refinement parameters are provided in (Table 3-1). USP7-NTD residues 
54–62 and 106–111 are disordered and were not built in the final model.  
 
   As previously shown, USP7-NTD forms a TRAF domain similar to that of tumor necrosis 
factor receptor associated factor (TRAF) 2, which consists of an eight-stranded antiparallel β-
sandwich fold with a shallow groove on the surface (Fig. 3-7A & B) (Park et al. 1999). The 
conserved 164DWGF167 motif is found in β-strand 7 which also contains a beta-bulge essential for 
its interaction with binding partners. The electron density allowed building of vIRF1 residues 44-
51 (SPGEGPSG) in the binding site of USP7-NTD (Fig. 3-7C). Residues 52 and 53 of the vIRF1 
peptide did not have interpretable electron density suggesting that they do not make contact with 
USP7-NTD. There are several polar and non-polar interactions that occur between USP7-NTD 
and the vIRF1 peptide (Fig. 3-7E). Ser50 of vIRF1 forms H-bonds through its side chain 
hydroxyl and backbone amide group with Asp164 of USP7-NTD β-strand 7. It also forms a 
hydrogen bond with ine104 of β-strand 3. The Glu47 side chain of vIRF1 forms a water-
mediated H-bond with Trp165 of USP7. Comparison between the EBNA1 and the vIRF1 
peptides revealed that they are superimposable and make very similar contacts with USP7-NTD 
(Fig. 3-7D). 
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Table 3-1: USP7-NTD:vIRF1 Peptide X-Ray Data Collection and Refinement Parameters. 
 
 
 USP7-NTD:vIRF1 peptide 
X-Ray Data  
Space Group P41 
Resolution (Å) 50.0 – 1.02 
Unit Cell Axes (Å3) 70.0 x 70.0 x 45.4 
Molecules / AU 1 
Total Observations (#) 684942 
Unique Reflections (#) 111563 
Intensity (I/s<I>) 20.6 (2.0) 
Completeness (%) 99.9 (98.2) 
Multiplicity 6.1 (5.5) 
aRmerge 0.039 (0.776) 
Refinement  
Rwork 0.171 
Rfree 0.176 
Protein Atoms (#) 1186 
Water Molecules (#) 268 
rmsd bonds (Å) 
rmsd angles (°) 
0.008 
1.29 
rmsd dihedrals (°) 25.2 
rmsd improper (°) 0.86 
thermal factors (Å2) 13.5 
Ramachandran Plot  
Most Favoured 0.95 
Additionally Allowed 0.05 
Numbers in brackets refer to the highest resolution shell, 1.023 Å 
to 1.02 Å. aRsym = S |I-<I>| /SI where I is the observed intensity 
and <I> is the average intensity from multiple observations of 
symmetry-related reflections. 
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Fig. 3-7: Crystal structure of the UPS7-NTD:vIRF1 peptide complex. A) Electrostatic surface 
representation of USP7-NTD showing the vIRF1 peptide 44SPGEGPSGTG53 in stick form 
(yellow). B) Ribbon diagram of USP7-NTD (green) showing the vIRF1 peptide in stick form 
(yellow). C)  Electron density prior to the addition of peptide with the final peptide model 
(yellow) contoured at 1 s. D) Superposition of the vIRF1 (44SPGEGPSGTG53, yellow) and 
EBNA1 (441DPGEGPSTGP450, fuchsia) peptides. E) Interactions formed between USP7-NTD 
(green) and the vIRF1 peptide (yellow). 
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USP7 and vIRF1 Interact in Vivo:  
 
   We investigated the vIRF1 interaction with USP7 in vivo. The ability of vIRF1 to interact with 
USP7 was examined by transfecting U2OS cells with Myc-tagged USP7 and FLAG-tagged WT 
vIRF1. After immunoprecipitation of the lysate with a USP7 antibody, immunoblotting with 
anti-FLAG led to the identification of FLAG-tagged vIRF1 (Fig. 3-8A). Lysate incubated with 
rabbit IgG served as a negative control and did not show any interaction. We also examined 
whether the PGEGPS vIRF1 deletion mutant (ΔvIRF1) could be co-immunoprecipitated with 
USP7. U2OS cells were transfected with Myc-tagged USP7 and FLAG-tagged ΔvIRF1. The 
lysate was immunoprecipitated with a USP7 antibody and immunoblotted with anti-FLAG, 
however, ΔvIRF1 could not be detected (Fig. 3-8A). These results indicated that USP7 was 
interacting with vIRF1 but not ΔvIRF1 in U2OS cells. We also performed the reciprocal 
experiments in which immunoprecipitation of the lysate with anti- FLAG rather than anti-USP7 
readily identified USP7 in complex with vIRF1 while ΔvIRF1 was not able to pull-down USP7 
(Fig. 3-8B). Combined, these results confirmed that the EGPS residues in vIRF1 are essential for 
interaction with USP7 in vivo.  
 
   Further, we examined the interaction of vIRF1 with endogenously expressed USP7 (performed 
by Olga Egorova). After transfection of U2OS cells with FLAG-tagged vIRF1, USP7 was 
immunoprecipitated with anti-USP7. Blotting for anti-FLAG readily identified vIRF1 (Fig. 3-
8C). In a reciprocal experiment, immunoprecipitation of FLAG-tagged vIRF1 from transfected 
U2OS lysate also successfully led to the detection of endogenous USP7. In each case lysate 
incubated with rabbit IgG served as negative control which did not show any interaction.  
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Fig. 3-8: vIRF1 and USP7 interaction in vivo. Overexpressed USP7 interacts with ectopically 
expressed vIRF1 but not EGPS deletion mutant vIRF1 (ΔvIRF1). U2OS cells were transfected 
with Myc-USP7 and FLAG-vIRF1 or FLAG-ΔvIRF1. Immunoprecipitation (IP) was carried out 
by incubating the lysate with (A) USP7 or (B) FLAG antibodies using rabbit IgG as the negative 
control. Immunoblotting (IB) was performed with antibodies against Myc and FLAG tags. (C) 
Endogenous USP7 interacts with vIRF1 in vivo. U2OS cells were transfected with FLAG-vIRF1. 
IP was performed using USP7 or FLAG antibodies followed by IB using antibodies against 
USP7 and FLAG (Figure C was prepared by Olga Egorova).    
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Effect of vIRF1 on p53, Hdm2 and ATM Stability:  
 
   USP7 stabilizes cellular levels of the tumor suppressor p53 and its negative regulator, Hdm2, 
through deubiquitination. Reduction in cellular levels of USP7 leads to instability of p53 whereas 
deletion of USP7 leads to degradation of Hdm2 resulting in stabilization of p53 (Cummins et al. 
2004; Li et al. 2002). We hypothesized that interaction between vIRF1 and USP7-NTD at the 
same binding site that is known to interact with p53 and Hdm2 should decrease the availability 
of USP7 and therefore lead to instability of p53. To test the effect of vIRF1 on p53, U2OS cells 
were transfected with expression vectors for FLAG-tagged vIRF1 or ΔvIRF1. Endogenous levels 
of p53, Ser15 phosphorylated p53 and USP7 were detected by immunoblotting after transfection. 
As shown in (Fig. 3-9A and C), transfection of cells with vIRF1 resulted in significant decrease 
in the level of p53 (about 50%) compared to levels in cells transfected with empty vector 
(p<0.01) or ΔvIRF1.  
 
   Considering that USP7 deubiquitinates and stabilizes Hdm2, we monitored Hdm2 as well as 
phospho-Hdm2 (Ser166) in cells transfected with vIRF1 or ΔvIRF1 to assure that changes in the 
levels of p53 were not a result of change in stability of Hdm2. Phosphorylation at Ser166 
stabilizes Hdm2 and stimulates p53 ubiquitination (Feng et al. 2004). To test our hypothesis, 
U2OS cells were transfected with expression vectors for FLAG-tagged vIRF1 or ΔvIRF1. As 
shown in (Fig. 3-9B and D), expression of vIRF1 or ΔvIRF1 had no effect on the endogenous 
levels of USP7, Hdm2 or Ser166 phosphorylated Hdm2 compared to control. This observation 
suggests that change in the stability of p53 is not caused by changes in the stability of Hdm2 or 
USP7. 
 
   It was previously reported that vIRF1 expression inhibits auto-phosphorylation of ATM on 
Ser1981 which is important for ATM activation. Decreased ATM activity resulted in reduced 
Ser15 phosphorylation of p53 (Shin et al. 2006). This p53 phosphorylation decreases the Hdm2 
affinity for p53 and leads to stability of p53 (Nakagawa et al. 1999). As shown in (Fig. 3-9A), we 
observed decreased levels of Ser1981 phosphorylated ATM as well as Ser15 phosphorylated p53 
in cells transfected with vIRF1 or ΔvIRF1, suggesting that under our experimental conditions, 
ΔvIRF1, which is incapable of binding to USP7, is still able to exert an inhibitory effect on ATM 
activation and Ser15 phosphorylation of p53. This indicates that the reduced p53 levels observed 
with ΔvIRF1 compared to vIRF1 are mainly due to the interaction between vIRF1 and USP7. 
Therefore, we show that interaction of vIRF1 with USP7 leads to destabilization of p5 
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Fig. 3-9: Effect of vIRF1 on p53, Hdm2 and ATM stability. A) Effect of vIRF1 expression on 
p53 and ATM. U2OS cells were transfected with FLAG-vIRF1 or FLAG-ΔvIRF1. After 24hrs, 
IB was performed using antibodies against ATM, phospho-ATM (Ser1981), USP7, p53, 
phospho-p53 (Ser15) and FLAG tag. Cells transfected with empty vector were used as negative 
control. GAPDH levels were detected as control for equal loading. B) Effect of vIRF1 on Hdm2. 
The levels of USP7, Hdm2 and Ser166 phosphorylated Hdm2 were monitored after expression of 
vIRF1 or ΔvIRF1 in U2OS cells. Cells were incubated for 24 hours following transfection with 
FLAG-tagged vIRF1 and ΔvIRF1. IB was performed on whole cell lysates using USP7, Hdm2, 
phospho-Hdm2 (Ser166) and FLAG tag antibodies. C&D) Fold change was determined by 
normalizing p53 and Hdm2 ratios to the vector control ratio. A paired t-test was performed to 
evaluate the statistical significance of the changes in p53 and Hdm2 levels after the introduction 
of vIRF1 or ΔvIRF1. Error bars indicate S.E.M. and are from 3 independently transfected U2OS 
lysates.  
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Discussion: 
 
   Members of the herpesvirus family such as herpes simplex virus type 1 (HSV-1), Epstein-Barr 
virus (EBV), Kaposi’s sarcoma-associated herpesvirus (KSHV) and human cytomegalovirus 
(HCMV) have evolved to interfere with the USP7-p53-Hdm2 pathway by competitively binding 
to USP7 and hindering its interaction with cellular substrates or binding proteins (Jager et al. 
2012; Lee et al. 2011; Saridakis et al. 2005; Emsley & Cowtan 2004; Meredith et al. 1994). For 
instance, HSV-1 expressed ICP0 protein is an E3 ubiquitin ligase that ubiquitinates and causes 
degradation of host proteins (Boutell & Everett 2003). ICP0 interaction with USP7 leads to its 
rescue from self-ubiquitination and proteasomal degradation (Boutell et al. 2005). UL35, a 
HCMV latent protein, interacts with USP7 and alters its subcellular localization (Salsman et al. 
2012). EBNA1 expressed by EBV and vIRF4, LANA and ORF45 expressed by KSHV interact 
with the USP7 N-terminal domain, block USP7 substrate interaction and cripple the cell’s 
interferon and innate immune response (Lee et al. 2009; Saridakis et al. 2005). Further, USP7 
interacting viral proteins such as ICP0, UL35 and EBNA1 also co-localize with and disrupt 
promyelocytic leukemia (PML) nuclear bodies and induce degradation of PML proteins 
(Sivachandran et al. 2008; Maul & Everett 1994). PML nuclear bodies (PML-NB), primarily 
composed of PML protein, are important mediators of critical cellular processes including 
apoptosis, DNA repair and intrinsic response to viral infection (Salsman et al. 2012; Salsman et 
al. 2008; Bernardi & Pandolfi 2007). Further, PML nuclear bodies recruit proteins such as p53 
and p300 (Seo et al. 2001; Li et al. 2000). USP7 is also known to associate with PML-NBs 
(Sarkari et al. 2011). vIRF1 protein expressed by KSHV was shown to interact with both p53 and 
p300. In addition, in KSHV infected BCBL-1 cells, vIRF1 was shown to localize with PMLs 
during both lytic and latent cycles (Pozharskaya et al. 2004).  
 
   Through analysis of viral protein sequences followed by biochemical, structural and in vivo 
studies, we identified KSHV vIRF1 as a novel USP7 binding protein. Fluorescence polarization 
indicated that the vIRF1 peptide, 44SPGEGPSGTG53, interacts with USP7-NTD with a Kd value 
of 2.0 µM compared to substrates such as Hdm2 and p53 that bind with Kd values varying 
between 10 µM and 45 µM respectively. A single point mutation of serine to alanine in the 
vIRF1 peptide decreased the dissociation constant approximately 25-fold indicating the 
importance of Ser50 in mediating interaction with the USP7-NTD binding site. The interaction 
between USP7-NTDDW and the vIRF1 peptide was completely abolished confirming that the 
vIRF1 47EGPS50 sequence interacts with the USP7-NTD 164DWGF167 motif. 
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   The vIRF1 peptide binds to a groove on the surface of USP7-NTD, forming identical 
interactions with USP7-NTD as those seen with the USP7-NTD:EBNA1 peptide complex 
structure. The HSQC NMR analysis revealed perturbations in USP7-NTD residues from β-
strands 3, 4, 6 and 7 upon addition of the vIRF1 peptide. These residues correlate well with the 
residues seen in the crystal structure analysis especially those found in β-strand 7. The side 
chains of residues from β-strands 3 and 7 form polar contacts with the vIRF1 peptide whereas the 
remaining residue side chains, from β-strands 4 and 6, are in close proximity to the vIRF1 
peptide but do not make any polar contacts. Along with EBNA1 and ORF45, vIRF1 contains a 
negatively charged glutamic acid residue at the position of P/A in the (P/A)XXS USP7 binding 
motif. Glutamic acid rather than proline or alanine in that position is thought to increase the 
affinity of EBNA1 for USP7-NTD therefore, allowing it to effectively compete with USP7 
cellular substrates (Sheng et al. 2006). Comparing the interaction with USP7-NTD made by 
glutamic acid rather than proline or alanine shows an increased number of H-bonds formed with 
glutamic acid to USP7-NTD. This unique mode of interaction achieved through substitution of a 
glutamic acid residue for alanine or proline is advantageous for vIRF1, ORF45 and EBNA1 in 
that it provides them with a higher binding affinity. This empowers the virus to sufficiently 
disrupt USP7 deubiquitination of cellular substrates such as p53. Identification of yet another 
USP7-NTD interacting herpesvirus protein suggests that these viruses target USP7 at least in part 
because it is a critical cellular regulator of p53.  
 
   Our in vivo data in U2OS cells indicates that vIRF1, but not ΔvIRF1, leads to a decrease in the 
levels of cellular p53. Therefore, vIRF1 binds USP7-NTD through its EGPS sequence and 
decreases availability of USP7 for binding and deubiquitinating p53. vIRF1 was previously 
reported to directly interact with p53 through its central region (residues 152-360), prevent p53 
acetylation by p300 and thus inhibit p53 transcriptional activation (Shin et al. 2006; Seo et al. 
2001). It was also reported that vIRF1 led to increased ubiquitination and degradation of p53 
(Shin et al. 2006). Our data suggests that increased ubiquitination and degradation of p53 can in 
part be attributed to vIRF1 hijacking USP7, thus decreasing USP7’s ability to deubiquitinate and 
stabilize p53. Since Hdm2, a p53 negative regulator, is also a substrate of USP7 and interacts 
through its 164DWGF167 motif, we monitored cellular levels of Hdm2 to investigate whether the 
vIRF1-mediated decrease in availability of USP7 also destabilized Hdm2. We were never able to 
detect any significant changes in the level of Hdm2 suggesting that the USP7:vIRF1 interaction 
preferably disrupted USP7 deubiquitination and stabilization of p53.  
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   It was previously reported that vIRF1 inhibits Ser1981 auto-phosphorylation (activation) of 
ATM which prevents ATM mediated Ser15 phosphorylation of p53 and leads to p53 degradation 
(Shin et al. 2006). We monitored ATM and Ser1981 phosphorylated ATM but did not observe 
any changes in their levels between vIRF1 and ΔvIRF1 transfected cells, however both showed 
lower levels compared to mock transfected cells, indicating that vIRF1 and ΔvIRF1 are still able 
to interact with ATM and inhibit its activity. As it was previously reported that vIRF1 interacts 
with ATM through its CTD while the USP7 binding motif that we identified is located N-
terminal to its DNA binding domain, we were not expecting changes in ATM levels (Shin et al. 
2006). 
 
   High levels of vIRF1 expression in KSHV infected BCBL-1 cells were only observed 
transiently during lytic infection. Whereas, low levels of vIRF1, localized with PML nuclear 
bodies, were reported during latency (Pozharskaya et al. 2004). In KSHV infected cells, p53 was 
only detectable in PML nuclear bodies during the lytic cycle while latently infected cells did not 
show detectable levels of p53 (Pozharskaya et al. 2004). These observations suggest that vIRF1 
may prevent USP7 deubiquitination of p53 during latency as all three proteins are localized to 
PML nuclear bodies. However, it is also important that vIRF1-mediated disruption of USP7 
regulation of p53 is only one of the many mechanisms used by vIRF1 and other KSHV 
expressed proteins to weaken the cellular anti-viral response (Jacobs & Damania 2011). 
 
   KSHV vIRF4, ORF45 and LANA interact with and inhibit multiple members of the USP7-
p53-Hdm2 pathway indicating the importance of p53 degradation for KSHV to establish and 
maintain life-long latency in host cells (Jager et al. 2012; Lee et al. 2011; Chen et al. 2010; Shin 
et al. 2006). vIRF1 also uses multiple redundant mechanisms to combat the cell’s anti-viral 
response by inhibiting multiple targets of the USP7-p53-Hdm2 pathway. Under normal 
(unstressed) cellular conditions, USP7 predominantly stabilizes Hdm2 which permits p53 
ubiquitination and degradation as low levels of p53 are required for normal cellular homeostasis 
(Fig. 3-10A). Upon cellular stress (DNA damage or viral entry into the nucleus) ATM kinase is 
activated which leads to phosphorylation of p53, Hdm2 and Hdmx. ATM-mediated Hdm2 
phosphorylation leads to p53 stabilization. ATM-mediated phosphorylation of p53 decreases its 
affinity for Hdm2, signals its acetylation and transactivation by p300 as well as its stabilization 
by USP7 (Fig. 3-10B). vIRF1 is a potent inhibitor of ATM kinase activity, p300 
acetyltransferase activity and p53 transcriptional activity (Fig. 3-10C). We’ve shown that vIRF1 
interaction with USP7 decreases p53 levels suggesting that it also blocks USP7 deubiquitination 
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and stabilization of p53. Our novel finding that vIRF1 also targets USP7 fits well with the 
mechanism that KSHV must destroy p53 for a successful lifelong infection. 
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Fig. 3-10: A new role for vIRF1 in hijacking USP7 and degrading p53. A-B) depicting USP7, 
Hdm2 and ATM effect on p53 signaling pathway under normal and stressed cellular conditions. 
C) vIRF1 disrupts the p53 signaling pathway during viral infection by (1) inhibiting ATM 
phosphorylation (2) inhibiting p53 transcription activation and (3) inhibiting p300 acetylation of 
p53. Our results suggest that vIRF1 also binds USP7 and decreases availability of USP7 for 
deubiquitinating and stabilizing p53 (Schematic representation was prepared by Ira Lacdao).  
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Chapter 4: Human Cytomegalovirus Tegument 
Transactivator pp71 Interacts with Human Deubiquitinating 
Enzyme USP7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Fig. 4-5 (Superimposed 15N HSQC spectra of USP7-NTD before and after titration with pp71 
peptide) Dr. Saridakis and Dr. Sheng supervised the experiment. The procedure was done with 
the help of Dr. Howard Hunter. I analyzed the data and produced the figures. In Fig. 4-8 
(Complex crystal structure of USP7-NTD and pp71 peptide) Dr. Sadridakis supervised the 
experiment, collected and refined crystal diffraction data and prepared Table 4-1. I set up and 
performed the experiments and produced the final figures. 
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Introduction: 
 
Human Cytomegalovirus: 
 
   Human cytomegalovirus (HCMV, also known as HHV-5) is a member of the human 
herpesvirus (HHV) family that has acquired the ability to evade the immune system and persist 
in latent form in healthy individuals throughout their life time. Disease symptoms and mortality 
occur in infants infected in the womb, newborns infected shortly after birth and in individuals 
with weakened immune system, such as organ transplant patients or older individuals (Griffiths 
et al. 2015; Penkert & Kalejta 2012). Similar to other members of the human herpesviruses, 
HCMV is very common. A recent survey revealed that by age 50 about 50% of Americans are 
positive for HCMV while for South America and parts of Europe this number reaches about 90% 
(Boeckh & Geballe 2011). HCMV is one the dominant causative agents behind congenital 
hearing loss and mental retardation in children and less commonly results in CMV 
mononucleosis (Goderis et al. 2016; Grosse et al. 2008).  
 
   HCMV is a b herpesvirus, a sub-family of Herpesviridae, with a linear double stranded DNA. 
Its genome is incased in an icosahedral protein capsid which is further enveloped by a lipid 
bilayer (Tomtishen III 2012). Between the capsid and the lipid envelope there is a layer known 
as tegument. The tegument contains about 38 viral & some cellular proteins along with some 
viral and cellular mRNAs (Smith et al. 2014; Varnum et al. 2004). Upon diffusion of the lipid 
envelope with the host cell membrane, components of the tegument are released into the 
cytoplasm and become active (Tomtishen III 2012). Tegument proteins, of which many are 
phosphorylated, play a crucial rule in preparation of the cellular environment for viral infection 
prior to viral gene expression (Rieder et al. 2017) . They are involved in immune repression, 
control of cell cycle, initiation of viral immediate early gene expression, transfer of capsid to the 
nucleus and virion assembly and exit from the host cell (Smith et al. 2014). For their crucial rule 
in initiation of the viral infection, tegument proteins have been studied as targets for HCMV 
infection treatment, therapeutic design and vaccine development (Xia et al. 2017; Kalejta 2008).  
HCMV pp71 Tegument Protein: 
 
   Upon release of the tegument proteins into the cytoplasm, pp71 (71-kDa phosphoprotein), the 
main HCMV tegument transactivator, is immediately transported to the nucleus. It activates 
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expression of viral immediate early (IE) genes from the major immediate early promoter. This 
leads to expression of the IE1 and IE2 proteins, necessary for initiation of lytic infection, and 
other IE genes that are important for efficient HCMV gene expression and replication 
(Bresnahan & Shenk 2000). pp71 translocation back to the cytoplasm during late infection leads 
to silencing of the majority of viral genes, which is important for establishment of a latent state 
(Penkert & Kalejta 2012). pp71 expression and its RNA have not been detected during latency. 
In addition, expression of pp71 mRNA does not lead to activation of lytic cycle in latently 
infected cells (Reeves & Sinclair 2010). It is reported that pp71 deletion mutant CMVs that lack 
pp71 in their tegument have 100 fold decrease in growth and show severe defect in expression of 
the IE genes (Bresnahan & Shenk 2000). The ability of pp71 to activate gene expression goes 
beyond the HCMV genome since it can also activate the herpes simplex virus type 1 (HSV-1) 
genome lacking functional proteins, such as the IE protein ICP0. pp71 disrupts the quiescent 
state of HSV-1 and resumes viral gene expression suggesting a similar function as HSV-1 ICP0 
protein in suppression of the host innate antiviral defense (Everett et al. 2013). 
   The HCMV genome is divided into two regions known as the unique long region (UL) and the 
unique short region (US). pp71 is the product of the 82nd open reading frame on the UL region 
and therefore it is also referred to as ppUL82 (phosphoprotein expressed from UL82) (Chee et al. 
1990). Primary amino acid sequence of pp71 analysis revealed sequence similarity to 2 ́-
deoxyuridine 5 ́-triphosphate pyrophosphatase (dUTPase) however, it lacks some of the 
conserved residues required for enzymatic activity and its dUTPase function has not been 
confirmed  (Davison & Stow 2005). The pp71 mid-region (MR), amino acids 94-300, have been 
identified as necessary for its localization to the nucleus (Fig. 4-1) (Shen et al. 2008). Nine 
phosphorylation sites have been identified on pp71 with one on threonine 223 within the MR, 
which has been proposed to be involved in pp71 cytoplasmic export (Fig. 4-1) (Shen et al. 2008). 
Since pp71 Thr223 is phosphorylated in the tegument, it is proposed that this phosphorylation 
occurs during late infection to promote pp71 transport to the cytoplasm where it can be packaged 
into virions (Shen et al. 2008).   
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Fig. 4-1: Schematic representation of pp71 sequence and domains. Known phosphorylation sites 
are indicated. Mid-region (residues 94-300) important for nuclear localization, two DAXX 
interaction sites (residues 206-213 and 324-331) and Rb family binding motif (residues 216-220) 
have been identified. S: Serine; T: Threonine. (Reprinted by permission from Future Medicine: 
Future Virology, (Penkert & Kalejta 2012), copyright 2012).  
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   Nuclear localization of pp71 upon viral entry into the cell depends on the differentiation status 
of the host cells. It has been observed that when HCMV infects fully differentiated cells, such as 
fibroblasts, it is immediately delivered to the nucleus where it localizes to promyelocytic 
leukemia nuclear bodies (PML-NBs) and initiates lytic infection (Penkert & Kalejta 2010; 
Hensel et al. 1996). However, infection of poorly differentiated cells, such as CD34+, leads to the 
cytoplasmic accumulation of pp71 and establishment of the latent state (Penkert & Kalejta 2010). 
It has been shown that compared to specialized cells, incompletely differentiated cells lack 
factors that are important for nuclear translocation of pp71 (Penkert & Kalejta 2010).  
   In the nucleus pp71 interacts with or disrupts function of the PML-NB components including 
PML, DAXX and ATRX (Hensel et al. 1996). PML and DAXX are regulated by interferons and 
are involved in antiviral response. PML-NBs are the sites of DNA synthesis for DNA viruses and 
their components in many cases are recruited by these viruses (Maul 1998). Further, PML-NBs 
are important sites for p53 tumor suppressor protein acetylation, which is indispensable for its 
transactivation and induction of cell cycle arrest (Reed & Quelle 2015; Pearson et al. 2000). 
pp71 localization to PML-NBs and the stimulation of IE gene expression depend on its 
interaction with the cellular DAXX protein, which subsequently leads to degradation of DAXX 
(Saffert & Kalejta 2007; Ishov et al. 2002). Investigation of the pp71 interaction with cellular 
proteins has proven challenging due to the observation that pp71 leads to degradation and 
decrease in the half-life of proteins it binds to. Since proteasome inhibitors have been able to 
restore levels of pp71 interacting proteins, their degradation is considered proteasome dependent 
(Winkler et al., 2013).   
pp71 Interaction with Cellular Proteins:    
    
   DAXX, death domain associated protein, is a transcriptional co-repressor that localizes to 
PML-NBs (Hofmann et al., 2002). It forms a complex with ATRX (chromatin remodeling 
protein) and acts as a histone chaperon for H3.3, a histone variant. The DAXX/ATRX complex 
formation is essential for H3.3 deposition into heterochromatin, maintenance of heterochromatin 
H3K9me3 modification and suppression of transcription at telomeres (He et al. 2016; Voon & 
Wong 2016). DAXX in complex with ATRX recruits histone deacetylases to the histones around 
the HCMV major IE promoter at PML-NBs and silences IE gene expression (Reeves & Sinclair 
2013; McFarlane & Preston 2011). Localization of the ATRX to PML-NBs entirely depends on 
its interaction with DAXX. Shortly after  HCMV infection (~2 h) ATRX is displaced from PML-
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NBs and spreads evenly in the nucleus (Lukashchuk et al., 2008). pp71 mutants unable to 
interact with DAXX and UL82-null HCMV mutants were not able to relocate ATRX and could 
not support IE gene expression (Lukashchuk et al., 2008). In human osteosarcoma cell line 
(U2OS), where DAXX is present in normal levels while ATRX is undetectable, UL-82 null 
HCMV mutants were able to activate IE gene expression to levels comparable to that of wild-
type HCMV infected fibroblast cells. This indicates that ATRX alone acts as a repressor of the 
major immediate early promoter and DAXX’s role is to localize ATRX to the accumulated viral 
genome at PML-NBs (McFarlane & Preston 2011). Two regions on DAXX interact with two 
short motifs on pp71 N-terminal and central regions (Fig. 4-1) (Hofmann et al. 2002). Deletion 
of any one of these interaction sites abolishes pp71/DAXX interaction (Hofmann et al. 2002). 
pp71 interrupts DAXX/ATRX complex formation and leads to ubiquitin independent-
proteasome dependent degradation of DAXX (Winkler et al., 2013). In latently infected cells, 
such as CD34+,  and during the late stage of viral infection DAXX remains stable since pp71 
accumulates in the cytoplasm where it is packaged into new viral particles (Shen et al. 2008). 
 
   Shortly after discovery of the pp71 and DAXX interaction, identification of a retinoblastoma 
(Rb) binding motif (LXCXD, where X stands for any amino acid) in pp71 revealed that it 
interacts with all three members of the Rb family of tumor suppressor proteins including Rb, 
p107 and p130 (Fig. 4-1) (Kalejta et al., 2003). pp71 leads to the proteasomal dependent 
degradation of hypophosphorylated Rb proteins which results in induction of DNA synthesis in 
quiescent cells and cell cycle progression into S phase (Kalejta et al. 2003). Mutation of the pp71 
Rb binding motif inhibited DNA synthesis activation in quiescent cells however, still allowed 
acceleration of the cell cycle through G1 phase. This observation indicated that aside from 
inhibition of the Rb proteins, pp71 should have other means of accelerating cell cycle 
progression (Kalejta & Shenk 2003). 
 
Human USP7: 
 
   Human ubiquitin specific protease 7 (USP7) plays crucial roles in regulating cellular levels of 
the p53 tumor suppressor and other proteins involved in the p53 pathway, such as Hdm2, an E3 
ligase and p53 negative regulator (Brooks et al. 2007). A highly conserved DWGF motif in the 
USP7 N-terminal tumor necrosis factor receptor-associated factor (TRAF) domain is efficiently 
recognized by its cellular substrates and interacting proteins through their (P/A/E)XXS sequence, 
where X stands for any amino acids and S is essential for this interaction (Sheng et al. 2006; 
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Saridakis et al. 2005). It’s been shown in multiple cases that human herpesviruses (HHVs) have 
evolved to exploit this interaction site and hijack USP7 to deregulate p53 and promote cell cycle 
progression, which in some cases leads to tumor formation and cancer (Lee et al. 2009; Saridakis 
et al. 2005; Everett et al. 1997). Epstein-Barr nuclear antigen 1 (EBNA1) expressed by Epstein-
Barr virus (EBV/HHV-4); viral interferon regulatory factor 1 and 4 (vIRF1 and vIRF4), latency-
associated nuclear antigen 1 (LANA) and ORF45 expressed by Kaposi’s sarcoma-associated 
herpesvirus (KSHV/HHV-8) interact with the USP7 N-terminal domain (NTD) at the same 
region as its cellular substrates and therefore block USP7-substrate interaction (Chavoshi et al. 
2016; Gillen et al. 2015; Jager et al. 2012; Lee et al. 2011; Sarkari et al. 2010; Saridakis et al. 
2005).    
Project Rationale:  
    
   Amino acid sequence analysis of HCMV pp71 protein revealed three possible interaction sites 
with USP7-NTD. Two N-terminal motifs: 4ASSS7 and 10EGPS13 and one C-terminal sequence: 
547ASTS550 (Fig. 4-2). The amino acid sequence 10EGPS13 in pp71 N-terminal region is identical 
to that of EBNA1, vIRF1 and ORF45 (of KSHV), which mediate interaction with the USP7 N-
terminal DWGF motif (Fig. 4-3) (Chavoshi et al. 2016; Gillen et al. 2015; Saridakis et al. 2005). 
In addition, similar to pp71, human USP7 is also found to associate with PML-NBs and 
negatively regulate PMLs through recruitment of other cellular proteins (Sarkari et al., 2011). 
HHV proteins such as ICP0 (expressed by HSV-1) and EBNA1 (expressed by EBV), which both 
are known to disrupt PML-NBs and cause degradation of the PML proteins also interact with 
USP7 with high affinity (Sivachandran et al. 2008; Boutell et al. 2003). Interaction with USP7 
was shown important for ICP0 and EBNA1 mediated disruption of PML-NB components 
(Sivachandran et al. 2008; Parkinson & Everett 2000). Furthermore, DAXX, which itself is a 
substrate of USP7, was shown to interact with Hdm2 and USP7 simultaneously and secure USP7 
mediated stabilization of Hdm2 (Tang et al. 2013; Tang et al. 2006). siRNA knockdown of USP7 
significantly decreased half-life and cellular levels of DAXX, indicating the important role of 
USP7 in stabilizing DAXX (Tang et al., 2010). Considering pp71’s disruptive effect on PML-
NBs, its strong interaction with and downregulation of DAXX and its effect on cell cycle 
progression, it proved to be a good candidate for interaction with USP7. Therefore, we 
investigated the possible pp71 interaction with the USP7 N-terminal domain. 
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        10         20         30         40         50         60  
MSQASSSPGE GPSSEAAAIS EAEAASGSFG RLHCQVLRLI TNVEGGSLEA GRLRLLDLRT  
 
        70         80         90        100        110        120  
NIEVSRPSVL CCFQENKSPH DTVDLTDLNI KGRCVVGEQD RLLVDLNNFG PRRLTPGSEN  
 
       130        140        150        160        170        180  
NTVSVLAFAL PLDRVPVSGL HLFQSQRRGG EENRPRMEAR AIIRRTAHHW AVRLTVTPNW  
 
       190        200        210        220        230        240  
RRRTDSSLEA GQIFVSQFAF RAGAIPLTLV DALEQLACSD PNTYIHKTET DERGQWIMLF  
 
       250        260        270        280        290        300  
LHHDSPHPPT SVFLHFSVYT HRAEVVARHN PYPHLRRLPD NGFQLLIPKS FTLTRIHPEY  
 
       310        320        330        340        350        360  
IVQIQNAFET NQTHDTIFFP ENIPGVSIEA GPLPDRVRIT LRVTLTGDQA VHLEHRQPLG  
 
       370        380        390        400        410        420  
RIHFFRRGFW TLTPGKPDKI KRPQVQLRAG LFPRSNVMRG AVSEFLPQSP GLPPTEEEEE  
 
       430        440        450        460        470        480  
EEEEDDEDDL SSTPTPTPLS EAMFAGFEEA SGDEDSDTQA GLSRALILTG QRRRSGNNGA  
 
       490        500        510        520        530        540  
LTLVIPSWHV FASLDDLVPL TVSVQHAALR PTSYLRSDMD GDVRTAADIS STLRSVPAPR  
 
       550  
PSPISTASTS STPRSRPRI  
 
 
Fig. 4-2: Human cytomegalovirus primary amino acid sequence. Identification of possible USP7 
N-terminal domain interaction sites in pp71 sequence. 
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Material and Methods:  
 
Plasmids and Expression of Recombinant Proteins: 
 
N-terminal 6xHis fusion tagged USP7 residues 54-205 (USP7-NTD), USP7 residues 62-205 
(USP7-NTD62-205) and mutant D164A/W165A USP7 residues 62-205 (USP7-NTDDW) were 
expressed from pET15b vector as described previously (Holowaty et al. 2003). 6xHis tagged 
USP7 amino acids 535-1102 (USP7-CTD) were expressed from p15TVL vector as described 
previously (Pfoh et al. 2015). Full-length 6xHis tagged USP7 was expressed in Spodoptera 
frugiperda (Sf9) cells from pFastBac vector, kindly provided by Dr. Lori Frappier (Holowaty et 
al., 2003). N-terminal GST fusion tagged USP7 amino acids 1-205 (GST-USP7-NTD) was 
expressed from pGEX-2TK plasmid vector as described previously (Jagannathan et al. 2014). 
HA-tagged full-length pp71 (Ul-82 gene) was expressed from pcGN71 plasmid (kindly provided 
by Dr. Tom Shenk). FLAG-tagged full-length or deletion mutant pp71 constructs were generated 
by PCR amplification and insertion of residues 1-559, 8-559, 16-559, 1-538, 8-538, 16-538 
between the BamHI and XbaI sites of pcDNA3.1/FLAG vector (Invitrogen, V790-20).  
 
Protein Purification: 
 
All USP7 constructs were expressed in E. coli BL21 mgk cells in TB (Terrific broth, Bioshop) 
(except 15N 6xHis tagged USP7 which was expressed in M9 media) with overnight 0.4 mM 
isopropyl β-D-1-thiogalactopyranoside induction at 16ºC. For NMR titration, uniformly labeled 
6xHis tagged N-terminal USP7 residues 54-205 (USP7-NTD) was expressed in M9 media 
enriched with 0.7 g/L 15NH4Cl as the sole nitrogen source. Cells expressing 6xHis tagged 
recombinant proteins were harvested at 7,446 x g for 20 minutes at 4ºC followed by sonication at 
30% amplitude in 50 mM Tris pH 7.5, 500 or 150 mM NaCl, 5 mM Imidazole, 1x protease 
inhibitor cocktail (1 mM Benzamidine and 0.5 mM PMSF) and 1x Protease inhibitor tablet 
(Roche cOmplete ULTRA Tablets). Lysates were clarified by centrifugation for 1 hour at 41,287 
x g for 30 minutes at 4ºC. Supernatants were allowed to interact with nickel-nitrilotriacetic acid 
beads (Qiagen) for 1 hour on a nutator at 4ºC. Beads were washed extensively with 50 mM Tris 
pH 7.5, 500 or 150 mM NaCl and 20 mM Imidazole. Proteins were eluted with addition of 50 
mM Tris pH 7.5, 500 or 150 mM NaCl and 250 mM Imidazole. Cells expressing GST fusion 
tagged proteins were sonicated at 30% amplitude in 50 mM Tris pH 7.5, 150 mM NaCl, 1x 
protease inhibitor cocktail (1mM Benzamidine and 0.5 mM PMSF) and 1x Protease inhibitor 
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tablet (Roche cOmplete ULTRA Tablets). The lysates were cleared by centrifugation and 
allowed to interact with glutathione-Sepharose resin (GE Healthcare) for 1 hour on a nutator at 
4ºC. After extensive washing with 50 mM Tris pH 7.5 and 150 mM NaCl, proteins were eluted 
with addition of 20 mM reduced glutathione (GSH).  
 
Peptide Synthesis and Preparation:  
 
Wild-type pp71 peptide co-crystallized with USP7 and used in NMR studies (7SPGEGPSSEA16) 
and the mutant pp71 peptide with point mutation in Ser50 to alanine (7SPGEGPASEA16) were 
synthesized with both N-terminal acetylation and C-terminal amidation to mimic the native 
peptides (CanPeptide Inc., Montreal, Canada). N-terminal FITC labeled wild-type 
(7SPGEGPSSEA16), (2SQASSSPGE10), (545STASTSSTP553) and Ser50 to alanine mutant 
(7SPGEGPASEA16) pp71 peptides used in fluorescence polarization assays were also synthesized 
with both N-terminal acetylation and C-terminal amidation by CanPeptide Inc. (Montreal, 
Canada).  
 
Fluorescence Polarization Binding Assay: 
 
USP7-NTD was further purified by size-exclusion chromatography using a HiLoad 16/60 
Superdex 200 (GE Healthcare) on an ÄKTApurifier 10 UPC system (GE Healthcare) in 150 mM 
NaCl and 50 mM Tris pH 8.0. FITC labeled pp71 wild-type (7SPGEGPSSEA16), 
(2SQASSSPGE10), (545STASTSSTP553) and mutant (7SPGEGPASEA16) peptides were initially 
dissolved in dimethyl sulfoxide dimethyl sulfoxide to a final concentration of 10 mM. Then 400 
nM working stock of each peptide was prepared in assay buffer (150 mM salt, 50 mM Tris pH 
8.0, 5% glycerol and 0.01% Triton X-100). 518 µM of USP7-NTD was serially diluted and 
incubated with 40 nM of each peptide. 10 µl of the above dilutions were transferred into a 384 
well plate (Corning) and fluorescence polarization was measured on a Synergy H4 microplate 
reader (BioTek, USA) with λex = 485 nm and λem = 520 nm. To obtain the equilibrium 
dissociation constant (Kd), polarization values were analyzed by Graphpad Prism 5.0 using a 
one-site binding model. Kds were calculated based on three individual experiments and used to 
calculate the standard deviation. 
 
NMR Spectroscopy: 
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To prepare samples for NMR, uniformly labeled 15N-USP7-NTD was incubated with thrombin to 
cleave the 6xHis fusion tag followed by dialysis into NMR buffer (200 mM NaCl, 25 mM 
sodium phosphate pH 7.0 and 10 mM DTT). Interaction of USP7-NTD with wild-type pp71 
peptide (7SPGEGPSSEA16) and mutant pp71 peptide (7SPGEGPASEA16) was monitored by 
analyzing 1H-15N HSQC spectra. Up to 0.4 mM unlabeled wild-type or mutant pp71 peptide was 
titrated in 0.2 mM of 15N-USP7-NTD (containing 10% D2O) up to 2:1 peptide:USP7 molar ratio. 
NMR data were recorded at 25ºC using a triple resonance cryoprobe-equipped Bruker 700 MHz 
NMR spectrometer. Spectra were processed with Topspin 3.2 and analyzed with SPARKY 
program (Ye et al. 2012; Monleon et al. 2002). 
 
GST Pull-Down Assay: 
 
Full-length FLAG-tagged pp71 and its deletion mutant constructs were transfected into U2OS 
cells and lysate was collected 24 hours post transfection. Prior to GST pull-down assays, purified 
GST-tagged USP7-NTD was dialyzed against assay buffer (100 mM NaCl, 50 mM Tris pH 8.0, 
5% glycerol, 5 mM β-Mercaptoethanol and 1x Protease inhibitor tablet (Roche cOmplete 
ULTRA Tablets). 2.5 nmoles of GST-USP7-NTD or GST alone (as negative control) were 
incubated with 20 µl of pre-equilibrated glutathione-Sepharose resin for 1 hour. The resin was 
then briefly washed with assay buffer and incubated with 100 µg of U2OS lysate containing each 
of the FLAG-tagged pp71 constructs in assay buffer for 2 hours at 4ºC. Mixtures were then 
transferred to a micro column and after extensive wash with assay buffer, bound proteins were 
eluted with 20mM reduced glutathione. Samples were resolved on 12% SDS-polyacrylamide 
gels. USP7-NTD and GST were detected by Coomassie Blue staining, while FLAG-tagged pp71 
proteins were detected by immunoblotting using a FLAG antibody. 
 
FLAG Pull-Down Assay: 
 
Prior to FLAG pull-down assay, purified His-tagged full-length USP7, USP7-NTD62-205, USP7-
NTDDW and USP7-CTD were dialyzed against assay buffer (100 mM NaCl, 50 mM Tris pH 8.0, 
5% glycerol, 5 mM β-Mercaptoethanol and 1x Protease inhibitor tablet (Roche cOmplete 
ULTRA Tablets)). U2OS cells were transfected with FLAG-tagged wild-type pp711-559 or empty 
pcDNA3.1/FLAG vector as negative control. Lysates were collected 24 hours post transfection. 
Anti-FLAG M2 affinity resin (Sigma) was pre-equilibrated with assay buffer. 500 µg of U2OS 
cell lysate, transfected with either FLAG-pp71 or empty pcDNA3.1/FLAG, was incubated with 
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anti-FLAG resin for 1 hour at 4ºC. Following a brief wash, anti-FLAG resin was incubated with 
5 nmoles of each of the USP7 constructs in assay buffer for 2 hours at 4ºC. Samples were 
washed extensively with assay buffer and then boiled in SDS sample loading dye. Interacting 
proteins were resolved on 12% SDS-polyacrylamide gels and immunoblotted using His and 
FLAG antibodies. 
 
Crystallization, X-ray Data Collection and Structure Determination: 
 
Prior to setting up crystal trials, purified USP7-NTD was incubated with thrombin to remove the 
6xHis N-terminal fusion tag. USP7 was further purified by size-exclusion chromatography using 
a HiLoad 26/60 Superdex 75 (GE Healthcare) on an ÄKTApurifier 10 UPC (GE Healthcare) in 
500 mM NaCl and 20 mM Hepes pH 7.5. USP7-NTD (100 mg/ml) was co-crystalized with at 
least 5-fold molar excess of pp71 peptide (7SPGEGPSSEA16) at 4ºC using hanging-drop vapor-
diffusion method. Rod-shaped crystals appeared after 4 days following one round of micro-
seeding using USP7-NTD:UbE2E1 peptide crystals as seed in 30% PEG 4000, 0.1 M Tris pH 8.5 
and 0.2 M LiSO4 (Sarkari et al., 2013). 
 
X-ray data were collected at 100K on a Rigaku MicroMax007 rotating anode diffractometer with 
a 944+ charge-coupled device detector. Diffraction data were integrated and scaled using 
HKL2000 software. The structure was determined by molecular replacement method employing 
USP7-NTD (Protein Data Bank identifier [ID] 1YY6, without the EBNA1 peptide) structure as 
the search model using CNS 1.3 (Brunger 2007). The electron density was visualized and the 
pp71 peptide model was built using Coot (Emsley & Cowtan 2004). CNS was used for 
refinement and water picking at 2.0 Å resolution. The data collection and refinement statistics 
are shown in Table 4-1. Fig. 4-8 was prepared using PyMOL (Schrödinger 2010).  
 
Cell Culture and Antibodies:  
 
Human osteosarcoma U2OS cells and human colon cancer HCT116 cells were grown in 
McCoy’s medium. BJ human foreskin fibroblast cells (kindly provided by Dr. Sam Benchimol) 
were grown in Dulbecco's Modified Eagle's medium medium.  All media were supplemented 
with 10% FBS and 1 mg/ml Penicillin-Streptomycin. The antibodies were rabbit polyclonal 
against USP7 (Bethyl Laboratories, A300-033A), mouse monoclonal against USP7 (Millipore, 
05-1946), rabbit polyclonal against FLAG tag (Bethyl Laboratories, A190-102A), mouse 
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monoclonal against FLAG tag (Sigma, F3165), mouse monoclonal against p53 (Santa Cruz, sc-
126), Rabbit polyclonal against DAXX (Upstate Biotechnology, 07-741), mouse monoclonal 
against Penta-His (Qiagen, 34660), Rabbit polyclonal against p21 (Santa Cruz, sc-397), rabbit 
polyclonal against phospho-p53 (Ser15) (Cell Signaling, 9284), rabbit monoclonal against ATM 
(Cell Signaling, 2873), rabbit mono- clonal against phospho-ATM (Ser1981) (Cell Signaling, 
5883), mouse monoclonal against MDM2 (Santa Cruz, sc-965), rabbit polyclonal against 
phospho-MDM2 (Ser166) (Cell Signaling, 3521) and mouse monoclonal against GAPDH (Santa 
Cruz, sc-47724). To detect proteins of interest HRP-conjugated anti-mouse IgG (Jackson 
ImmunoResearch 115-035-166) and anti-rabbit IgG (Jackson ImmunoResearch 111-035-003) 
antibodies were used. 
 
Co-immunoprecipitation: 
 
U2OS cells were transfected with 9 µg pCMV/N-Myc-USP7 and 1 µg pcDNA3.1/FLAG-pp71 
(wild-type or triple deletion mutant) vectors (total of 10 µg of DNA per 15 cm tissue culture 
plate) using PolyJet transfection reagent according to the manufacturer’s protocol (SignaGen 
Laboratories). The cells were washed 6 hours post transfection and incubated with 10 µM 
MG132 proteasome inhibitor overnight. Cells were harvested 24 hours post-transfection and 
lysed in radioimmunoprecipitation buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% 
Nonidet P-40, 20% glycerol, 1X protease inhibitor cocktail (Roche)) followed by 2 sec 
sonication at 10% amplitude. Cell lysates were incubated with either rabbit polyclonal anti-USP7 
primary antibody or rabbit polyclonal anti-FLAG primary antibody overnight at 4ºC followed by 
the addition of pre-cleared protein A/G Plus-Agarose beads (Santa Cruz, sc-2003) for 1 hour. 
Immunoprecipitates were washed with radioimmunoprecipitation buffer five times and then 
boiled in SDS sample buffer for 5 minutes at 95ºC. Samples were resolved on 12% SDS-
polyacrylamide gels and immunoblotted using antibodies described above.  
 
Immunoblotting:  
 
All cells were transfected with pcDNA3.1/FLAG empty vector and pcDNA3.1/FLAG pp711-559 
(wild-type) or pp7116-538 (triple deletion mutant) vectors (4 µg of DNA per 15 cm tissue culture 
plate) using PolyJet transfection reagent according to the manufacturer’s protocol (SignaGen 
Laboratories). U2OS cells were also co-transfected with 5 µg pCMV/N-Myc USP7 vector. Cells 
were harvested 24 hours post-transfection and lysed in radioimmunoprecipitation buffer (50 mM 
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Tris-HCl pH 8.0, 150 mM NaCl, 0.5% Nonidet P-40, 1X protease inhibitor cocktail (Roche)) 
followed by 1 sec sonication at 10% amplitude. Supernatants were boiled in SDS sample buffer 
for 5 minutes at 95ºC and resolved on 12% SDS-polyacrylamide gels. Immunoblotting was 
performed using antibodies described above. 
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Results: 
 
pp71 Sequence Analysis for the USP7 N-Terminus Interaction Motifs:  
 
   To initiate viral IE gene expression, most immediate role of pp71 post HCMV infection is to 
translocate to the nucleus, interact with DAXX and disrupt the DAXX/ATRX complex (Ishov et 
al. 2002). USP7 interaction with DAXX is important for DAXX stability (Tang et al. 2010). 
Considering the interaction of DAXX with Hdm2 (a well-studied USP7 substrate) and its 
involvement in Hdm2 stability and p53 regulation, we believed pp71 would be a good candidate 
for interaction with USP7 (Tang et al. 2013; Tang et al. 2006). Such interaction would further 
disrupt the USP7/DAXX complex and lead to instability of DAXX. USP7 substrates, such as 
Hdm2, p53 and Hdmx, interact with the highly conserved 164DWGF167 region in its N-terminal 
domain through their (P/A)XXS motifs with Kds ranging from 8-45 µM (Sarkari et al. 2010; 
Sheng et al. 2006). While HHV proteins, such as EBNA1, ORF45 and vIRF1, bind the USP7 
DWGF motif through an EGPS sequence (Chavoshi et al. 2016; Gillen et al. 2015; Saridakis et 
al. 2005). In case of EBNA1 and vIRF1, Kd ranges from 0.9-2 µM which is much lower than that 
of USP7 cellular substrates (Chavoshi et al. 2016; Sheng et al. 2006).  Other USP7 interacting 
KSHV proteins, vIRF4 and LANA, bind the NTD domain through their 211ASTS214 and 
977PGPS980 motifs (Lee et al. 2014; Jager et al. 2012). 
 
   We analyzed the pp71 sequence for possible interaction sites with USP7-NTD. Three candidate 
interaction motifs were identified in the pp71 sequence including two N-terminal 4ASSS7 and 
10EGPS13 motifs and one C-terminal 547ASTS550 sequence (Fig. 4-2). The 10EGPS13 sequence in 
pp71 aligns with that of EBNA1, vIRF1 and ORF45 (Fig. 4-3). We examined the possibility of 
this interaction. 
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Fig. 4-3: Alignment of the pp71 EGPS motif with those of vIRF1, EBNA1 and ORF45 proteins. 
Asterisks represent conserved residues, and the period represents semi-conserved substitution.  
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Binding Analysis of pp71 Peptide and USP7-NTD: 
 
   To investigate interaction of the pp71 (7SPGEGPSSEA16) peptide with USP7-NTD, we first 
performed a fluorescence polarization binding assay. Fluorescein isothiocyanate (FITC) tagged 
pp71 peptide with the potential USP7 binding motif (7SPGEGPSSEA16) and mutant pp71 peptide 
with an alanine substitution for serine (7SPGEGPASEA16) were titrated with increasing 
concentration of USP7-NTD to obtain the dissociation constant. 40nM fixed concentration of 
FITC labeled pp71 wild-type (7SPGEGPSSEA16) and mutant (7SPGEGPASEA16) peptides were 
titrated in increasing concentrations of USP7-NTD of 0-518 µM. Complex formation was 
measured by detecting changes in the polarization values. A dissociation constant (Kd) of 4.6 ± 
0.3 µM was obtained for wild-type peptide while Kd of mutant peptide increased to 126.4 ± 9 µM 
(Fig. 4-4A). This Kd value indicates higher affinity for USP7-NTD than its cellular substrates 
such as Hdm2 and p53 and compares well with that of vIRF1 and EBNA1. 
 
  The experiment was repeated to investigate potential binding of ASTS and ASSS motifs of 
pp71 with USP7-NTD. FITC tagged pp71 peptides, 2SQASSSPGE10 and 545STASTSSTP553, 
were titrated with increasing concentration of USP7-NTD of 0-664 µM. Dissociation constants 
of 2.0 ± 0.2 µM and 18.7 ± 2.0 µM were obtained for 545STASTSSTP553 and 2SQASSSPGE10 
respectively compared to Kd of 3.4 ± 0.2 µM for the EGPS containing peptide 7SPGEGPSSEA16 
(Fig. 4-4B). These data suggest that all three pp71 binding sites can potentially interact with 
USP7-NTD. 
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Fig. 4-4: Binding analysis of USP7-NTD and pp71 peptides via fluorescence polarization assay. 
A) The assay was performed using FITC labeled wild-type pp71 peptide (7SPGEGPSSEA16 in 
black) or mutant pp71 peptide (7SPGEGPASEA16 in red). Table represents dissociation constant 
(Kd) for the USP7-NTD interaction with FITC labeled wild-type and mutant pp71 peptides. B) 
Fluorescence polarization assay was performed using FITC labeled pp71 peptides 
(2SQASSSPGE10 in red), (7SPGEGPSSEA16 in black) and (545STASTSSTP553 in blue). Table 
represents dissociation constant (Kd) for the USP7-NTD interaction with FITC labeled pp71 
peptides. mP, milipolarization. Error bars indicate standard error. Average values with standard 
deviation for four or more experiments are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 165 
NMR Evidence for pp71 EGPS Motif Interaction with USP7-NTD: 
 
   After obtaining a Kd of 4.6 µM, we further monitored 1H–15N HSQC resonances of uniformly 
15N-labeled USP7-NTD in the presence and absence of unlabeled pp71 (7SPGEGPSSEA16) 
peptide. 0.2 mM concentration of 15N-USP7-NTD was titrated with 0.4 mM of wild-type pp71 
peptides (2:1 peptide to USP7-NTD ratio). Figure 4-5 represents the USP7-NTD 1H-15N HSQC 
spectra (in black) over-laid by USP7-NTD titrated with 0.4 mM of wild-type pp71 peptide 
(7SPGEGPSSEA16 in blue). Strong disturbances were observed in the USP7-NTD chemical shift 
spectra after addition of pp71 peptide. Using the previously assigned USP7-NTD spectra 
(deposited in Biological Magnetic Resonance Data Bank Entry 6939), we were able to identify 
residues that were most disturbed by this interaction and compare the affected residues with that 
of EBNA1 and vIRF1 involved in binding with USP7-NTD (Chavoshi et al. 2016; Saridakis et 
al. 2005). Similar to that of EBNA1 and vIRF1, interaction of pp71 peptide with the USP7 N-
terminal domain mostly affected residues from ß-strand 7 specially the conserved 164DWGF167 
motif such as Asp164, Trp165 (shift was observed in indole side chain), Gly166, Phe167, 
Ser168, and Met171 (Fig. 4-5 A&B). Residues from ß-strands 3, 4 and 6 such as Met100, 
Phe118 and Ser155 were also affected.  
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Fig. 4-5: Superimposed 15N HSQC spectra of USP7-NTD before and after titration with pp71 
peptide. A) 15N-labeled USP7-NTD spectra (in black) was titrated with 2:1 molar ratio of wild-
type pp71 peptide 7SPGEGPSSEA16 (in blue). B) Residues from USP7-NTD ß-strand 7 and 
M100 from ß-strand 3 that were largely affected by pp71 peptide interaction are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 168 
pp71 Specifically Interacts with the USP7 N-Terminal Domain: 
 
   To further examine pp71 interaction with USP7 we performed an in vitro FLAG tag pull-down 
assay using anti-FLAG affinity resin. FLAG and His antibodies were used to detect pp71 and 
USP7 constructs respectively. U2OS cell lysate transfected with full-length FLAG-tagged pp71 
or empty pcDNA3.1/FLAG vector, as negative control, were first incubated with anti-FLAG 
affinity resin and later with either full-length USP7, USP7 N-terminal or USP7 C-terminal 
domains. Both full-length USP7 and USP7-NTD were retained by the FLAG-tagged pp71, while 
U2OS lysate expressing empty pcDNA3.1/FLAG vector was not able to pull-down any of the 
USP7 constructs. Also, the C-terminal domain of USP7 did not show any interaction with pp71, 
indicating that pp71 exclusively recognizes the USP7 N-terminal domain (Fig. 4-6A). We then 
tested interaction of FLAG-tagged pp71 with double mutant USP7-NTDDW containing alanine 
substitution for Asp164 and Trp165 within the 164DWGF167 motif. USP7-NTD with mutations in 
the DWGF motif lost its interaction with pp71, indicating the importance of 164DWGF167 for 
pp71 recognition and binding with the USP7 N-terminus (Fig. 4-6B). 
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Fig. 4-6: pp71 interacts with the USP7 N-terminal domain in vitro. A) FLAG-tag pull-down 
experiments showed that U2OS cell lysate expressing FLAG-pp71 was able to pull-down full-
length USP7 and USP7-NTD but not USP7-CTD. U2OS lysate expressing empty 
pcDNA3.1/FLAG vector was used as control. B) pp71 did not pull-down double mutant USP7-
NTDDW with alanine substitution for DW in the 164DWGF167 motif. In, input; E, elution. 
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Investigating Interaction of the Three USP7-NTD Binding Sites of pp71: 
 
   As previously shown, other than 7SPGEGPSSEA16 sequence two more possible USP7 N-
terminal domain interaction motifs were identified in pp71 (Fig. 4-2). Binding affinity of 
2SQASSSPGE10, 7SPGEGPSSEA16 and 545STASTSSTP553 peptides were initially investigated 
through FITC polarization assay. To further study the interaction of USP7 binding sites of pp71: 
4ASSS7, 10EGPS13 and 547ASTS550, we designed and engineered five pcDNA3.1/FLAG vectors 
expressing FLAG-tagged pp71 deletion mutant constructs lacking one, two or all three possible 
interaction sites as follows: pp718-559 with deletion in the 4ASSS7 motif, pp7116-599 with deletion 
in both 4ASSS7 and 10EGPS13 motifs, pp711-538 missing the C-terminus 547ASTS550 sequence, 
pp718-538 with deletions in the 4ASSS7 and 547ASTS550 motifs and pp7116-538 missing all three 
potential interaction sites. 
 
   A series of GST pull-down assays were set up to test interaction of the FLAG-tagged pp71 
constructs with the GST-tagged USP7 N-terminal domain. 2.5 nmoles of GST-USP7-NTD, was 
allowed to interact with GST beads. Later beads were incubated with 100 µg of U2OS cell lysate 
expressing either full-length or one of the deletion mutant pp71 constructs. GST-USP7-NTD was 
detected by Coomassie Blue staining, while the FLAG-tagged pp71 constructs were detected by 
western blot, using FLAG antibody. All pp71 constructs retained binding with GST-USP7-NTD 
except the triple mutant pp71, FLAG-pp7116-538, lacking all three binding sites. These 
observations revealed that all three USP7 N-terminal domain interaction sites of pp71 are able to 
recognize and bind USP7, indicating a strong evolutionary pressure for interaction of pp71 with 
USP7. 
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Fig. 4-7: All three USP7-NTD interaction motifs of pp71 bind the USP7 N-terminal domain. 
GST pull-down assay was performed using GST-tagged USP7-NTD and either full-length or one 
of the deletion mutant pp71 constructs. FLAG-tagged full-length pp71 (residues 1-559) and 
deletion mutant constructs missing either one, two or three of the 4ASSS7, 10EGPS13 and 
547ASTS550 motifs were expressed in U2OS cells. All of the FLAG-tagged pp71 constructs 
retained binding with USP7-NTD except pp7116-538 with deletion mutation of all three binding 
sites. 
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Co-crystal Structure of the USP7-NTD and pp71 Peptide: 
 
   To gain further insight into the molecular basis of this interaction, we setup trials to obtain a 
complex crystal of USP7-NTD and pp71 7SPGEGPSSEA16 peptide. Crystals were resolved to 
2.0 Å resolution and the complex structure was determined using molecular replacement. There 
was no visible electron density for residues 54-62 and 106-111 and we could not fit them in the 
final model, suggesting that they are disordered. A summary of data collection and refinement 
statistics is presented in Table 4-1. 
 
   The structure of USP7-NTD has been previously well characterized (Saridakis et al. 2005). 
Briefly, the USP7-NTD forms an eight-stranded antiparallel beta sandwich similar to all MATH 
domain containing proteins (Fig. 4-8, A & B). The pp71 peptide 7SPGEGPSSEA16 was found on 
the surface of USP7 and interacts with residues in b-strand 7 of the USP7 N-terminal domain, 
which contains the conserved 164DWGF167 motif. Electron density only allowed building of pp71 
residues 7SPGEGPSS14 into the map and there was no visible density for residues Glu15 and 
Ala16 (Fig. 4-8C). A closer look at the site of interaction reveled that pp71 Ser13, which is 
essential for the 7SPGEGPSSEA16 interaction with the USP7 N-terminal domain, makes the most 
extensive contact (Fig. 4-8D). Ser13 interacts with Asp164 of b-strand 7 by forming two 
hydrogen bonds, one through its hydroxyl side chain and one through its backbone amide group. 
The Ser13 carbonyl group also forms a hydrogen bond with Arg104 of b-strand 3. Glu10 of pp71 
forms H-bond with Trp165 of b-strand 7 through its side chain carboxylic acid. Also, the 
carbonyl group of pp71 Ser7 forms a H-bond with side chain amide of Asn169 of b-strand 7. 
There are 4 hydrogen bonds formed through backbone interactions between pp71 peptide and 
USP7 b-strand 7. A comparison between pp71 7SPGEGPSSEA16 peptide and that of EBNA1 and 
vIRF1 revealed that they are superimposable and have similar mode of interaction with the USP7 
N-terminal binding pocket (Fig. 4-8, E-H). 
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Table 4-1: USP7-NTD:pp71 Peptide X-Ray Data Collection and Refinement Parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 USP7-NTD:pp71 peptide 
X-Ray Data  
Space Group P41 
Resolution (Å) 50.0 – 2.01 
Unit Cell Axes (Å3) 70.0 x 70.0 x 45.5 
Molecules / AU 1 
Total Observations (#) 70748 
Unique Reflections (#) 14708 
Intensity (I/s<I>) 32.4 (9.6) 
Completeness (%) 99.1 (100) 
aRsym 0.087 (0.188) 
Refinement  
Rwork 0.157 
Rfree 0.195 
Protein Atoms (#) 1298 
Water Molecules (#) 135 
rmsd bonds (Å) 
rmsd angles (°) 
0.010 
1.25 
rmsd dihedrals (°) 25.3 
rmsd improper (°) 0.87 
thermal factors (Å2) 22.20 
Ramachandran Plot  
Most Favoured 0.97 
Numbers in brackets refer to the highest resolution shell, 
2.04 Å to 2.01 Å. aRsym = S |I-<I>| /SI where I is the 
observed intensity and <I> is the average intensity from 
multiple observations of symmetry-related reflections. 
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Fig. 4-8: Complex crystal structure of USP7-NTD and pp71 peptide. A) Surface representation 
of the USP7 N-terminal domain (brown) bound to pp71 peptide 7SPGEGPSSEA16 in stick form 
(green). B) Ribbon diagram representation of USP7-NTD (brown) and pp71 peptide in stick 
form (green). C) Electron density of the pp71 peptide. D) Detailed interactions between USP7-
NTD (brown) and pp71 peptide (green). Dashed lines indicate hydrogen bonds. E) Comparison 
between pp71 peptide (7SPGEGPSSEA16, green) with that of EBNA1 (441DPGEGPSTGP450, 
pink) and vIRF1(44SPGEGPSGTG53, yellow). F) Superimposition of the three peptides. 
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Effect of pp71 on the Cellular Levels of USP7: 
 
   Previously it was reported that pp71 decreases cellular levels of proteins it interacts with, such 
as DAXX and the Rb family (Rb, p107 and p130), in a ubiquitin independent but proteasome 
dependent manner (Winkler et al. 2013; Kalejta et al. 2003). Thus, we investigated the effect of 
pp71 on USP7. Experiment was performed in three cell lines: human fibroblast cells, human 
osteosarcoma cells (U2OS) and human colon cancer cells (HCT116). FLAG and USP7 
antibodies were used to detect pp71 and USP7 levels respectively. First U2OS cells transfected 
with wild-type FLAG-pp711-559 and Myc-USP7 were incubated for 24 or 48 hours (Fig. 4-9A). 
Within 24 hours post transfection, a significant decrease in the level of USP7 was observed as 
compared to cells that were transfected with empty pcDNA3.1/FLAG vector. U2OS, BJ 
fibroblast and HCT116 cells were transfected for 24 hours with wild-type pp711-559 or triple 
mutant pp7116-538 (Fig. 4-9B-D). It was interesting to observe that even though triple mutant 
pp7116-538 lost its binding with USP7-NTD (Fig. 4-7) it was still able to decrease cellular levels 
of USP7. This observation suggest that decreases in the levels of USP7 might not be caused by 
direct interaction with pp71 but through pp71 effect on another cellular factor. Fold change 
analysis revealed that in U2OS cells both wild-type and mutant pp71 (p<0.01) significantly 
reduced levels of USP7 by about 30% when compared with control (Fig. 4-9E). In fibroblast 
cells, wild-type and mutant pp71 decreased levels of USP7 by about 40 and 60% respectively 
(p<0.05) (Fig. 4-9F). 
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Fig. 4-9: pp71 decreases cellular levels of USP7. A) U2OS cells were transfected with Myc-
USP7 and FLAG-pp71 and further incubated for 24 or 48 hours post transfection. FLAG and 
USP7 antibodies were used to identify pp71 and USP7 respectively. B-D) U2OS, BJ fibroblast 
and HCT116 cells were transfected with either wild-type pp711-559, triple mutant pp7116-538 or 
empty pcDNA3.1/FLAG vector as negative control. Cells were incubated for 24 hours post 
transfection. E&F) Fold change in USP7 was calculated by normalizing USP7 levels and 
comparing them to the vector ratio in U2OS and BJ fibroblast cells. A paired t test was used to 
calculate the statistical significance of the changes in USP7 levels after expression of wild-type 
(WT) or triple mutant (Mut) pp71. Error bars indicate standard error and are from three 
independently transfected U2OS or fibroblast cell lysates.  
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pp71 and USP7 Interaction in vivo: 
 
   To test in vivo interaction of pp71 with USP7, U2OS cells were transfected with Myc-USP7 
and FLAG-tagged pp71. Previously we observed that pp71 significantly decreases USP7 levels 
therefore, in vivo immunoprecipitation assay was optimized to allow pull-down and detection of 
USP7. U2OS cells were transfected with only 1/5 of the recommended pp71 expression vector 
(based on manufacturer’s protocol) and MG132 was used to inhibit proteasomal degradation. 
Also, cells were co-transfected with Myc-USP7 to increase the levels of available USP7 for 
immunoprecipitation.  
 
   U2OS lysate was incubated with USP7 antibody to immunoprecipitate USP7 followed by 
immunoblotting with FLAG antibody, which led to identification of FLAG-tagged pp71 (Fig. 4-
10A). In a reciprocal experiment, lysate was incubated with FLAG antibody followed by 
immunoblotting with anti-USP7 which led to identification of USP7. Lysate incubated with 
rabbit IgG served as negative control which did not show any interaction. Further, we tested the 
effect of deletion mutations of pp71 4ASSS7, 10EGPS13 and 547ASTS550 sequences on its binding 
with USP7. U2OS lysate transfected with Myc-USP7 and triple mutant pp7116-538 was 
immunoprecipitated with anti-USP7 followed by immunoblotting with FLAG antibody (Fig. 4-
10B). In a reciprocal experiment lysate was immunoprecipitated with FLAG antibody followed 
by immunoblotting using anti-USP7. In both cases USP7 did not co-immunoprecipitate with 
triple mutant pp7116-538. Lysate immunoprecipitated with rabbit IgG served as negative control. 
Results indicate that wild-type pp71 but not the triple mutant pp7116-538 interacts with USP7 in 
vivo. 
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Fig. 4-10: Wild-type pp71 but not triple mutant pp71 interacts with USP7 in vivo. A) U2OS cells 
were transfected with wild-type FLAG-pp71 and Myc-USP7 followed by proteasome inhibition 
using MG132. Lysate was incubated with either USP7or FLAG antibodies to 
immunoprecipitated USP7 or pp71 respectively. In both cases USP7 and pp71 were successfully 
co-immunoprecipitated. Lysate incubated with rabbit IgG served as negative control. B) U2OS 
cells were transfected with deletion mutant FLAG-pp7116-538 and Myc-USP7 followed by 
proteasome inhibition. Lysate was incubated with either USP7 or FLAG antibodies for 
immunoprecipitation. Mutant pp7116-538 was not able to co-immunoprecipitate with USP7. In, 
input; E, elution. 
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pp71 Expression Effect on Hdm2 and p53 Levels in U2OS Cells: 
 
   USP7 is a critical regulator of p53 and Hdm2 stability and an important component of the 
USP7-Hdm2-p53 pathway. While both p53 and Hdm2 are deubiquitinated and stabilized through 
interaction with the USP7 N-terminal DWGF motif, Hdm2 is the preferred substrate and shows 
higher affinity (Brooks et al. 2007; Li et al. 2002). Considering that pp71 also interacts with the 
USP7-NTD DWGF motif and further decreases USP7 levels, we set out to investigate the effect 
of pp71 expression on p53 and Hdm2 stability. In addition, we monitored levels of Ser15 
phosphorylated p53 and Ser166 phosphorylated Hdm2 post pp71 transfection. Ser15 
phosphorylation is important for p53 stability and transactivation while Ser166 phosphorylation 
stabilizes Hdm2, by inhibiting its self-ubiquitination, and promotes its translocation to the 
nucleus, where it can target p53 (Reed & Quelle 2015; Feng et al. 2004). Further, we analyzed 
levels of p21, a cyclin-dependent kinase inhibitor and one of the major targets of p53 
transactivation, to monitor p53 transcriptional activity (Cazzalini et al. 2010; Sun 2006). Cellular 
levels of DAXX were detected as a positive control for pp71 activity (Cantrell & Bresnahan 
2006).  
 
   U2OS cells were transfected with FLAG-tagged wild-type pp711-559 and triple mutant pp7116-
538. In addition, all cells were transfected with Myc-USP7 to compensate for pp71 induced loss 
of USP7. Endogenous levels of p53 and Ser15 phosphorylated p53 as well as Hdm2 and Ser166 
phosphorylated Hdm2 were detected. As shown in figure 11A, and shown previously in figure 9, 
both wild-type pp71 and triple mutant pp7116-538 were able to decrease cellular levels of USP7. 
Wild-type pp711-559 was able to decrease Hdm2 (by 50%, p=0.019) and Ser166 phosphorylated 
Hdm2 in U2OS cells (Fig. 4-11 A&B), while mutant pp7116-538 did not show any significant 
effect. We also observed a significant decrease of about 40% in the levels of p53 (p=0.01) and 
Ser15 p53 in U2OS cells within 24 hours post transfection with wild-type pp71 (Fig. 4-11 A&E). 
Mutant pp71 did not have a significant effect on Ser15 phosphorylated p53 however, p53 levels 
decreased by about 15% (p=0.05). Instability of p53 was followed by a drop in p21 levels, 
indicating decrease in p53 transcriptional activity. As reported previously, we also noticed 
decline in the levels of cellular DAXX post pp71 transfection (Ishov et al. 2002). These 
observations imply that in U2OS cells pp71 mediated downregulation of USP7 and DAXX 
destabilizes Hdm2 however, it seems the remaining Hdm2 and possibly the activity of other p53 
negative regulators are potent enough to downregulate p53 when USP7 is compromised (Wang 
et al. 2011).  
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Fig. 4-11: The effect of pp71 expression on Hdm2 and p53 stability in U2OS cells. Cellular 
levels of p53, Ser15 phosphorylated p53 (p-p53), Hdm2 and Ser166 phosphorylated Hdm2 (p-
Hdm2) were monitored in U2OS cells after transfection with Myc-USP7 and cotransfection with 
either wild-type pp711-559, mutant pp7116-538 or empty pcDNA3.1/FLAG vector as control. Cells 
were collected 24 hours post transfection. DAXX and p21 levels were monitored as control for 
pp71 and p53 activity respectively. GAPDH levels were detected as loading control. B) Fold 
change in Hdm2 was determined by normalizing Hdm2 levels and comparing them to that of 
vector ratio in U2OS cells. C) Fold change differences in p53 were calculated by normalizing 
p53 levels and comparing them to that of vector ratio in U2OS cells. A paired t test statistical 
analysis was used to calculate the significance of changes in the Hdm2 and p53 levels after 
expression of wild-type (WT) pp711-559 and triple mutant (Mut) pp7116-538. Error bars indicate 
standard error (n=3). 
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pp71 Expression Effect on Hdm2 and p53 Levels in BJ Fibroblast Cells: 
 
   We further investigated expression effect of pp71 on endogenous levels of p53, Ser15 
phosphorylated p53, Hdm2 and Ser166 phosphorylated Hdm2 in human fibroblast cells. Cellular 
levels of DAXX and p21 were monitored as positive control for pp71 and p53 activity 
respectively. Fibroblast cells were transfected with FLAG-tagged wild-type pp711-559 or triple 
mutant pp7116-538. As shown in figure 12A, and shown previously in figure 9, both wild-type 
pp711-559 and triple mutant pp7116-538 were able to destabilize USP7. However, in contrast to 
what was observed in U2OS cells, in fibroblast cells both wild-type pp711-559 and mutant pp7116-
538 decreased Hdm2 (by 40%, p<0.05) and Ser166 Hdm2 levels (Fig. 4-12 A&B). Further, both 
wild-type and mutant pp71 also decreased cellular levels of p53 (by 40-50%, p<0.05) and Ser15 
phosphorylated p53 within 24 hours post transfection (Fig. 4-12 A&C). Instability of p53 was 
followed by a drop in p21 level, indicating decrease in p53 transcriptional activity. We also 
noticed significant decrease in the levels of cellular DAXX in the presence of both wild-type and 
mutant pp71. Our results in figure 12 indicate that in fibroblast cells, the primary cells infected 
by HCMV, although triple deletion mutation in pp71 disrupts its interaction with USP7, it does 
not affect pp71 mediated downregulation of USP7 and DAXX, which is followed by decline in 
Hdm2 and p53 concentrations. 
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Fig. 4-12: The effect of pp71 expression on Hdm2 and p53 levels in BJ fibroblast cells. Cellular 
levels of p53, Ser15 phosphorylated p53 (p-p53), Hdm2 and Ser166 phosphorylated Hdm2 (p-
Hdm2) were monitored in BJ fibroblast cells 24 hours post transfection with wild-type pp711-559, 
mutant pp7116-538 or empty pcDNA3.1/FLAG vector as negative control. Levels of DAXX and 
p21 were monitored as control for pp71 and p53 activity respectively. GAPDH levels were 
detected as loading control. B) Fold change in Hdm2 was determined by normalizing Hdm2 
levels and comparing them to that of vector ratio in fibroblast cells. C) Fold change differences 
in p53 were calculated by normalizing p53 levels and comparing them to that of vector ratio in 
fibroblast cells. A paired t test statistical analysis was used to calculate the significance of 
changes in Hdm2 and p53 levels after expression of wild-type (WT) pp711-559 and triple mutant 
(Mut) pp7116-538. Error bars indicate standard error (n=3). 
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pp71 Expression Effect on ATM Kinase Stability:  
 
   Double stranded DNA (ds-DNA) breaks initiate kinase activity of ataxia telangiectasia mutated 
(ATM) serine-protein kinase through intermolecular autophosphorylation of serine 1981 
(Bakkenist & Kastan 2003). DNA replication of some viruses, such as KSHV and HCMV, inside 
the nucleus exposes the ends of the viral genomes, which are recognized as ds-DNA breaks, and 
activate the ATM mediated ds-DNA damage response (Gaspar & Shenk 2006; Shin et al. 2006). 
It was observed that post HCMV transfection, several checkpoint proteins, including ATM 
kinase, instead of accumulating in the nucleus were mislocalized to the cytoplasm, resulting in 
suppression of the cellular DNA damage response (Gaspar & Shenk 2006). Considering that 
pp71 expression decreased Ser15 phosphorylated p53 levels and since ATM is responsible for 
Ser15 phosphorylation and stabilization of p53, we investigated ATM stability and its 
autophosphorylation on Ser1981 post pp71 transfection. 
 
   U2OS cells were transfected with Myc-USP7 followed by cotransfection with either wild-type 
pp711-559, triple mutant pp7116-538 or empty vector as control. BJ fibroblast cells were transfected 
with wild-type pp711-559, triple mutant pp7116-538 or empty vector. Levels of ATM and Ser1981 
phosphorylated ATM were detected by western blotting using ATM and Ser1981-ATM 
antibodies. As shown in figure 13, wild-type pp71 transfection decreased cellular levels of ATM 
by about 40% in U2OS cells and 30% in BJ fibroblasts. Ser1981 phosphorylated ATM levels 
were also decreased in both cell lines within 24 hours post transfection (Fig. 4-13). In U2OS 
cells triple mutant pp7116-538 lost its effect on ATM and Ser1981 phosphorylated ATM, while in 
fibroblast cells triple mutant pp7116-538 still was able to significantly reduce ATM levels 
(p=0.015). These observations suggest that pp71, either directly or through indirect interactions, 
significantly destabilizes ATM (p=0.016 & 0.0002) and inhibits its autophosphorylation with in 
24 hours post transfection. 
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Fig. 4-13: The effect of pp71 expression on ATM kinase. (A) U2OS cells were transfected with 
Myc-USP7 followed by cotransfection with either wild-type pp711-559, triple mutant pp711-538 or 
empty pcDNA3.1/FLAG vector as negative control. (B) BJ fibroblast cells were transfected with 
wild-type pp711-559, triple mutant pp711-538 or empty pcDNA3.1/FLAG vector. 24 h post 
transfection whole cell lysates were collected and immunoblotting was performed using ATM, 
Ser1981 phosphorylated ATM and FLAG antibodies. GAPDH levels were monitored as loading 
control. C & D) Fold change differences in ATM was calculated by normalizing ATM levels and 
comparing them to that of vector ratio in U2OS (C) and fibroblast cells (D). A paired t test 
statistical analysis was used to calculate the significance of changes in ATM levels after 
expression of wild-type pp711-559 (WT) and triple mutant pp7116-538 (Mut). Error bars indicate 
standard error (n=3). 
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Discussion 
 
   Human cytomegalovirus (HHV-5), similar to other members of the HHV family, has evolved 
to suppress the immune system and establish a latent state in the host. One of the mechanisms 
that HHVs employ to suppress the intrinsic cellular antiviral response is inhibition of the tumor 
suppression pathways and disruption of proteins that regulate cell cycle progression, such as p53 
(Alibek et al. 2014). Proteins expressed by HSV-1, EBV, KSHV and HCMV interfere with the 
USP7-p53-Hdm2 pathway by either competitively interacting with or disrupting function of its 
components (Chavoshi et al. 2016; Pfoh et al. 2015; Salsman et al. 2012; Lee et al. 2011; 
Saridakis et al. 2005; Meredith et al. 1994). Loss of the p53 or inhibition of its transactivity is 
strongly correlated with cell transformation and oncogenesis (Kawauchi & Wolf 2014). In 
addition, HHVs disrupt PML nuclear bodies, sites of the cellular factors that inhibit initiation of 
the viral gene expression (Frappier 2011). They code for proteins that localize to PML-NBs and 
specifically target their components, such as PML, DAXX, Sp100 and ATRX (Tavalai & 
Stamminger 2011; Everett 2001). For instance, ICP0, expressed by HSV-1, is an E3 ligase 
involved in degradation of the host proteins. It destabilizes p53 through direct ubiquitination and 
by hijacking USP7 for self-stabilization (Boutell et al. 2005; Boutell & Everett 2003). Further, 
ICP0 induces degradation of PML proteins (Maul & Everett 1994). Similarly, EBNA1 expressed 
by EBV strongly binds the USP7 N-terminal domain and blocks USP7 interaction with its 
cellular substrates (Saridakis et al. 2005). EBNA1 also disrupts PML-NBs and decreases levels 
of PML through interaction with USP7 (Sivachandran et al. 2008). Likewise, vIRF1, vIRF4, 
LANA and ORF45 expressed by KSHV have been shown to interact with the USP7 N-terminal 
domain at the same site as its cellular substrates (Chavoshi et al. 2016; Jager et al. 2012; Gillen et 
al. 2015; Lee et al. 2011). They block USP7 substrate interaction, destabilize p53 and suppress 
p53 mediated apoptosis (Lee et al. 2009; Saridakis et al. 2005). vIRF1 and LANA also directly 
interact with p53 and inhibit its acetylation and transactivation, while vIRF4 destabilizes p53 by 
interacting with Hdm2 and inhibiting its autoubiquitination (Lee et al. 2009; Seo et al. 2001; Li 
et al. 2000; Friborg et al. 1999).  
   pp71, HCMV main tegument transactivator, has a crucial role in preparing the cellular 
environment for lytic infection and activation of IE gene expression (Torres & Tang 2015; 
Bresnahan & Shenk 2000). Upon release to the host cell cytoplasm, pp71 is immediately 
translocated to the nucleus and localizes to PML-NBs through interaction with DAXX, which 
subsequently leads to DAXX degradation and disruption of the DAXX/ATRX complex 
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(Lukashchuk et al. 2008; Ishov et al. 2002). Primary amino acid sequence analysis of pp71 
revealed three potential interaction sites with the USP7 N-terminal domain including: 4ASSS7, 
10EGPS13 and 547ASTS550. Considering that USP7 localizes to PML-NBs and it is also known to 
interact with and stabilize DAXX, we investigated the possibility of pp71 interacting with USP7. 
The pp71/USP7 interaction was confirmed through in vitro biochemical, structural and 
functional studies. FITC polarization binding assays revealed that pp71 2SQASSSPGE10, 
7SPGEGPSSEA16 and 545STASTSSTP553 peptides interact with the USP7 N-terminal domain 
with Kds of 18.7 µM, 3.4 µM and 2.0 µM respectively. Binding affinities of 7SPGEGPSSEA16 
and 545STASTSSTP553 peptides are much higher than that of USP7 cellular substrates, such as 
Hdm2, p53 and Hdmx, that bind USP7-NTD with Kds ranging from 8 to 45 µM (Sarkari et al. 
2010; Sheng et al. 2006). A single point mutation of Ser13 to alanine in 7SPGEGPSSEA16 
peptide increased the Kd to 126.4 µM, indicating the importance of this residue in interaction 
with the USP7 N-terminal binding site.  
 
   In vitro pull-down experiments revealed that pp71 exclusively interacts with the USP7 N-
terminal domain. Substitution mutations of Asp164 and Trp165 of the USP7 164DWGF167 motif 
to alanine abolished full-length pp71 interaction with USP7, indicating that pp71 (including all 
three USP7 interaction sites) recognizes and interacts with the DWGF motif of the USP7 N-
terminal domain. In addition, we generated 5 deletion-mutant pp71 constructs missing one, two 
or all three potential USP7 N-terminal domain interaction sites of pp71. Only the pp71 construct 
with deletion mutation of all three potential USP7-NTD binding sites lost interaction, indicating 
that all three USP7 interaction sites of pp71 bind the USP7 N-terminal domain. 
   Further, we monitored the USP7-NTD 1H-15N HSQC spectra after titration with pp71 
7SPGEGPSSEA16 peptide. Strong disturbances were observed mostly in the USP7-NTD ß-strand 
7 residues comprising the conserved 164DWGF167 motif and residues from ß-strands 3, 4 and 6. 
Observed disturbances in the USP7-NTD chemical shift closely correlated with residues that 
were affected by pp71 peptide interaction seen in our complex crystal structure of the USP7-
NTD and pp71 7SPGEGPSSEA16 peptide. The pp71 peptide forms hydrogen bonds with Asp164, 
Trp165 and Asn169 of b-strand 7 and Arg104 of b-strand 3. Residues from b-strand 4 and 6 are 
affected due to close proximity to pp71 peptide but do not make polar contact. The pp71 peptide 
(7SPGEGPSSEA16), similar to that of EBNA1, vIRF1 and ORF45, instead of the more 
commonly identified USP7-NTD binding sequence of (P/A)XXS, contains a negatively charged 
glutamic acid residue and interacts with the DWGF motif of USP7-NTD through an EGPS 
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sequence. The glutamic acid residue in EGPS makes more H-bonds with the USP7 N-terminal 
domain DWGF motif and therefore increases the affinity of the EGPS containing proteins for 
USP7 compared to its cellular substrates or other viral proteins that incorporate a (P/A)XXS 
motif in their binding site. Identification of another USP7-NTD interacting herpesvirus protein 
suggests that these viruses target USP7 for its role in regulating stability of tumor suppressor 
proteins, such as p53. 
   Our functional analysis showed that pp71 not only interacts with USP7, it also significantly 
decreases its cellular levels. Even though triple deletion mutant pp7116-538 loses its interaction 
with USP7, it was still able to reduce USP7 levels. Our findings suggest that direct interaction is 
not the only mechanism by which pp71 destabilizes USP7 and other cellular factors might be 
involved. In fibroblast cells both wild-type and mutant pp71 were still able to destabilize DAXX. 
This was expected as pp71 residues 206-213 and 324-331, that are involved in interaction with 
DAXX, are not altered in our deletion mutant pp71 construct (Hofmann et al. 2002). Further, 
USP7 was previously shown to interact with and stabilize DAXX (Tang et al. 2006). Deletion 
mutant pp71, that has lost its interaction sites with USP7-NTD, can potentially effect USP7 
through simultaneous interaction with DAXX, which can bring pp71 and USP7 in close 
proximity. However, this hypothesis must be further investigated since in U2OS cell line triple 
mutant pp71 lost its reducing effect on DAXX but it was still able to destabilize USP7. This 
observation puts forward the possibility that pp71 recruits or regulates another cellular factor to 
exert its effect on USP7.  
   We noticed that in fibroblast cells, the primary cells infected by HCMV, wild-type pp711-559 
and triple mutant pp7116-538 were able to significantly decrease both p53 and Hdm2 levels. 
Downregulation of USP7 was expected to mainly effect p53 stability, since Hdm2 has higher 
affinity for USP7. Considering that simultaneous interaction of DAXX with USP7 and Hdm2 
allows for efficient deubiquitination and stabilization of Hdm2 and since DAXX also enhances 
Hdm2 E3 ligase activity, it can be suggested that significant decrease in the levels of DAXX and 
USP7, under pp71 influence, compromises Hdm2 stability (Tang et al. 2006). This is supported 
by our in vivo data from U2OS cell line where triple mutant pp71 that was not able to alter 
DAXX levels had also no effect Hdm2, even though it was still able to decrease cellular levels of 
USP7.  We further investigated the cellular levels of Ser166 phosphorylated Hdm2. Ser166 
phosphorylation stabilizes Hdm2 by inhibiting its self-ubiquitination and promotes its shuttling 
to the nucleus, where it can target p53 (Feng et al. 2004; Mayo & Donner 2001; Lambert et al. 
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1998). In addition, Ser166/186 phosphorylated Hdm2 cannot interact with ARF, its negative 
regulator, and is more stable (Weber et al. 2000). Our results indicated decreases in the levels of 
Ser166 phosphorylated Hdm2, suggesting that post pp71 transfection, Hdm2 is mostly 
cytoplasmic and cannot affect p53. Also, decrease in Ser166 phosphorylation correlates with 
self-ubiquitination and instability of Hdm2, which further explains the observed decrease in 
Hdm2 levels. Ser166 and 186 phosphorylation of Hdm2 is mediated through PI3-kinase and its 
downstream targets, Akt/PKB kinases (Feng et al. 2004). Human herpesviruses such as HSV-1 
and KSHV have already been shown to interact with PI3-kinase & deregulate the Akt/PKB 
signaling pathway (Wagner & Smiley 2011; Uddin et al. 2005).  
   Despite downregulation of Hdm2, p53 negative regulator, p53 levels showed significant 
decrease after transfection with pp71. In part instability of p53 can be correlated with 
downregulation of USP7. To further explain the concurrent decrease in the levels of p53 and 
Hdm2, we investigated Ser15 phosphorylated p53 levels. Ser15 is located in the Hdm2/p53 
binding pocket and its phosphorylation inhibits p53 interaction with Hdm2 and stabilizes p53 
(Moll & Petrenko 2003). Also, this phosphorylation is important for p300/CBT mediated 
acetylation and transcriptional activation of p53 (Iyer et al. 2004; Lambert et al. 1998). Our data 
indicated decreases in Ser15 phosphorylated p53 after pp71 transfection, which suggest increase 
in p53/H2m2 interaction. Further, we investigated cellular levels of p21, an essential mediator of 
the cell cycle arrest at G1/S and G2 phase and one of the major targets of p53 transactivation 
(Cazzalini et al., 2010). Reduced p53 levels post pp71 transfection was followed by decrease in 
p21 expression, indicating suppression of the p53 transcriptional activity. 
   It was previously reported that HCMV leads to the mislocalization of ATM, DNA damage 
check point protein, from the nucleus to the cytoplasm and inhibits its activation upon viral DNA 
replication (Gaspar & Shenk 2006). Observing a decrease in the levels of Ser15 phosphorylated 
p53 led us to investigate stability and auto-activation of ATM by monitoring ATM and Ser1981 
phosphorylated ATM levels post pp71 transfection. ATM is a key kinase involved in the 
regulation of the USP7-p53-Hdm2 pathway components. Activated ATM phosphorylates Ser15 
on p53 and thereby leads to its acetylation by p300 and transactivation (Shiloh & Ziv 2013). 
Further, ATM phosphorylates and activates cycle checkpoint kinase 2 (Chk2), which results in 
Chk2 mediated phosphorylation of p53 on Ser20 and interruption of the p53/Hdm2 interaction 
(Sancar et al., 2004). Consequently, Ser15/Ser20 phosphorylated p53 induces expression of its 
downstream targets such as p21 and leads to cell cycle arrest or apoptosis (Chehab et al. 2000; 
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Craig et al. 1999). In addition, activated ATM phosphorylates Hdm2 on Ser395 and inhibits 
Hdm2 mediated shuttling of p53 to the cytoplasm (Maya 2001). Furthermore, upon DNA break 
signal ATM mediated phosphorylation of DAXX on Ser564 disrupts DAXX/Hdm2 interaction 
and results in Hdm2 autoubiquitination and p53 stabilization (Tang et al. 2013). Indeed, we 
noted significant decrease in the levels of ATM and Ser1981 phosphorylated ATM, indicating 
that under pp71 influence not only ATM is destabilized, its auto-activation is also reduced. In 
fibroblast cells both wild-type and triple mutant pp71 were able to decrease levels of ATM 
which correlated with the observed decrease in the levels of p53 and p21. In U2OS cells, triple 
mutant pp71 that had lost its effect on ATM kinase was also unable to reduce p53 and p21 levels. 
Therefore, p53 destabilization despite downregulation of Hdm2 can be in part due to inhibition 
of ATM mediated phosphorylating of p53 on Ser15 and Ser20 (indirectly). In addition, decrease 
in p53 acetylation by p300/CBT further downregulates p53 and inhibits its transactivation.  
 
   It was noted that pp71 degradation of the Rb proteins results in the induction of DNA synthesis 
in quiescent cells and cell cycle progression into the S phase (Kalejta et al. 2003). However, 
mutation of the pp71 Rb binding motif still allowed cell cycle progression through the G1 phase, 
indicating that apart from inhibiting the Rb proteins pp71 should have other means of 
accelerating the cell cycle (Kalejta et al. 2003). In addition, it has been shown that activated 
ATM blocks the G1/S cycle progression by phosphorylating and activating Chk2 kinase and 
stabilizing p53, which together mediate arrest at the G1/S phase through expression of p21 
(Sancar et al. 2004; Chehab et al. 2000). Our data shows significant decrease in the levels of 
ATM, activated Ser1981 phosphorylated ATM and p21 24 hours post pp71 transfection. Here we 
suggest that pp71, other than mislocalization of ATM kinase, inhibits cell cycle arrest through 
downregulation of ATM and p53.  
 
   In summary, we have identified that tegument transactivator pp71, expressed by human 
cytomegalovirus, as a novel interactor of USP7. Further, we have shown that pp71 targets USP7 
and ATM to downregulate p53 induced cell cycle arrest upon entering the host cell. This 
correlates well with the function of pp71, which is preparing the cellular environment for HCMV 
immediate early gene activation and lytic infection.  
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Chapter 5: Thesis Summary, General Discussion and Future 
Directions 
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Summary:  
 
   Ubiquitin mediated degradation was first described by Hershko, Ciechanover and Rose in the 
1990s which led to the 2004 Nobel Prize in Chemistry. Their discovery revealed that the system 
involved in proteolysis in eukaryotes is more complex than lysosomal degradation. Since then, 
extensive research and investigations have demonstrated that the process of protein 
ubiquitination and deubiquitination is far more sophisticated than was originally expected. To 
date, it is well appreciated that deubiquitinating enzymes, other than their essential role in protein 
stabilization, are implicated in many non-proteolytic cellular functions, such as protein 
trafficking, cell cycle progression, DNA repair and regulation of transcription (He et al. 2016; 
Hanpude et al. 2015).  
 
Chapter 2: Investigating Expression and Purification of Yeast S. 
cerevisiae Ubps from E. coli for Protein Crystallography.  
 
   When I started my project, there were many ongoing investigations on the structure and 
function of human USP deubiquitinating enzymes; however, the roles in regulating cellular 
processes and the structures of budding yeast S. cerevisiae Ubps were not well characterized. S. 
cerevisiae Ubps have shown significant conservation of sequence, function and structure with 
their human homologues. Lack of introns in UBP genes and less complicated post-translational 
modifications make them more convenient targets for cloning, expression and purification and 
further functional studies compared to their human homologues. The availability of the S. 
cerevisiae complete genome sequence and the convenience of working with yeast proteins rather 
than more complicated eukaryotic orthologues persuaded us to start an investigation into yeast S. 
cerevisiae Ubp enzymes and examine the possibility of obtaining soluble Ubp constructs from E. 
coli (Heinicke et al. 2007). In chapter 2, I described my efforts in obtaining soluble recombinant 
S. cerevisiae Ubps from E. coli. I examined various optimization methods such as employing 
different expression vectors and designing multiple constructs per protein or per domains of each 
protein as recommended by previous publications (Luna-Vargas et al. 2011; Dyson et al. 2004). 
Out of 127 constructs that were designed to express 16 S. cerevisiae Ubps and their domains in 
E. coli, 10 soluble proteins were purified including Ubp1 (aa 92-741), Ubp3 catalytic domain (aa 
449-912), Ubp6 full-length (aa 1-499), Ubp12 N-terminal domain (aa 1-361, 90-361 and 98-345) 
and Ubp15 N-terminal and C-terminal domains (aa 1-204 and 538-1230). I was able to obtain 
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protein crystals for S. cerevisiae Ubp1, Ubp6 and Ubp12 N-terminal DUSP domain. X-ray 
diffraction data obtained from Ubp6 protein crystal was used to determine the three-dimensional 
structure of its catalytic domain. 
 
   Despite designing 127 constructs for 16 S. cerevisiae Ubp enzymes (including Sad1 and Pan2 
which are catalytically inactive Ubps) and extensive optimizations based on the previously tested 
methods (Dyson et al. 2004), we were able to obtain only 10% soluble expression of the 
recombinant proteins in E. coli. As was expected, expression in E. coli, even though convenient 
and less costly, is inefficient for eukaryotic proteins or their domains. Methods examined by 
other research groups to increase the efficiency of soluble recombinant protein expression in E. 
coli, such as expression of the same construct from a collection of vectors at once,  have 
produced encouraging results (Luna-Vargas et al. 2011). If handling a large number of proteins, 
however, one would end up dealing with an overwhelming number of constructs. Another option 
is to use a yeast expression system. Even though much smaller amounts of recombinant protein 
are expressed in yeast, purification is more cumbersome and laboratory procedure is costly, 
expressed protein is potentially soluble and properly folded. Many research groups have 
explored the efficiency of different expression systems in yeast and have attempted to optimize 
them for high-level production of secreted as well as soluble cytosolic fusion proteins (Liu et al. 
2012; Rasmussen et al. 2011; Mitchell et al. 1993; Romanos et al. 1992). Certain Ubps of interest 
can be expressed and purified from yeast using large multi-liters of culture to hopefully obtain 
enough protein for crystal trials. Full-length or domains of S. cerevisiae Ubps can be cloned in 
yeast expression vectors such as pEGH (based on pEG(KG) vector under the control of GAL1/10 
promoter) for expression in S. cerevisiae (Zhu et al. 2001; Mitchell et al. 1993). Further, S. 
cerevisiae open reading frames (ORFs) collections, cloned into yeast expression plasmids, are 
commercially available. They code for more than 5000 yeast proteins with a C-terminal fusion 
tag (Gelperin et al. 2005). However, expression in S. cerevisiae results in much lower yield as 
compared to expression in E. coli, which makes protein purification for crystallization trials quite 
cumbersome. Therefore, to date expression of proteins in E. coli remains the easiest, quickest 
and cheapest method. 
 
Automation of Protein Expression, Detection and Crystal Screening:  
 
   For future experiments, automation of steps involved in recombinant protein purification from 
E. coli cells that are interlinked, such as cell lysis, affinity binding and elution of the recombinant 
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proteins can speed up the experimental process. Also, automation of protein expression detection 
and solubility testing using methods such as 96-well microplate array sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and fusion tag interacting biarsenical fluorescein derivatives, 
which allow detection of small quantities of tagged proteins, will save a considerable amount of 
time when handling a large number of samples (Pomorski & Krezel 2011; Feldman et al. 2004).  
 
   Recently an automated droplet robot has been described which allows set up of crystallization 
screens using 4-8 nL droplets combined with microfluidic techniques, that involve preparation of 
nanoliters of protein samples in microchannels, valves or chambers (Zhu et al. 2014; Zhu & Fang 
2013). The proposed automation method decreases required purified protein amounts by 50-500 
fold as compared to the current 96 well crystal trial set ups (Zhu et al. 2014). Currently, available 
automated protein crystallization setups, such as Phoenix (Art Robbins Instruments, Inc.), 
Mosquito (TTP Labtech, Ltd.), and OryxNano (Douglas Instruments, Ltd.), allow preparation of 
trials with droplets in the range of 25-100 nLs. More advanced robotics techniques will make set 
up of crystal trials using small amounts of purified proteins from yeast expression system much 
more feasible. However, despite the high potential of the automated robotics for protein 
expression detection and crystallization screening, employing these techniques requires set up 
and operation of microfluidic devices and specific equipment and robotics which are not readily 
available in many structural biology labs. 
 
Chapter 2: Crystal Structure of S. cerevisiae Ubp6. 
 
   I was able to express and purify the full-length Ubp6 protein (aa 1-499) from the p15TV-L 
vector in BL21 E. coli cells. Ubp6 protein crystals diffracted to 2.5 Å resolution. Even though 
full-length protein was crystallized, the electron density map only contained information for the 
Ubp6 catalytic domain, indicating the flexibility of the Ubp6 N-terminal Ubl domain. 
Superimposition of the Ubp6 catalytic domain residues 103-499 with that of USP14, its human 
homologue, revealed the conserved extended right-hand architecture (similar to that of the USP7 
catalytic domain) with structures representing the thumb, fingers and palm subdomains (Hu et al. 
2005). Further, the blocking loops 1 and 2 (BL1 and BL2), which are located in the predicated 
ubiquitin binding pocket and hover over the catalytic residues, are also conserved in S. cerevisiae 
Ubp6 and superimpose well with that of USP14. My structure revealed that the catalytic triad 
residues are arranged in an active conformation. Further, superimposition of the USP14 and 
Ubp6 catalytic domain structures revealed that compared to the USP14 a-helix 8, Ubp6 contains 
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two extended a-helices 11 and 12. In the reconstructed model of Ubp6 bound to the 26S 
proteasome, it was shown that interaction of the Ubl domain with 19S RP Rpn1 subunit allows 
the two C-terminal helices of Ubp6 to contact the AAA+ domain of Rpt1 (Bashore et al. 2016). 
This suggests a function for extended a-helices 11 and 12 in stabilizing and docking Ubp6 
catalytic domain in the 19S RP.  
   Future high resolution full-length Ubp6 structure is required to examine how the Ubl domain 
interacts with the catalytic domain and effects its catalytic activity or function. It is shown 
through yeast-two-hybrid experiment that the 19S RP Rpn1 subunit residues 391-642 are 
necessary and sufficient for interaction with the Ubl domain of Ubp6 and proteasome shuttling 
receptors in S. cerevisiae (Gomez et al. 2011). The Ubp6 Ubl domain is stabilized through 
interaction with the 19S Rpn1 subunit (Bashore et al. 2016; Gomez et al. 2011). Therefore, the 
cocrystal structure of Ubp6 and Rpn1 (residues 391-642) can help stabilize the Ubl domain and 
allow obtaining the full-length Ubp6 structure. Such structure will further help clarify the 
mechanism involved in stimulation of Ubp6 deubiquitination activity through the Ubl-Rpn1 
interaction. 
Chapter 2: An Insight into the S. cerevisiae Ubp15 N-Terminal 
Domain Protein Interaction Mechanism.  
  
   The USP7 N-terminal DWGF motif is highly conserved among all Ubp15/USP7 homologs, 
indicating its essential functional importance. Considering the significant conservation of 
domains and sequence between the well-characterized human USP7 and less studied S. 
cerevisiae Ubp15, I investigated the mechanism of the Ubp15 N-terminal domain (NTD) protein 
interaction compared with that of USP7. Using fluorescence polarization assay (FITC) and NMR 
titration, I showed that Ubp15-NTD, similar to its human homologue USP7, interacts with 
EGPS, AXXS and PXXS motifs of proteins that previously have shown interaction with human 
USP7, including the EGPS containing vIRF1 peptide, the PSTS containing MCMBP peptide and 
the PSTSS containing Hdm2 peptide. Ubp15 showed higher affinity for PSSS, PSTS and PXXSS 
sequences. Interestingly, Yeast Cdh1 that has previously shown strong binding with Ubp15-NTD 
(Bozza & Zhuang 2011) contains a PSSS motif at its N-terminus (residues 13-16), which is 
highly conserved among fungi. The possibility of this motif involvement in Cdh1 interaction 
with Ubp15-NTD can be further investigated.  
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   To further identify S. cerevisiae Ubp15 potential substrates or the N-terminal domain 
interacting proteins, yeast-2-hybrid experiment using Ubp15-NTD as a bait or tandem affinity 
purification (TAP) using TAP-tagged Ubp15-NTD can be employed. C-terminal fusion TAP-
tagged Ubp15 full-length protein has previously shown strong interaction with S. cerevisiae 
Ecm30, Trr1 and Sdd1 proteins (Lam 2010, Unpublished doctoral dissertation). Both Ecm30 and 
Trr1 possess a PSSS motif, while Sdd1 protein contains a PGSS motif. These proteins may 
interact with Ubp15 using these motifs and should be further investigated.  
 
Ubp15 Involvement in the DNA Damage Response and Cell Cycle 
Progression: 
    
   The main components of the DNA damage checkpoints, such as Tel1 (ATM homologue), Rad3 
(ATR homologue), Cds1 (CHK1 homologue) and Chk2, are also conserved in yeast. However, 
p53 protein has not been identified in yeast and is considered an additional response to DNA 
damage that has evolved in multicellular eukaryotes (Lane & Verma 2012; Wahl & Carr 2001). 
Despite the absence of the most notable USP7 homologues, p53 and Hdm2, in yeast, it was 
shown that Ubp15, similar to USP7, is involved in regulation of the cell cycle progression. It 
interacts with Cdh1, the APC complex activator, and stabilize Clb5, a type-B cyclin involved in 
DNA replication (Ostapenko et al. 2015). 
 
   Human USP7 is also implicated in activation of the DNA damage response through 
stabilization of RAD18 E3 ligase (also Rad18 in yeast), which along with its cognate E2 enzyme 
RAD6 (also Rad6 in yeast) mono-ubiquitinates PCNA and leads to initiation of the post-
replication repair (PRR) (Zlatanou et al. 2015). RAD18 interacts with USP7-NTD through 
179PDPS183 and 190PSTS194 consensus sequences (Zlatanou et al. 2015). Preliminary examination 
of the yeast Rad18 sequence also revealed three possible USP7 interaction sites: 114PENSS118 
and 159PLSS162, which are located between the Rad18 RING domain (residues 28-65) and the 
Zinc-binding motif (residues 190-210), and a 346PQNSS350 sequence that is located C-terminus of 
the Zinc-binding motif. The possibility of Ubp15 involvement in the stabilization of Rad18 needs 
to be investigated.  
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Chapter 3: Identification of Kaposi Sarcoma Herpesvirus (KSHV) 
vIRF1 Protein Interaction with Human Deubiquitinating Enzyme 
USP7. 
 
   In Chapters 3 and 4 I focused my research on the interaction of human herpesvirus (HHV) 
proteins with the USP7-NTD. Through these investigations, I was able to identify two novel 
HHV proteins that interacted with USP7-NTD. When I started my research, a few HHV proteins 
had already been identified as USP7 binding partners. The strong interaction of HSV-1 ICP0 
protein with USP7-CTD was previously described (Meredith et al. 1994). EBNA1, an Epstein-
Barr virus (EBV) expressed latent protein and its functional homologue, LANA, expressed by 
KSHV had also shown a strong affinity for USP7-NTD (Jager et al. 2012; Saridakis et al. 2005). 
UL35, an HCMV latent protein, had shown binding with USP7 affecting its cellular localization 
(Salsman et al. 2012). And more recently vIRF4 and ORF45, expressed by KSHV, showed 
binding with the USP7-NTD at the same region as its cellular substrates, including p53, Hdm2 
and HdmX  (Gillen et al. 2015; Lee et al. 2011). It was becoming apparent that HHVs tend to 
aim for destruction and deregulation of the USP7-p53-Hdm2 pathway by competitively binding 
to USP7. They block USP7 substrate interaction and cripple the cell’s interferon and innate 
immune response and p53 mediated apoptosis. Since mutations and loss of function in p53 are 
responsible for greater than half of all human tumors, it is not surprising that KSHV and HCMV 
are linked to multiple human malignancies (Olivier et al. 2010; Hainaut et al. 1997). To date, 
KSHV is recognized as the causative agent of three human malignancies: Kaposi’s sarcoma, 
primary effusion lymphoma and multicentric Castleman’s disease (Wen & Damania 2010). 
 
KSHV vIRF1 Protein Interaction with USP7: 
 
   KSHV expresses a large number of oncogenes and immunomodulatory proteins with 
homology to the host cell cycle regulatory proteins and inflammatory cytokines, such as viral 
IRFs (vIRFs). KSHV expressed vIRF1, a lytic protein, inhibits IRF1 and IRF3 transcription 
activation and blocks IFNα/β and IFNγ induced gene transcription (Baresova et al. 2013). 
Further, vIRF1 was previously reported to directly interact with the p53 central DNA binding 
region (residues 152-360) and hinder its DNA binding ability. At the same time, vIRF1 is a 
potent inhibitor of the transcriptional coactivator p300/CREB and inhibits p53 acetylation by 
p300, which is essential for its transcriptional activation (Shin et al. 2006; Seo et al. 2001).We 
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identified a 45PGEGPS50 consensus sequence in vIRF1 that is identical to the motifs reported in 
EBNA1 and ORF45 (of KSHV) responsible for mediating their interaction with USP7-NTD 
(Gillen et al. 2015; Saridakis et al. 2005). I showed that vIRF1 interacts with the 164DWGF167 
motif of USP7-NTD with high affinity and that this interaction leads to a decrease in the cellular 
levels of tumor suppressor protein p53. Further, my cellular data revealed that vIRF1 also 
hinders ATM function by inhibiting its autophosphorylation, but does not destabilize USP7, 
ATM or Hdm2. Therefore, vIRF1 not only inhibits p53 activity through direct binding, but it also 
destabilizes it by blocking the p53-USP7 interaction and inhibiting ATM autophosphorylation.  
 
KSHV Expressed vIRF Proteins Inhibitory Effect on USP7 and p53: 
 
   Multiple interferon-modulating proteins and known oncogenes in KSHV have been identified 
as USP7-NTD interacting proteins including vIRF1, vIRF4 and ORF45. It is interesting to find 
out why KSHV has evolved to express various USP7 inhibitors. It is possible that these proteins 
work together and their effect is up or downregulated by other viral proteins. However, since 
KSHV proteins are expressed in a timely manner during lytic infection and latent state, it is more 
likely that these proteins exert their effect independently at different time points and therefore 
evoke distinct mechanisms of IFN and p53 pathway invasion. For future directions, localization 
of vIRFs, their expression levels and their effect on p53 pathway components during different 
stages of infection should be compared to gain a better understanding of their specific role in 
KSHV infection. Subcellular localization of vIRFs can be examined in tetracycline-inducible 
TRExBJAB and TRExBCBL-1 cells, a B-cell-tumor-derived cell line infected with KSHV, 
which allows the efficient introduction of test genes into the latently infected BCBL-1 primary 
effusion lymphoma cell line (Nakamura et al. 2003). After induction of lytic infection, 
localization of vIRFs can be investigated by immunofluorescence using confocal microscopy.  
 
   Other than stabilization of p53 and Hdm2, USP7 has also been implicated in the IFN pathway. 
It stabilizes RAUL, a HECT domain E3 ligase enzyme, which negatively regulates IFN 
transcription by ubiquitinating IRF3 and IRF7 (Yu & Hayward 2010). It was shown that RTA, 
an immediate-early gene encoded by KSHV ORF50 and a critical switch for initiating lytic 
replication, recruits USP7 and RAUL to form a complex and further induces USP7 mediated 
stabilization of RAUL (Ashizawa et al. 2012; Deng et al. 2007). Recently it was reported that 
USP7 upregulates the IFNα pathway through direct interaction and deubiquitination of IFNα-2 
receptors. USP7 knock-down downregulates cellular levels of signal transducer and 
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transcriptional activator proteins, STAT-1 and STAT-2, and selected IFN inducible genes (Yu et 
al. 2017). In a recent doctoral dissertation (Fowotade 2017), it was shown that USP7 further 
upregulates the IFNα pathway through stabilization of STAT2. Considering the involvement of 
USP7 in IFN signaling and the p53 pathway it is not surprising that so many KSHV proteins 
have evolved to deregulate USP7 as they hit two birds with one stone. It would be interesting to 
examine if transfection with vIRFs affects the stability of IFNα-2 receptors and STAT2 proteins 
as compared with USP7 binding mutant vIRFs. Further, cellular levels of IFNα-2 receptors and 
STAT2 proteins can be examined in tetracycline-inducible TRExBJAB and TRExBCBL-1 cells 
after induction of lytic infection.  
 
vIRF1 Effect on the Host Cell as an Oncogene and Immunosuppressor: 
 
   Upon viral infection, interferons are activated as part of the immune response and trigger tumor 
suppression and apoptosis by regulating the cell cycle. vIRF1, by interfering with various 
interferon and apoptotic signaling pathways, greatly influences tumorigenicity of KSHV and is 
recognized as a viral oncogene (Mesri et al. 2014). It inhibits IRF transactivation, cyclic GMP-
AMP synthase (cGAS) and STING signaling, Toll-like receptors 3 (TLR3) activation and p300 
function, which further inhibits expression of type I IFNs and IFN-induced proteins (Dittmer & 
Damania 2016). Also, vIRF1 directly interacts with GRIM19 and pro-apoptotic BIM and inhibits 
GRIM19 induced IFN mediated apoptosis (Choi & Nicholas 2010; Seo et al. 2002; Lin et al. 
2001). In addition, vIRF1 modulates apoptosis by inhibiting ATM autophosphorylation and p53 
transactivation (Chavoshi et al. 2016; Shin et al. 2006).  
                 
   vIRF1 expression was shown to significantly reduce p53 mediated apoptosis through down-
regulation of cyclin-dependent kinase inhibitor p21 and apoptotic activator Bax genes 
(Nakamura et al. 2001). My data further indicated that vIRF1 destabilizes p53 through disruption 
of the USP7-p53 interaction, based on the observation that mutant vIRF1 that cannot bind USP7-
NTD was unable to decrease the cellular levels of p53. The Ser50Ala mutant vIRF1 that has lost 
its ability to bind USP7 and destabilize p53 should still be able to directly interact with p53 and 
p300 as it hasn’t lost its p53 and p300 binding sites. For future investigations, I would like to test 
whether USP7 binding mutant vIRF1 can still inhibit p53 mediated apoptosis as that would 
clarify if the interaction of vIRF1 with USP7 only leads to destabilization of p53 without 
affecting its transactivation. Also, expression levels of the well-known downstream p53 targets 
such as p21 and BAX should be studied in the presence of wild-type and mutant vIRF1. Further, 
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using reporter gene assays ability of p53 to activate transcription should be analyzed in the 
presence of mutant vIRF1 compared to wild-type vIRF1. To do so, p53 null cells can be 
transfected with vectors expressing p53, vIRF1 and a vector coding for a reporter gene followed 
by a p53 DNA binding site such as PG13-Lu plasmid (with a Luciferase reporter gene) (el-Deiry 
et al. 1993).  
 
   It is proposed that targeting LANA, a latent KSHV protein that also inhibits IFN-β and IFN- γ 
activity, can potentially help cure latent KSHV infection (Dittmer & Damania 2016). Also, it 
was shown that knock-down of vIRF1 in KSHV infected cells significantly increased IFN-β 
production, suppressed viral gene transcription and attenuated KSHV lytic replication (Ma et al. 
2015). Since vIRF1 is a lytic protein and a potent oncogene, targeting vIRF1 can help cripple 
KSHV during lytic infection. vIRF1 interacts with USP7-NTD through an EGPS sequence, as 
opposed to (P/A)XXS sequence, which is used by the majority of the USP7 cellular substrates. 
Therefore, identifying and optimizing a compound that targets vIRF1, especially its USP7 
interaction motif, can potentially weaken vIRF1, decrease KSHV tumorigenicity and increase 
p53 induced apoptosis without effecting USP7 cellular substrates. To identify small molecule 
inhibitors, high throughput high content screening methods can be employed (Nickischer et al. 
2018; Evensen et al. 2010). Promising hits can be further validated using techniques such as 
surface plasmon resonance. In addition, immunotherapy can be used to target KSHV vIRF1 
protein as an intracellular target for anti-tumor therapy. It has been shown that monoclonal 
antibodies can enter human cells, for instance through Fc receptor-mediated endocytosis, and 
provide an effective antiviral immunity (Hong & Zeng 2014; Mallery et al. 2010). 
 
USP7 as a Therapeutic Target for KSHV Related Malignancies: 
 
   Understanding the mechanism through which KSHV deregulates and exploits the USP7-p53-
Hdm2 pathway provides the basis for the development of therapeutics against KSHV related 
cancers. Currently, there are no standard guidelines for KSHV related malignancies and 
treatment based on the tumor location, the severity of the symptoms and immune competence is 
in most cases surgical excision, chemotherapy or radiotherapy (Mariggiò et al. 2017; Coen et al. 
2014). To date, therapeutic interventions mostly focus on blocking Hdm2-p53 interaction by 
employing Hdm2 inhibitors, such as Nutlin-3A small molecule inhibitor, that has shown strong 
stabilization effect on p53 (Vu & Vassilev 2011). Considering that USP7 is a strong stabilizer of 
both Hdm2 and HdmX, blocking the function of this enzyme would effectively inhibit both 
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proteins and yield a more potent p53 response (Turnbull et al. 2017). Since USP7 seems to be a 
common host target for HHVs and its deregulation is necessary to support their life cycle and 
pathogenesis, it is considered to be a potential target for HHV derived tumor therapy. For 
instance, as shown by (Lee et al. 2011) two vIRF4 derived USP7 interacting peptides 
successfully blocked USP7-substrate interaction and induced apoptosis in KSHV-induced 
primary effusion lymphoma tumor cell lines (carrying wild-type p53) and led to marked tumor 
regression in primary effusion lymphoma tumor-bearing mice. However, since targeting USP7 
causes severe cytotoxicity, localized delivery of anti USP7 therapeutic agents can help reduce 
side the effects. 
 
Chapter 4: Identification of Human Cytomegalovirus (HCMV) 
Tegument Transactivator pp71 Interaction with USP7. 
 
   Amino acid sequence analysis of HCMV pp71 protein revealed three possible interaction sites 
with USP7-NTD. Two N-terminal motifs: 4ASSS7 and 8PGEGPS13 and one C-terminal sequence: 
547ASTS550. Considering the involvement of pp71 with PML-NBs, its strong interaction with and 
down-regulation of DAXX, a known USP7 substrate, and its effect on the cell cycle progression, 
it proved to be a good candidate for interaction with USP7. My initial analysis of the EGPS 
containing pp71 peptide revealed a high-affinity interaction with USP7-NTD 164DWGF167 motif. 
Later my data revealed that all three pp71 peptides are able to interact with USP7 with affinities 
ranging from 2.0 to 18.7 µM. pp71 7SPGEGPSSEA16 and 545STASTSSTP553 peptides interacted 
with USP7-NTD with Kds of 3.4 µM and 2.0 µM respectively, which are much lower than that of 
USP7 cellular substrates (Sarkari et al. 2010; Sheng et al. 2006). My work further strengthens the 
idea that HHVs have evolved to specifically interact with USP7 to destabilize p53 and inhibit 
cellular antiviral responses. 
 
pp71 Expression Effect on the p53 Pathway Components: 
 
   My data suggest that within 24 to 48 hours post-transfection of U2OS and human fibroblast 
cells pp71 reduces cellular levels of USP7, p53, Hdm2 and ATM kinase. The decrease in the 
levels of Hdm2 can be correlated with the degradation of DAXX and USP7, its known 
stabilizers. Also, downregulation of USP7 destabilizes HdmX, Hdm2 homologue, which is a 
substrate of USP7 and a binding partner and stabilizer of Hdm2 (Sarkari et al. 2010). 
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Investigating cellular levels of HdmX upon pp71 transfection can further explain the instability 
of Hdm2. In addition, upon pp71 transfection, my in vivo data indicated a decrease in the levels 
of cellular p53. Considering the destabilization of Hdm2, we expected to see an increase in p53 
levels, even though USP7 was also downregulated. Such discrepancy has been previously 
observed. For instance, transfection of cells with EBV EBNA1 protein, which is known to inhibit 
USP7 strongly, has shown a significant decrease in the levels of both p53 and Hdm2 (Sarkari 
2010, Doctoral dissertation, Chapter 3). It seems the remaining amounts of Hdm2 and further 
activity of the other p53 negative regulators, such as Cop1 and Pirh2, are potent enough to 
downregulate p53 (Wang et al. 2011). Also, considering that ATM kinase phosphorylates p53 on 
Ser15 and Ser20 (indirectly) and stabilize it upon DNA damage signal, instability of ATM post 
pp71 transfection can further explain downregulation of p53. Since HHVs proteins, such as 
vIRF1 and vIRF4 of KSHV, each tend to interact with multiple components of the USP7-p53-
Hdm2 pathway, it won’t be surprising to find out that pp71 also exerts it downregulating effect 
on p53 through direct interaction (Chavoshi et al. 2016; Lee et al. 2011; Shin et al. 2006; Seo et 
al. 2001).  
 
   pp71 has already shown downregulating effect on cellular proteins it interacts with, such as Rb 
family of tumor suppressors and DAXX (Kalejta & Shenk 2003; Ishov et al. 2002). In my 
functional analysis, pp71 significantly decreased cellular levels of ATM kinase and its 
autophosphorylation on Ser1981. In addition, previously it was reported that upon HCMV 
infection ATM is mislocalized to the cytoplasm (Gaspar & Shenk 2006). ATM kinase is a 
critical regulator of the USP7-p53-Hdm2 pathway and is involved in inhibition of the G1/S cell 
cycle progression; therefore, destabilization of ATM will give HCMV virus power to cripple 
intrinsic antiviral defense mechanism (Sancar et al., 2004). Since pp71 downregulates proteins it 
interacts with, the possible binary interaction of pp71 with ATM kinase should be further 
investigated.  
 
Suppressing and Targeting pp71 for Therapeutic Drug Design: 
 
   Similar to the other members of human herpesviruses, HCMV is very common, infecting as 
much as 88-96% of adults especially in Europe and South America (Boeckh & Geballe 2011). 
Further, it is the leading viral cause of congenital hearing loss and mental retardation in 
newborns (Cohen et al. 2014; Grosse et al. 2008). To date, lack of suitable treatments exposes 
infected fetuses to serious side effects (Torres & Tang 2015). Upon HCMV entrance into the 
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host cell, activation of the immediate early (IE) genes expression followed by activation of the 
early genes by IE proteins is critical for acute infection. Accordingly, targeting IE proteins 
activation has proven effective in inhibiting viral replication and blocking lytic infection (Stinski 
& Isomura 2008). To date, there are multiple vaccine candidates that are proposed to protect 
developing fetuses and organ transplant recipient, such as ones designed to elicit immune 
reaction against tegument proteins and phospholipid envelope glycoproteins (Xia et al. 2017; 
Smith et al. 2013). HCMV tegument transactivator pp71 is responsible for immediate early 
activation of IE genes transcription from the major immediate early promoter and hence it is 
essential for successful lytic infection (Bresnahan & Shenk 2000). pp71 deletion mutant HCMV 
has limited growth and inefficient productive replication (Bresnahan & Shenk 2000). Therefore, 
identifying small molecule inhibitors that target pp71 can help inhibit IE gene transcription and 
lytic infection in infected individuals.  
 
   USP7 is considered a potential target for HHV derived tumor therapies. However, targeting 
host USP7 to inhibit HCMV multiplication in infected fetuses causes severe cytotoxicity and is 
not an option. Therefore, considering the pp71 critical role in activation of viral gene 
transcription and its downregulating effect on cell cycle regulating proteins, such as USP7 and 
p53, targeting pp71 to suppress HCMV lytic infection is quite promising. To inhibit pp71 
suppression of p53 mediated apoptosis, identifying pp71 amino acid sequence responsible for the 
destabilization of USP7 is important. Deletion mutation of small sequences within pp71 and 
analyzing the effect of mutants on USP7 post transfection can help identify amino acids that are 
implicated in USP7 downregulation. Using mutational studies and structural data I have been 
able to pinpoint the exact interaction sites between pp71 and USP7. Identifying blocking agents 
that target USP7 interaction motifs of pp71 can help upregulate p53 and DAXX levels in 
infected cells and potentially lead to silencing of the viral genome and induction of the cell cycle 
arrest.  
 
   Also, to suppress downregulating effect of pp71 on USP7, DAXX and Rb proteins it is 
necessary to find out how pp71 destabilizes its binding partners. Previously it was reported that 
pp71 decreases cellular levels DAXX and Rb proteins (Rb, p107 and p130) in a ubiquitin-
independent but proteasome-dependent manner (Winkler et al. 2013; Kalejta et al. 2003). 
Further, it was shown that the 19S RP is necessary for pp71 imposed degradation of Rb and 
DAXX and that 19S RP subunits Rpn1was critical for pp71-mediated DAXX degradation 
(Winkler et al. 2013). For future investigations, it is important to initially examine whether 
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proteasome inhibition results in accumulation of USP7 post pp71 transfection. Furthermore, 
proteins known as proteasome shuttling receptors, such as Rad23 in yeast (hHR23B in human), 
specifically recognize Lys48-linked Ub chains as well as proteasome subunits, such as Rpn1 and 
Rpn13, and shuttle tagged proteins to the proteasome (Shi et al. 2016). Possible direct interaction 
of pp71 with proteasome subunits, such as Rpn1 and Rpn13, should be investigated. 
 
Concluding Remarks: 
 
   In this thesis, I have examined the soluble expression of the yeast Saccharomyces cerevisiae 
ubiquitin processing enzymes, Ubps, in E. coli for protein crystallography. I have employed 
multiple optimization methods which some have proven to be beneficial. Since E. coli remains 
the preferred microbial cell factory for recombinant protein expression, hopefully, the current 
advances in robotics and automation of the protein purification and expression methods can help 
facilitate large-scale protein expression from E. coli. Also, I was able to obtain the three-
dimensional structure of the S. cerevisiae Ubp6 catalytic domain which helped clarify its 
catalytic active site arrangement. In addition, my work on the Ubp15 N-terminal domain 
revealed its similar mode of substrate interaction as compared to human USP7 and provided 
important clues for identification of Ubp15 cellular substrates in future investigations. 
Furthermore, my research on KSHV expressed vIRF1 protein and HCMV expressed pp71 
protein has shown novel interactions between these viral oncogenes and human USP7. My 
findings in part have helped clarify these viral proteins mechanism of p53 pathway suppression. 
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Appendix A: List of Primers Used in Chapter 2 for p15TVL Cloning.  
 
UBP Residues Forward Primer Reverse Primer 
1 
1-809 ttgtatttccagggcatggatttgtttattgaaagc  caagcttcgtcatcagtttacatctttaccaga 
92-741 ttgtatttccagggcgagatcttgaaaagaggt caagcttcgtcatcattcatcaaagtcatattcg 
92-809 ttgtatttccagggcgagatcttgaaaagaggt caagcttcgtcatcagtttacatctttaccaga 
93-753 ttgtatttccagggcatgatcttgaaaagaggtggt caagcttcgtcatcaaatagcttccaaatcatc 
97-741 ttgtatttccagggcggtggtttcattgctggt caagcttcgtcatcattcatcaaagtcatattcg 
97-809 ttgtatttccagggcggtggtttcattgctggt caagcttcgtcatcagtttacatctttaccaga 
101-739 ttgtatttccagggcatggctggtttagttaatgat  ttgtatttccagggcatggctggtttagttaatgat  
2 
1-735 ttgtatttccagggcatgatgccgaacgaagataat caagcttcgtcatcatggccaattttctggcgg 
434-832 ttgtatttccagggcatgaatgagcaaactcattcg caagcttcgtcatcatgccaaatatgctagctc 
724-1271 ttgtatttccagggcatgatagatccaaattccttg caagcttcgtcatcatagaattcttttcaatgg 
725-1271 ttgtatttccagggcgatccaaattccttgccg caagcttcgtcatcatagaattcttttcaatggctc 
725-1259 ttgtatttccagggcgatccaaattccttgccg caagcttcgtcatcatccttgtttgacatatac 
731-1271 ttgtatttccagggcccagaaaattggccaact caagcttcgtcatcatagaattcttttcaatggctc 
731-1259 ttgtatttccagggcccagaaaattggccaact caagcttcgtcatcatccttgtttgacatatac 
736-1259 ttgtatttccagggcatgactggcattaataatatc  caagcttcgtcatcatccttgtttgacatatac 
3 
1-912 gcgcccatgggcatgaacatgcaagacgctaac gcgctcgagatttctcttttgatacattaaaatataggc 
148-912 gcgcccatgggcaacagtggcagcaatgcg gcgctcgagatttctcttttgatacattaaaatataggc 
189-912 gcgcccatgggcgatgtcactaaattaaagaatctc gcgctcgagatttctcttttgatacattaaaatataggc 
1-912 ttgtatttccagggcatgaacatgcaagacgctaac  caagcttcgtcatcaatttctcttttgatacat 
1-459 ttgtatttccagggcatgatgaacatgcaagacgct caagcttcgtcatcatggaataatggaatggac 
50-912 ttgtatttccagggctaccccacacaaatacct caagcttcgtcatcaatttctcttttgatacat 
104-912 ttgtatttccagggcggcattaccaataacaatgga caagcttcgtcatcaatttctcttttgatacat 
148-912 ttgtatttccagggcaacagtggcagcaatgcg caagcttcgtcatcaatttctcttttgatacat 
189-912 ttgtatttccagggcgatgtcactaaattaaagaatctc caagcttcgtcatcaatttctcttttgatacat 
412-912 ttgtatttccagggcatgaaatacgttccaccttct caagcttcgtcatcaatttctcttttgatacat 
426-909 ttgtatttccagggcggttcgattgcgttaaga caagcttcgtcatcattgatacattaaaatataggc 
426-912 ttgtatttccagggcggttcgattgcgttaaga caagcttcgtcatcaatttctcttttgatacat 
429-909 ttgtatttccagggcgcgttaagaatgtgttttg caagcttcgtcatcattgatacattaaaatataggc 
429-912 ttgtatttccagggcgcgttaagaatgtgttttg caagcttcgtcatcaatttctcttttgatacat 
445-909 ttgtatttccagggcaataaagatgttgaaaac caagcttcgtcatcattgatacattaaaatataggc 
445-912 ttgtatttccagggcaataaagatgttgaaaac caagcttcgtcatcaatttctcttttgatacat 
447-909 ttgtatttccagggcgatgttgaaaacaaaatacca caagcttcgtcatcattgatacattaaaatataggc 
447-912 ttgtatttccagggcgatgttgaaaacaaaatacca caagcttcgtcatcaatttctcttttgatacat 
449-909 ttgtatttccagggcgaaaacaaaataccagtc caagcttcgtcatcattgatacattaaaatataggc 
449-912 ttgtatttccagggcgaaaacaaaataccagtc caagcttcgtcatcaatttctcttttgatacat 
454-912 ttgtatttccagggcgtccattccattattcca caagcttcgtcatcaatttctcttttgatacat 
459-912 ttgtatttccagggcatgagaggcataattaacaga  caagcttcgtcatcaatttctcttttgatacat 
 
For cloning 
in pET-28b 
vector 
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UBP Residues Forward Primer Reverse Primer 
4 
1-323 ttgtatttccagggcatgatggagcagaatattatt caagcttcgtcatcaatttgacttaagccaacc 
1-330 ttgtatttccagggcatggagcagaatattattagt caagcttcgtcatcatgatgatacttgcctccc 
1-561 ttgtatttccagggcatgatggagcagaatattatt caagcttcgtcatcacgcgaaatcaaggtcata 
2-315 ttgtatttccagggcgagcagaatattattagtacc caagcttcgtcatcaaccagattccagaatga 
324-561 ttgtatttccagggcatgtatgggaggcaagtatca caagcttcgtcatcacgcgaaatcaaggtcata 
545-926 ttgtatttccagggcatgcatacagatgttacacca caagcttcgtcatcaaacaccgtagacgcggtg 
551-926 ttgtatttccagggcacttcttctcataattatgac caagcttcgtcatcaaacaccgtagacgcggt 
556-926 ttgtatttccagggctatgaccttgatttcgcg caagcttcgtcatcaaacaccgtagacgcggt 
562-924 ttgtatttccagggcatggttggtttggaaaatcta caagcttcgtcatcagtagacgcggtgataaaa 
5 
1-280 ttgtatttccagggcatgatgggctcagaacaagcc caagcttcgtcatcatataagatctagatcaag 
1-289 ttgtatttccagggcatgggctcagaacaagcc caagcttcgtcatcacgctgtttcactgacaga 
1-445 ttgtatttccagggcatgatgggctcagaacaagcc caagcttcgtcatcatataagatctagatcaag 
3-270 ttgtatttccagggctcagaacaagccttaagt caagcttcgtcatcacccattttccaaaatgag 
3-280 ttgtatttccagggctcagaacaagccttaagt caagcttcgtcatcatataagatctagatcaag 
281-445 ttgtatttccagggcatgtatcaatcatctgtcagt caagcttcgtcatcatataagatctagatcaag 
431-805 ttgtatttccagggcatgaccatcctaaacaac caagcttcgtcatcatcaaaaaattctttcgta 
434-805 ttgtatttccagggcctaaacaactcacaagtg caagcttcgtcatcatcaaaaaattctttcgta 
440-805 ttgtatttccagggccttgatctagatcttatag caagcttcgtcatcatcaaaaaattctttcgta 
446-805 ttgtatttccagggcatggtaggattggaaaatata caagcttcgtcatcaaaaaattctttcgtaaaa 
6 1-499 ttgtatttccagggcatgatgagcggagaaacgttt caagcttcgtcatcacagaccaaatcctttata 
109-488 ttgtatttccagggcatggttggtttcaagaatatg caagcttcgtcatcaactatcactttcgccccc 
7 
1-460 ttgtatttccagggcatgatgctagacgatgataag caagcttcgtcatcacaagtaatcttcaataga 
1-608 ttgtatttccagggcatgatgagcggagaaacgttt caagcttcgtcatcacagaccaaatcctttata 
593-1071 ttgtatttccagggcatgattccaactattgaacgc caagcttcgtcatcactagtcataaaccctttc 
598-1070 ttgtatttccagggccgcagtccaaacgtatac caagcttcgtcatcaataaaccctttcataaaa 
598-1071 ttgtatttccagggccgcagtccaaacgtatac caagcttcgtcatcactagtcataaaccctttc 
603-1070 ttgtatttccagggctacgtttcgttgtccatc caagcttcgtcatcaataaaccctttcataaaa 
603-1071 ttgtatttccagggctacgtttcgttgtccatc caagcttcgtcatcactagtcataaaccctttc 
608-1070 ttgtatttccagggcatgacgggactaagaaatttg caagcttcgtcatcaataaaccctttcataaaa 
8 1-136 ttgtatttccagggcatgatgagcatttgtccacat caagcttcgtcatcaaagcccatctcttctttc 
137-469 ttgtatttccagggcatgtctggcctgatcaacatg caagcttcgtcatcattgacgaatggtgtagaa 
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UBP Residues Forward Primer Reverse Primer 
9 
1-754 ttgtatttccagggcatgatgataaaaagatggtta caagcttcgtcatcatttgatgaagctcaatat 
122-671 ttgtatttccagggcatgccatatggggatggt caagcttcgtcatcaattttcggtcttatcagc 
122-707 ttgtatttccagggcgatttaatgccatatggg caagcttcgtcatcatttacgatcccttaacca 
124-674 ttgtatttccagggcatgccatatggggatggt caagcttcgtcatcaattttcggtcttatcagc 
128-671 ttgtatttccagggcgatggttccaataaagtg caagcttcgtcatcacttatcagcctgtgtttc 
128-707 ttgtatttccagggcgatggttccaataaagtg caagcttcgtcatcatttacgatcccttaacca 
134-668 ttgtatttccagggcatgtttggttatgaaaatttt caagcttcgtcatcactgtgtttctttatagaa 
311-668 ttgtatttccagggcatggcttcaactacagattgt caagcttcgtcatcactgtgtttctttatagaa 
10 
1-361 ttgtatttccagggcatgatgaccactcaagaatcg caagcttcgtcatcaaggcttcaaattggtgaa 
336-746 ttgtatttccagggcatgatcaatgatcgtggttct caagcttcgtcatcaggcagatttcgccaatgg 
351-734 ttgtatttccagggcaattggggcgacaaattc caagcttcgtcatcaagttagcctcgtgtatag 
351-746 ttgtatttccagggcaattggggcgacaaattc caagcttcgtcatcaagatttcgccaatggcaa 
356-734 ttgtatttccagggcttcaccaatttgaagcct caagcttcgtcatcaagttagcctcgtgtatag 
356-746 ttgtatttccagggcttcaccaatttgaagcct caagcttcgtcatcaagatttcgccaatggcaa 
362-734 ttgtatttccagggcatgcgtggccttttgaatcat caagcttcgtcatcaagttagcctcgtgtatag 
11 
1-297 ttgtatttccagggcatgatgttattaaacccagat caagcttcgtcatcaaatagataactctgataa 
1-135 ttgtatttccagggcatgatgttattaaacccagat caagcttcgtcatcatctttttctttttatggt 
297-710 ttgtatttccagggcatgactggcctgcaaaatcca caagcttcgtcatcaatccattctttcgtagaa 
283-713 ttgtatttccagggcatgccagtaattgaagattct caagcttcgtcatcattcatagttctcttcatc 
287-717 ttgtatttccagggcgaagattctaatgatctg caagcttcgtcatcaacagaattcttcttcatag 
291-717 ttgtatttccagggcctgttatcagagttatct caagcttcgtcatcaacagaattcttcttcatag 
12 
1-1123 ttgtatttccagggcatgggttcttcagatgtttca caagcttcgtcatcactgtagtttagagctgcc 
1-345 ttgtatttccagggcatgggttcttcagatgtttca caagcttcgtcatcagtgattcccttctatagg 
1-361 ttgtatttccagggcatgggttcttcagatgtttca caagcttcgtcatcatgatgctggttcgagttt 
1-367 ttgtatttccagggcatgggttcttcagatgtttca caagcttcgtcatcagaccaaaccagtagtacc 
90-361 ttgtatttccagggcatgaatggtcaagatggaaga caagcttcgtcatcatgatgctggttcgagttt 
98-345 ttgtatttccagggcgtcttagaacaacaaaga caagcttcgtcatcagtgattcccttctatagg 
98-361 ttgtatttccagggcgtcttagaacaacaaaga caagcttcgtcatcatgatgctggttcgagttt 
90-1123 ttgtatttccagggcatgaatggtcaagatggaaga caagcttcgtcatcactgtagtttagagctgcc 
98-1123 ttgtatttccagggcgtcttagaacaacaaaga caagcttcgtcatcactgtagtttagagctgcc 
101-1119 ttgtatttccagggcatgggtactactggtttggtc caagcttcgtcatcaatgacggcgaatgtaaaa 
353-1123 ttgtatttccagggcgcttataataaactcgaac caagcttcgtcatcactgtagtttagagctgcc 
358-1123 ttgtatttccagggcgaaccagcatcaggtact caagcttcgtcatcactgtagtttagagctgcc 
362-1119 ttgtatttccagggcatgggtactactggtttggtc caagcttcgtcatcaatgacggcgaatgtaaaa 
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UBP Residues Forward Primer Reverse Primer 
13 
1-747 ttgtatttccagggcatgatgatcagaagatggcta caagcttcgtcatcagcttttcctaaaactaaa 
139-669 ttgtatttccagggcatgtttggatacgaaaatttt caagcttcgtcatcaatacatcgctttataaaa 
129-673 ttgtatttccagggctcaatgccctatggagac caagcttcgtcatcaagcgtttgaatacatcgc 
129-682 ttgtatttccagggctcaatgccctatggagac caagcttcgtcatcatgccatattttcacgatc 
134-673 ttgtatttccagggcatggacggctccaacaaagtt caagcttcgtcatcaagcgtttgaatacatcgc 
134-682 ttgtatttccagggcatggacggctccaacaaagtt caagcttcgtcatcatgccatattttcacgatc 
329-669 ttgtatttccagggcatgaataacctggacttgaaa caagcttcgtcatcaatacatcgctttataaaa 
14 
1-781 ttgtatttccagggcatggcagaagcagtactagaa caagcttcgtcatcagcatcttgtatagaaata 
1-322 ttgtatttccagggcatggcagaagcagtactagaa caagcttcgtcatcagccataattcttactagc 
40-277 ttgtatttccagggccattcattgaatatatgc caagcttcgtcatcattcttgtatgttaattccg 
312-781 ttgtatttccagggctttgaaaaattatccgct caagcttcgtcatcagcatcttgtatagaaata 
316-781 ttgtatttccagggcatggctagtaagaattatggc caagcttcgtcatcagcatcttgtatagaaata 
317-781 ttgtatttccagggcgctagtaagaattatggc caagcttcgtcatcagcatcttgtatagaaata 
322-781 ttgtatttccagggcatgtgtggtctgatcaatttg caagcttcgtcatcagcatcttgtatagaaata 
15 
215-537 ttgtatttccagggcatggttggcttccgaaatcag caagcttcgtcatcattcttgacgtatataaac 
1-204 ttgtatttccagggcatgatgagctctgaagacgaa caagcttcgtcatcaatagcccgtgactttctt 
538-1230 ttgtatttccagggcatgcaagaggaggatttgctg caagcttcgtcatcagtttttaatgatcattgg 
16 
41-497 ttgtatttccagggcggggattctaagcagagt caagcttcgtcatcaatttacacgttcgtagtatag 
46-499 ttgtatttccagggcatgagtattgggaagtacacg caagcttcgtcatcatttatttacacgttcgta 
47-497 ttgtatttccagggcattgggaagtacacgaca caagcttcgtcatcaatttacacgttcgtagtatag 
53-499 ttgtatttccagggcatggtgggcttaattaatcgt caagcttcgtcatcatttatttacacgttcgta 
SAD1 
1-149 ttgtatttccagggcatgatggaggttgataacaaa caagcttcgtcatcaaaatccattcagatatgt 
44-448 ttgtatttccagggctctgagaaaatttgctgc caagcttcgtcatcactcttgcttttcccatac 
150-448 ttgtatttccagggcatgatagggttcaccaatgcg caagcttcgtcatcactcttgcttttcccatac 
PAN2 
1-504 ttgtatttccagggcatgatgaataattggcaacat caagcttcgtcatcaatactcagtgttattaaa 
493-826 ttgtatttccagggcaattttgattttacgccc caagcttcgtcatcaaggttttcgtaattcttcc 
505-846 ttgtatttccagggcatgtcaggattggatccagat caagcttcgtcatcatgttttccaagggtatgt 
847-1115 ttgtatttccagggcatgccagaaattatcatatat caagcttcgtcatcatccctttgaagtttctgg 
 
 
 
 
 
 
